HIV/AIDS: Difference between revisions

HIV/AIDS
HIV/AIDS
Specialty	Infectious diseases

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 10:26, 4 March 2013

Human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS) is a disease of the human immune system caused by infection with human immunodeficiency virus (HIV).^[1] During the initial infection, a person may experience a brief period of influenza-like illness. This is typically followed by a prolonged period without symptoms. As the illness progresses, it interferes more and more with the immune system, making the person much more likely to get infections, including opportunistic infections and tumors that do not usually affect people who have working immune systems.

HIV is transmitted primarily via unprotected sexual intercourse (including anal and even oral sex), contaminated blood transfusions, hypodermic needles, and from mother to child during pregnancy, delivery, or breastfeeding.^[2] Some bodily fluids, such as saliva and tears, do not transmit HIV.^[3] Prevention of HIV infection, primarily through safe sex and needle-exchange programs, is a key strategy to control the spread of the disease.

There is no cure or vaccine; however, antiretroviral treatment can slow the course of the disease and may lead to a near-normal life expectancy. While antiretroviral treatment reduces the risk of death and complications from the disease, these medications are expensive and may be associated with side effects.

Genetic research indicates that HIV originated in west-central Africa during the early twentieth century.^[4] AIDS was first recognized by the Centers for Disease Control and Prevention (CDC) in 1981 and its cause—HIV infection—was identified in the early part of the decade.^[5] Since its discovery, AIDS has caused nearly 30 million deaths (as of 2009).^[6] As of 2010, approximately 34 million people have contracted HIV globally.^[7] AIDS is considered a pandemic—a disease outbreak which is present over a large area and is actively spreading.^[8]

HIV/AIDS has had a great impact on society, both as an illness and as a source of discrimination. The disease also has significant economic impact. There are many misconceptions about HIV/AIDS such as the belief that it can be transmitted by casual non-sexual contact. The disease has also become subject to many controversies involving religion.

Signs and symptoms

There are three main stages of HIV infection: acute infection, clinical latency and AIDS.^[9]^[10]

Acute infection

The initial period following the contraction of HIV is called acute HIV, primary HIV or acute retroviral syndrome.^[9]^[11] Many individuals develop an influenza-like illness or a mononucleosis-like illness 2–4 weeks post exposure while others have no significant symptoms.^[12]^[13] Symptoms occur in 40–90% of the cases and most commonly include fever, large tender lymph nodes, throat inflammation, a rash, headache, and/or sores of the mouth and genitals.^[11]^[13] The rash, which occurs in 20–50% of cases, presents itself on the trunk and is classically maculopapular.^[14] Some people also develop opportunistic infections at this stage.^[11] Gastrointestinal symptoms such as nausea, vomiting or diarrhea may occur, as may neurological symptoms of peripheral neuropathy or Guillain-Barre syndrome.^[13] The duration of the symptoms varies, but is usually one or two weeks.^[13]

Due to their nonspecific character, these symptoms are not often recognized as signs of HIV infection. Even cases that do get seen by a family doctor or a hospital are often misdiagnosed as one of the many common infectious diseases with overlapping symptoms. Thus, it is recommended that HIV be considered in patients presenting an unexplained fever who may have risk factors for the infection.^[13]

Clinical latency

The initial symptoms are followed by a stage called clinical latency, asymptomatic HIV, or chronic HIV.^[10] Without treatment, this second stage of the natural history of HIV infection can last from about three years^[15] to over 20 years^[16] (on average, about eight years).^[17] While typically there are few or no symptoms at first, near the end of this stage many people experience fever, weight loss, gastrointestinal problems and muscle pains.^[10] Between 50 and 70% of people also develop persistent generalized lymphadenopathy, characterized by unexplained, non-painful enlargement of more than one group of lymph nodes (other than in the groin) for over three to six months.^[9]

Although most HIV-1 infected individuals have a detectable viral load and in the absence of treatment will eventually progress to AIDS, a small proportion (about 5%) retain high levels of CD4⁺ T cells (T helper cells) without antiretroviral therapy for more than 5 years.^[13]^[18] These individuals are classified as HIV controllers or long-term nonprogressors (LTNP).^[18] Another group is those who also maintain a low or undetectable viral load without anti-retroviral treatment who are known as "elite controllers" or "elite suppressors". They represent approximately 1 in 300 infected persons.^[19]

Acquired immunodeficiency syndrome

Acquired immunodeficiency syndrome (AIDS) is defined in terms of either a CD4⁺ T cell count below 200 cells per µL or the occurrence of specific diseases in association with an HIV infection.^[13] In the absence of specific treatment, around half the people infected with HIV develop AIDS within ten years.^[13] The most common initial conditions that alert to the presence of AIDS are pneumocystis pneumonia (40%), cachexia in the form of HIV wasting syndrome (20%) and esophageal candidiasis.^[13] Other common signs include recurring respiratory tract infections.^[13]

Opportunistic infections may be caused by bacteria, viruses, fungi and parasites that are normally controlled by the immune system.^[20] Which infections occur partly depends on what organisms are common in the person's environment.^[13] These infections may affect nearly every organ system.^[21]

People with AIDS have an increased risk of developing various viral induced cancers including: Kaposi's sarcoma, Burkitt's lymphoma, primary central nervous system lymphoma, and cervical cancer.^[14] Kaposi's sarcoma is the most common cancer occurring in 10 to 20% of people with HIV.^[22] The second most common cancer is lymphoma which is the cause of death of nearly 16% of people with AIDS and is the initial sign of AIDS in 3 to 4%.^[22] Both these cancers are associated with human herpesvirus 8.^[22] Cervical cancer occurs more frequently in those with AIDS due to its association with human papillomavirus (HPV).^[22]

Additionally, people with AIDS frequently have systemic symptoms such as prolonged fevers, sweats (particularly at night), swollen lymph nodes, chills, weakness, and weight loss.^[23] Diarrhea is another common symptom present in about 90% of people with AIDS.^[24]

Transmission

Template:Risk of acquiring HIV HIV is transmitted by three main routes: sexual contact, exposure to infected body fluids or tissues, and from mother to child during pregnancy, delivery, or breastfeeding (known as vertical transmission).^[2] There is no risk of acquiring HIV if exposed to feces, nasal secretions, saliva, sputum, sweat, tears, urine, or vomit unless these are contaminated with blood.^[25] It is possible to be co-infected by more than one strain of HIV—a condition known as HIV superinfection.^[26]

Sexual

The most frequent mode of transmission of HIV is through sexual contact with an infected person.^[2] Worldwide, the majority of cases of transmission occur through heterosexual contacts (i.e. sexual contacts between people of the opposite sex).^[2] However, the pattern of transmission varies significantly between countries. In the United States, as of 2009, most sexual transmission occurred in men who have sex with men,^[2] with this population accounting for 64% of all new cases.^[27]

As regards unprotected heterosexual contacts, estimates of the risk of HIV transmission per sexual act appear to be four to ten times higher in low-income countries than in high-income countries.^[28] In low-income countries, the risk of female-to-male transmission is estimated as 0.38% per act, and of male-to-female transmission as 0.30% per act; the equivalent estimates for high-income countries are 0.04% per act for female-to-male transmission, and 0.08% per act for male-to-female transmission.^[28] The risk of transmission from anal intercourse is especially high, estimated as 1.4–1.7% per act in heterosexual as well as homosexual contacts.^[28]^[29] While the risk of transmission from oral sex is relatively low, it is still present.^[30] The risk from receiving oral sex has been described as "nearly nil"^[31] however a few cases have been reported.^[32] The per act risk is estimated at 0–0.04% for receptive oral intercourse.^[33] In settings involving commercial sex in low income countries, risk of female-to-male transmission has been estimated as 2.4% per act and male-to-female transmission as 0.05% per act.^[28]

Risk of transmission increases in the presence of many sexually transmitted infections^[34] and genital ulcers.^[28] Genital ulcers appear to increase the risk approximately fivefold.^[28] Other sexually transmitted infections, such as gonorrhea, chlamydia, trichomoniasis, and bacterial vaginosis, are associated with somewhat smaller increases in risk of transmission.^[33]

The viral load of an infected person is an important risk factor in sexual as well as mother-to-child transmission.^[35] During the first 2.5 months of an HIV infection a person's infectiousness is twelve times higher due to this high viral load.^[33] If the person is in the late stages of infection, rates of transmission are approximately eightfold greater.^[28]

Rough sex can be a factor associated with an increased risk of transmission.^[36] Sexual assault is also believed to carry an increased risk of HIV transmission as condoms are rarely worn, physical trauma to the vagina or rectum is likely, and there may be a greater risk of concurrent sexually transmitted infections.^[37]

Body fluids

The second most frequent mode of HIV transmission is via blood and blood products.^[2] Blood-borne transmission can be through needle-sharing during intravenous drug use, needle stick injury, transfusion of contaminated blood or blood product, or medical injections with unsterilised equipment. The risk from sharing a needle during drug injection is between 0.63 and 2.4% per act, with an average of 0.8%.^[38] The risk of acquiring HIV from a needle stick from an HIV-infected person is estimated as 0.3% (about 1 in 333) per act and the risk following mucus membrane exposure to infected blood as 0.09% (about 1 in 1000) per act.^[25] In the United States intravenous drug users made up 12% of all new cases of HIV in 2009,^[27] and in some areas more than 80% of people who inject drugs are HIV positive.^[2]

Blood transfusions with infected blood result in transmission of infection in about 93% of cases.^[38] In developed countries the risk of acquiring HIV from a blood transfusion is extremely low (less than one in half a million) where improved donor selection and HIV screening is performed.^[2] In the UK the risk is reported at one in five million.^[39] However, in low income countries only half of the blood used for transfusions may be appropriately screened (as of 2008).^[40] It is estimated that up to 15% of HIV infections in these areas come from transfusion of infected blood and blood products, representing between 5% and 10% of global infections.^[2]^[41]

Unsafe medical injections play a significant role in HIV spread in sub-Saharan Africa. In 2007, between 12 and 17% of infections in this region were attributed to medical syringe use.^[42] The World Health Organisation estimates the risk of transmission as a result of a medical injection in Africa at 1.2%.^[42] Significant risks are also associated with invasive procedures, assisted delivery, and dental care in this area of the world.^[42]

People giving or receiving tattoos, piercings, and scarification are theoretically at risk of infection but no confirmed cases have been documented.^[43] It is not possible for mosquitoes or other insects to transmit HIV.^[44]

Mother-to-child

HIV can be transmitted from mother to child during pregnancy, during delivery, or through breast milk.^[45]^[46] This is the third most common way way in which HIV is transmitted globally.^[2] In the absence of treatment, the risk of transmission before or during birth is around 20% and in those who also breastfeed 35%.^[45] As of 2008, vertical transmission accounted for about 90% of cases of HIV in children.^[45] With appropriate treatment the risk of mother-to-child infection can be reduced to about 1%.^[45] Preventive treatment involves the mother taking antiretroviral during pregnancy and delivery, an elective caesarean section, avoiding breastfeeding, and administering antiretroviral drugs to the newborn.^[47] Many of these measures are however not available in the developing world.^[47] If blood contaminates food during pre-chewing it may pose a risk of transmission.^[43]

Virology

A circular structure with purple structures coming out of it and a number of objects inside the circle representing different aspects of the virus — A diagram showing the structure of HIV virus

HIV is the cause of the spectrum of disease known as HIV/AIDS. HIV is a retrovirus that primarily infects components of the human immune system such as CD4⁺ T cells, macrophages and dendritic cells. It directly and indirectly destroys CD4⁺ T cells.^[48]

HIV is a member of the genus Lentivirus,^[49] part of the family of Retroviridae.^[50] Lentiviruses share many morphological and biological characteristics. Many species of mammals are infected by lentiviruses, which are characteristically responsible for long-duration illnesses with a long incubation period.^[51] Lentiviruses are transmitted as single-stranded, positive-sense, enveloped RNA viruses. Upon entry into the target cell, the viral RNA genome is converted (reverse transcribed) into double-stranded DNA by a virally encoded reverse transcriptase that is transported along with the viral genome in the virus particle. The resulting viral DNA is then imported into the cell nucleus and integrated into the cellular DNA by a virally encoded integrase and host co-factors.^[52] Once integrated, the virus may become latent, allowing the virus and its host cell to avoid detection by the immune system.^[53] Alternatively, the virus may be transcribed, producing new RNA genomes and viral proteins that are packaged and released from the cell as new virus particles that begin the replication cycle anew.^[54]

Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that was originally discovered (and initially referred to also as LAV or HTLV-III). It is more virulent, more infective,^[55] and is the cause of the majority of HIV infections globally. The lower infectivity of HIV-2 as compared with HIV-1 implies that fewer people exposed to HIV-2 will be infected per exposure. Because of its relatively poor capacity for transmission, HIV-2 is largely confined to West Africa.^[56]

Pathophysiology

A large round blue object with a smaller red object attached to it. Multiple small green spots are speckled over both. — Scanning electron micrograph of HIV-1, colored green, budding from a cultured lymphocyte.

After the virus enters the body there is a period of rapid viral replication, leading to an abundance of virus in the peripheral blood. During primary infection, the level of HIV may reach several million virus particles per milliliter of blood.^[57] This response is accompanied by a marked drop in the number of circulating CD4⁺ T cells. The acute viremia is almost invariably associated with activation of CD8⁺ T cells, which kill HIV-infected cells, and subsequently with antibody production, or seroconversion. The CD8⁺ T cell response is thought to be important in controlling virus levels, which peak and then decline, as the CD4⁺ T cell counts recover. A good CD8⁺ T cell response has been linked to slower disease progression and a better prognosis, though it does not eliminate the virus.^[58]

The pathophysiology of AIDS is complex.^[59] Ultimately, HIV causes AIDS by depleting CD4⁺ T cells. This weakens the immune system and allows opportunistic infections. T cells are essential to the immune response and without them, the body cannot fight infections or kill cancerous cells. The mechanism of CD4⁺ T cell depletion differs in the acute and chronic phases.^[60] During the acute phase, HIV-induced cell lysis and killing of infected cells by cytotoxic T cells accounts for CD4⁺ T cell depletion, although apoptosis may also be a factor. During the chronic phase, the consequences of generalized immune activation coupled with the gradual loss of the ability of the immune system to generate new T cells appear to account for the slow decline in CD4⁺ T cell numbers.^[61]

Although the symptoms of immune deficiency characteristic of AIDS do not appear for years after a person is infected, the bulk of CD4⁺ T cell loss occurs during the first weeks of infection, especially in the intestinal mucosa, which harbors the majority of the lymphocytes found in the body.^[62] The reason for the preferential loss of mucosal CD4⁺ T cells is that the majority of mucosal CD4⁺ T cells express the CCR5 protein which HIV uses as a co-receptor to gain access to the cells, whereas only a small fraction of CD4⁺ T cells in the bloodstream do so.^[63]

HIV seeks out and destroys CCR5 expressing CD4⁺ T cells during acute infection.^[64] A vigorous immune response eventually controls the infection and initiates the clinically latent phase. CD4⁺ T cells in mucosal tissues remain particularly affected.^[64] Continuous HIV replication results in a state of generalized immune activation persisting throughout the chronic phase.^[65] Immune activation, which is reflected by the increased activation state of immune cells and release of pro-inflammatory cytokines, results from the activity of several HIV gene products and the immune response to ongoing HIV replication. It is also linked to the breakdown of the immune surveillance system of the gastrointestinal mucosal barrier caused by the depletion of mucosal CD4⁺ T cells during the acute phase of disease.^[66]

Diagnosis

A graph with two lines. One in blue moves from high on the right to low on the left with a brief rise in the middle. The second line in red moves from zero to very high, then drops to low and gradually rises to high again — A generalized graph of the relationship between HIV copies (viral load) and CD4⁺ T cell counts over the average course of untreated HIV infection.
CD4⁺ T Lymphocyte count (cells/mm³)

HIV RNA copies per mL of plasma

HIV/AIDS is diagnosed via laboratory testing and then staged based on the presence of certain signs or symptoms.^[11] HIV testing is recommended for all those at high risk, which includes anyone diagnosed with a sexually transmitted illness.^[14] In many areas of the world a third of HIV carriers only discover they are infected at an advanced stage of the disease when AIDS or severe immunodeficiency has become apparent.^[14]

HIV testing

Most people infected with HIV develop specific antibodies (i.e. seroconvert) within three to twelve weeks of the initial infection.^[13] Diagnosis of primary HIV before seroconversion is done by measuring HIV-RNA or p24 antigen.^[13] Positive results obtained by antibody or PCR testing are confirmed either by a different antibody or by PCR.^[11]

Antibody tests in children younger than 18 months are typically inaccurate due to the continued presence of maternal antibodies.^[67] Thus HIV infection can only be diagnosed by PCR testing for HIV RNA or DNA, or via testing for the p24 antigen.^[11] Much of the world lacks access to reliable PCR testing and many places simply wait until either symptoms develop or the child is old enough for accurate antibody testing.^[67] In sub-Saharan Africa as of 2007–2009 between 30–70% of the population was aware of their HIV status.^[68] In 2009 between four and 42% of the population was tested.^[68] These figures represent substantial increases from ten years previous.^[68]

Classifications of HIV infection

Two main clinical staging systems are used to classify HIV and HIV-related disease for surveillance purposes: the WHO disease staging system for HIV infection and disease,^[11] and the CDC classification system for HIV infection.^[69] The CDC's classification system is more frequently adopted in developed countries. Since the World Health WHO's staging system does not require laboratory tests, it is suited to the resource-restricted conditions encountered in developing countries, where it can also be used to help guide clinical management. Despite their differences, the two systems allow comparison for statistical purposes.^[9]^[11]^[69]

The World Health Organization first proposed a definition for AIDS in 1986.^[11] Since then, the WHO classification has been updated and expanded several times, with the most recent version being published in 2007.^[11] The WHO system uses the following categories:

Primary HIV infection: May be either asymptomatic or associated with acute retroviral syndrome.^[11]
Stage I: HIV infection is asymptomatic with a CD4⁺ T cell count (also known as CD4 count) greater than 500/uL.^[11] May include generalized lymph node enlargement.^[11]
Stage II: Mild symptoms which may include minor mucocutaneous manifestations and recurrent upper respiratory tract infections. A CD4 count of less than 500/uL.^[11]
Stage III: Advanced symptoms which may include unexplained chronic diarrhea for longer than a month, severe bacterial infections including tuberculosis of the lung as well as a CD4 count of less than 350/uL.^[11]
Stage IV or AIDS: severe symptoms which includes toxoplasmosis of the brain, candidiasis of the esophagus, Vertebrate trachea, bronchi or lungs and Kaposi's sarcoma. A CD4 count of less than 200/uL.^[11]

The United States Center for Disease Control and Prevention also created a classification system for HIV, and updated it in 2008.^[69] In this system HIV infections are classified based on CD4 count and clinical symptoms,^[69] and describes the infection in three stages:

Stage 1: CD4 count ≥ 500 cells/uL and no AIDS defining conditions
Stage 2: CD4 count 200 to 500 cells/uL and no AIDS defining conditions
Stage 3: CD4 count ≤ 200 cells/uL or AIDS defining conditions
Unknown: if insufficient information is available to make any of the above classifications

For surveillance purposes, the AIDS diagnosis still stands even if, after treatment, the CD4⁺ T cell count rises to above 200 per µL of blood or other AIDS-defining illnesses are cured.^[9]

Prevention

Sexual contact

Consistent condom use reduces the risk of HIV transmission by approximately 80% over the long term.^[70] When one partner of a couple is infected, consistent condom use results in rates of HIV infection for the uninfected person of below 1% per year.^[71] There is some evidence to suggest that female condoms may provide an equivalent level of protection.^[72] Application of a vaginal gel containing tenofovir (a reverse transcriptase inhibitor) immediately before sex seems to reduce infection rates by approximately 40% among African women.^[73] By contrast, use of the spermicide nonoxynol-9 may increase the risk of transmission due to its tendency to cause vaginal and rectal irritation.^[74] Circumcision in Sub-Saharan Africa "reduces the acquisition of HIV by heterosexual men by between 38% and 66% over 24 months".^[75] Based on these studies, the World Health Organization and UNAIDS both recommended male circumcision as a method of preventing female-to-male HIV transmission in 2007.^[76] Whether it protects against male-to-female transmission is disputed^[77]^[78] and whether it is of benefit in developed countries and among men who have sex with men is undetermined.^[79]^[80]^[81] Some experts fear that a lower perception of vulnerability among circumcised men may result in more sexual risk-taking behavior, thus negating its preventive effects.^[82] Women who have undergone female genital cutting have an increased risk of HIV.^[83]

Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk.^[84] Evidence for a benefit from peer education is equally poor.^[85] Comprehensive sexual education provided at school may decrease high risk behavior.^[86] A substantial minority of young people continues to engage in high-risk practices despite knowing about HIV/AIDS, underestimating their own risk of becoming infected with HIV.^[87] It is not known if treating other sexually transmitted infections is effective in preventing HIV.^[34]

Pre-exposure

Treating people with HIV whose CD4 count ≥ 350cells/µL with antiretrovirals protects 96% of their partners from infection.^[88] Pre-exposure prophylaxis with a daily dose of the medications tenofovir, with or without emtricitabine, is effective in a number of groups including: men who have sex with men, couples where one is HIV positive, and young heterosexuals in Africa.^[73]

Universal precautions within the health care environment are believed to be effective in decreasing the risk of HIV.^[89] Intravenous drug use is an important risk factor and harm reduction strategies such as needle-exchange programmes and opioid substitution therapy appear effective in decreasing this risk.^[90]^[91]

Post-exposure

A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV positive blood or genital secretions is referred to as post-exposure prophylaxis.^[92] The use of the single agent zidovudine reduces the risk of subsequent HIV infection fivefold following a needle stick injury.^[92] Treatment is recommended after sexual assault when the perpetrator is known to be HIV positive but is controversial when their HIV status is unknown.^[93] Current treatment regimes typically use lopinavir/ritonavir and lamivudine/zidovudine or emtricitabine/tenofovir and may decrease the risk further.^[92] The duration of treatment is usually four weeks^[94] and is frequently associated with adverse effects (with zidovudine in about 70% of cases, including nausea in 24%, fatigue in 22%, emotional distress in 13%, and headaches in 9%).^[25]

Mother-to-child

Programs to prevent the vertical transmission of HIV (from mothers to children) can reduce rates of transmission by 92–99%.^[45]^[90] This primarily involves the use of a combination of antiviral medications during pregnancy and after birth in the infant and potentially includes bottle feeding rather than breastfeeding.^[45]^[95] If replacement feeding is acceptable, feasible, affordable, sustainable, and safe, mothers should avoid breastfeeding their infants; however exclusive breastfeeding is recommended during the first months of life if this is not the case.^[96] If exclusive breastfeeding is carried out, the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission.^[97]

Vaccination

As of 2012 there is no effective vaccine for HIV or AIDS.^[98] A single trial of the vaccine RV 144 published in 2009 found a partial reduction in the risk of transmission of roughly 30%, stimulating some hope in the research community of developing a truly effective vaccine.^[99] Further trials of the RV 144 vaccine are ongoing.^[100]^[101]

Management

There is currently no cure or effective HIV vaccine. Treatment consists of high active antiretroviral therapy (HAART) which slows progression of the disease^[102] and as of 2010 more than 6.6 million people were taking them in low and middle income countries.^[7] Treatment also includes preventative and active treatment of opportunistic infections. A case of a two-year-old child in Mississippi being cured of HIV was documented in 2012. ^[103]

Antiviral therapy

Current HAART options are combinations (or "cocktails") consisting of at least three medications belonging to at least two types, or "classes," of antiretroviral agents.^[104] Initially treatment is typically a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside analogue reverse transcriptase inhibitors (NRTIs).^[104] Typical NRTIs include: zidovudine (AZT) or tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC).^[104] Combinations of agents which include a protease inhibitors (PI) are used if the above regime loses effectiveness.^[104]

When to start antiretroviral therapy is subject to debate.^[14]^[105] Both the World Health Organization, European guidelines and the United States recommends antiretrovirals in all adolescents, adults and pregnant women with a CD4 count less than 350/uL or those with symptoms regardless of CD4 count.^[14]^[104] This is supported by the fact that beginning treatment at this level reduces the risk of death.^[106] The United States in addition recommends them for all HIV-infected people regardless of CD4 count or symptoms, however makes this recommendation with less confidence for those with higher counts.^[107] While the WHO also recommends treatment in those who are co-infected with tuberculosis and those with chronic active hepatitis B.^[104] Once treatment is begun it is recommended that it is continued without breaks or "holidays".^[14] Many people are diagnosed only after the moment treatment ideally should have begun.^[14] The desired outcome of treatment is a long term plasma HIV-RNA count below 50 copies/mL.^[14] Levels to determine if treatment is effective are initially recommended after four weeks and once levels fall below 50 copies/mL checks every three to six months are typically adequate.^[14] Inadequate control is deemed to be greater than 400 copies/mL.^[14] Based on these criteria treatment is effective in more than 95% of people during the first year.^[14]

Benefits of treatment include a decreased risk of progression to AIDS and a decreased risk of death.^[108] In the developing world treatment also improves physical and mental health.^[109] With treatment there is a 70% reduced risk of acquiring tuberculosis.^[104] Additional benefits include a decreased risk of transmission of the disease to sexual partners and a decrease in mother-to-child transmission.^[104] The effectiveness of treatment depends to a large part on compliance.^[14] Reasons for non-adherence include: poor access to medical care,^[110] inadequate social supports, mental illness and drug abuse.^[111] As well the complexity of treatment regimens (due to pill numbers and dosing frequency) and adverse effects may create intentional non-adherence.^[112] Adherence is however just as good in low income as high income countries.^[113]

Specific adverse events are related to the agent taken.^[114] Some relatively common ones include: lipodystrophy syndrome, dyslipidemia, and diabetes mellitus especially with protease inhibitors.^[9] Other common symptoms include: diarrhea,^[114]^[115] and an increased risk of cardiovascular disease.^[116] Adverse effects are however less with some of the newer recommended treatments.^[14] Cost may be an issue with some medications being expensive^[117] however as of 2010, 47% of those who needed them were taking them in low and middle income countries.^[7] Certain medications may be associated with birth defects and thus not suitable for women hoping to have children.^[14]

Treatment recommendations for children are slightly different from those for adults. In the developing world, as of 2010, 23% of children who were in need of treatment had access.^[118] Both the World Health Organization and the United States recommend treatment for all children less than twelve months of age.^[119]^[120] The United States recommends in those between one year and five years of age treatment in those with HIV RNA counts of greater than 100,000 copies/mL, and in those more than five years treatments when CD4 counts are less than 500/ul.^[119]

Opportunistic infections

Measures to prevent opportunistic infections are effective in many people with HIV/AIDS. Treatment with antivirals often improves current, as well as decreases the risk of future, opportunistic infections.^[114] Vaccination against hepatitis A and B is advised for all people at risk of HIV before they become infected however may also be given after infection.^[121] Trimethoprim/sulfamethoxazole prophylaxis between four to six weeks of age and finishing breastfeeding in infants born to HIV positive mothers is recommended in resource limited settings.^[118] It is also recommended to prevent PCP when peoples' CD4 count is below 200 cells/uL and in those who have or have previously had PCP.^[122] People with substantial immunosuppression are also advised to receive prophylactic therapy for toxoplasmosis and Cryptococcus meningitis.^[123] Appropriate preventive measures have reduced the rate of these infections by 50% between 1992 and 1997.^[124]

Alternative medicine

In the US, approximately 60% of people with HIV use various forms of complementary or alternative medicine.^[125] The effectiveness of most of these therapies however has not been established.^[126] With respect to dietary advice and AIDS some evidence has shown a benefit from micronutrient supplements.^[127] Evidence for supplementation with selenium is mixed with some tentative evidence of benefit.^[128] There is some evidence that vitamin A supplementation in children reduces mortality and improves growth.^[127] In Africa in nutritionally compromised pregnant and lactating women a multivitamin supplementation has improved outcomes for both mothers and children.^[127] Dietary intake of micronutrients at RDA levels by HIV-infected adults is recommended by the World Health Organization.^[129]^[130] The WHO further states that several studies indicate that supplementation of vitamin A, zinc, and iron can produce adverse effects in HIV positive adults.^[130] There is not enough evidence to support the use of herbal medicines.^[131]

Prognosis

HIV/AIDS has become a chronic rather than an acutely fatal disease in many areas of the world.^[132] Prognosis varies between people, and both the CD4 count and viral load are useful for predicted outcomes.^[13] Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype.^[133] After the diagnosis of AIDS, if treatment is not available, survival ranges between 6 and 19 months.^[134]^[135] HAART and appropriate prevention of opportunistic infections reduces the death rate by 80%, and raises the life expectancy for a newly diagnosed young adult to 20–50 years.^[132]^[136]^[137] This is between two thirds^[136] and nearly that of the general population.^[14]^[138] If treatment is started late in the infection, prognosis is not as good:^[14] for example, if treatment is begun following the diagnosis of AIDS, life expectancy is ~10–40 years.^[14]^[132] Half of infants born with HIV die before two years of age without treatment.^[118]

The primary causes of death from HIV/AIDS are opportunistic infections and cancer, both of which are frequently the result of the progressive failure of the immune system.^[124]^[139] Risk of cancer appears to increase once the CD 4 count gets below 500/uL.^[14] The rate of clinical disease progression varies widely between individuals and has been shown to be affected by a number of factors such as a person's susceptibility and immune function;^[140] their access to health care and the presence of co-infections;^[134]^[141] as well as the particular strain (or strains) of the virus involved.^[142]^[143]

Tuberculosis co-infection is one of the leading causes of sickness and death in those with HIV/AIDS being present in a third of all HIV infected people and resulting in 25% of HIV related deaths.^[144] HIV is also one of the most important risk factors for tuberculosis.^[145] Hepatitis C is another very common co-infection where each disease increases the progression of the other.^[146] The two most common cancers associated with HIV/AIDS are Kaposi's sarcoma and AIDS-related non-Hodgkin's lymphoma.^[139]

Even with anti-retroviral treatment, over the long term HIV-infected people may experience neurocognitive disorders,^[147] osteoporosis,^[148] neuropathy,^[149] cancers,^[150]^[151] nephropathy,^[152] and cardiovascular disease.^[115] It is not clear whether these conditions result from the HIV infection itself or are adverse effects of treatment.

Epidemiology

HIV/AIDS is a global pandemic.^[154] As of 2010 approximately 34 million people have HIV worldwide.^[7] Of these approximately 16.8 million are women and 3.4 million are less than 15 years old.^[7] It resulted in about 1.8 million death in 2010, down from 3.1 million in 2001.^[7]

Sub-Saharan Africa is the region most affected. In 2010, an estimated 68% (22.9 million) of all HIV cases and 66% of all deaths (1.2 million) occurred in this region.^[155] This means that about 5% of the adult population is infected^[156] and it is believed to be the cause of 10% of all deaths in children.^[157] Here in contrast to other regions women compose nearly 60% of cases.^[155] South Africa has the largest population of people with HIV of any country in the world at 5.9 million.^[155] Life expectancy has fallen in the worst-affected countries due to HIV/AIDS; for example, in 2006 it was estimated that it had dropped from 65 to 35 years in Botswana.^[8]

South & South East Asia is the second most affected; in 2010 this region contained an estimated 4 million cases or 12% of all people living with HIV resulting in approximately 250,000 deaths.^[156] Approximately 2.4 million of these cases are in India.^[155] Prevalence is lowest in Western and Central Europe at 0.2% and East Asia at 0.1%.^[156]

In 2008 in the United States approximately 1.2 million people were living with HIV, resulting in about 17,500 deaths. The Centre for Disease Control and Prevention estimated that in 2008 20% of infected Americans were unaware of their infection.^[158] In the United Kingdom as of 2009 there where approximately 86,500 cases which resulted in 516 deaths.^[159] In Canada as of 2008 there were about 65,000 cases which results in 53 deaths.^[160] Between the first recognition of AIDS in 1981 and 2009 it has led to nearly 30 million deaths.^[6]

History

Discovery

AIDS was first clinically observed in 1981 in the United States.^[22] The initial cases were a cluster of injecting drug users and homosexual men with no known cause of impaired immunity who showed symptoms of Pneumocystis carinii pneumonia (PCP), a rare opportunistic infection that was known to occur in people with very compromised immune systems.^[161] Soon thereafter, an unexpected number of gay men developed a previously rare skin cancer called Kaposi's sarcoma (KS).^[162]^[163] Many more cases of PCP and KS emerged, alerting U.S. Centers for Disease Control and Prevention (CDC) and a CDC task force was formed to monitor the outbreak.^[164]

In the early days, the CDC did not have an official name for the disease, often referring to it by way of the diseases that were associated with it, for example, lymphadenopathy, the disease after which the discoverers of HIV originally named the virus.^[165]^[166] They also used Kaposi's Sarcoma and Opportunistic Infections, the name by which a task force had been set up in 1981.^[167] At one point, the CDC coined the phrase "the 4H disease", since the syndrome seemed to affect Haitians, homosexuals, hemophiliacs, and heroin users.^[168] In the general press, the term "GRID", which stood for gay-related immune deficiency, had been coined.^[169] However, after determining that AIDS was not isolated to the gay community,^[167] it was realized that the term GRID was misleading and the term AIDS was introduced at a meeting in July 1982.^[170] By September 1982 the CDC started referring to the disease as AIDS.^[171]

In 1983, two separate research groups led by Robert Gallo and Luc Montagnier independently declared that a novel retrovirus may have been infecting AIDS patients, and published their findings in the same issue of the journal Science.^[172]^[173] Gallo claimed that a virus his group had isolated from an AIDS patient was strikingly similar in shape to other human T-lymphotropic viruses (HTLVs) his group had been the first to isolate. Gallo's group called their newly isolated virus HTLV-III. At the same time, Montagnier's group isolated a virus from a patient presenting with swelling of the lymph nodes of the neck and physical weakness, two characteristic symptoms of AIDS. Contradicting the report from Gallo's group, Montagnier and his colleagues showed that core proteins of this virus were immunologically different from those of HTLV-I. Montagnier's group named their isolated virus lymphadenopathy-associated virus (LAV).^[164] As these two viruses turned out to be the same, in 1986, LAV and HTLV-III were renamed HIV.^[174]

Origins

Both HIV-1 and HIV-2 are believed to have originated in non-human primates in West-central Africa and were transferred to humans in the early 20th century.^[4] HIV-1 appears to have originated in southern Cameroon through the evolution of SIV(cpz), a simian immunodeficiency virus (SIV) that infects wild chimpanzees (HIV-1 descends from the SIVcpz endemic in the chimpanzee subspecies Pan troglodytes troglodytes).^[175]^[176] The closest relative of HIV-2 is SIV(smm), a virus of the sooty mangabey (Cercocebus atys atys), an Old World monkey living in litoral West Africa (from southern Senegal to western Côte d'Ivoire).^[56] New World monkeys such as the owl monkey are resistant to HIV-1 infection, possibly because of a genomic fusion of two viral resistance genes.^[177] HIV-1 is thought to have jumped the species barrier on at least three separate occasions, giving rise to the three groups of the virus, M, N, and O.^[178]

There is evidence that humans who participate in bushmeat activities, either as hunters or as bushmeat vendors, commonly acquire SIV.^[179] However, SIV is a weak virus which is typically suppressed by the human immune system within weeks of infection. It is thought that several transmissions of the virus from individual to individual in quick succession are necessary to allow it enough time to mutate into HIV.^[180] Furthermore, due to its relatively low person-to-person transmission rate, SIV can only spread throughout the population in the presence of one or more of high-risk transmission channels, which are thought to have been absent in Africa prior to the 20th century.

Specific proposed high-risk transmission channels, allowing the virus to adapt to humans and spread throughout the society, depend on the proposed timing of the animal-to-human crossing. Genetic studies of the virus suggest that the most recent common ancestor of the HIV-1 M group dates back to circa 1910.^[181] Proponents of this dating link the HIV epidemic with the emergence of colonialism and growth of large colonial African cities, leading to social changes, including a higher degree of sexual promiscuity, the spread of prostitution, and the accompanying high frequency of genital ulcer diseases (such as syphilis) in nascent colonial cities.^[182] While transmission rates of HIV during vaginal intercourse are low under regular circumstances, they are increased many fold if one of the partners suffers from an sexually transmitted infection resulting in genital ulcers. Early 1900s colonial cities were notable due to their high prevalence of prostitution and genital ulcers, to the degree that, as of 1928, as many as 45% of female residents of eastern Kinshasa were thought to have been prostitutes, and, as of 1933, around 15% of all residents of the same city were infected by one of the forms of syphilis.^[182]

An alternative view holds that unsafe medical practices in Africa during years following World War II, such as unsterile reuse of single use syringes during mass vaccination, antibiotic and anti-malaria treatment campaigns, were the initial vector that allowed the virus to adapt to humans and spread.^[180]^[183]^[184]

The earliest well documented case of HIV in a human dates back to 1959 in the Congo.^[185] The virus may have been present in the United States as early as 1966,^[186] but the vast majority of infections occurring outside sub-Saharan Africa (including the U.S.) can be traced back to a single unknown individual who got infected with HIV in Haiti and then brought the infection to the United States some time around 1969.^[187] The epidemic then rapidly spread among high-risk groups (initially, sexually promiscuous men who have sex with men). By 1978, the prevalence of HIV-1 among gay male residents of New York and San Francisco was estimated at 5%, suggesting that several thousand individuals in the country had been infected.^[187]

Society and culture

Stigma

A teenage male with the hand of another resting on his left shoulder smiling for the camera — Ryan White became a poster child for HIV after being expelled from school because he was infected.

AIDS stigma exists around the world in a variety of ways, including ostracism, rejection, discrimination and avoidance of HIV infected people; compulsory HIV testing without prior consent or protection of confidentiality; violence against HIV infected individuals or people who are perceived to be infected with HIV; and the quarantine of HIV infected individuals.^[188] Stigma-related violence or the fear of violence prevents many people from seeking HIV testing, returning for their results, or securing treatment, possibly turning what could be a manageable chronic illness into a death sentence and perpetuating the spread of HIV.^[189]

AIDS stigma has been further divided into the following three categories:

Instrumental AIDS stigma—a reflection of the fear and apprehension that are likely to be associated with any deadly and transmissible illness.^[190]
Symbolic AIDS stigma—the use of HIV/AIDS to express attitudes toward the social groups or lifestyles perceived to be associated with the disease.^[190]
Courtesy AIDS stigma—stigmatization of people connected to the issue of HIV/AIDS or HIV- positive people.^[191]

Often, AIDS stigma is expressed in conjunction with one or more other stigmas, particularly those associated with homosexuality, bisexuality, promiscuity, prostitution, and intravenous drug use.^[192]

In many developed countries, there is an association between AIDS and homosexuality or bisexuality, and this association is correlated with higher levels of sexual prejudice such as anti-homosexual/bisexual attitudes.^[193] There is also a perceived association between AIDS and all male-male sexual behavior, including sex between uninfected men.^[190] However, the dominant mode of spread worldwide for HIV remains heterosexual transmission.^[194]

Economic impact

HIV/AIDS affects the economics of both individuals and countries.^[157] The gross domestic product of the most affected countries have decreased due to the lack of human capital.^[157]^[195] Without proper nutrition, health care and medicine, large numbers of people die from AIDS-related complications. They will not only be unable to work, but will also require significant medical care. It is estimated that as of 2007 there where 12 million AIDS orphans.^[157] Many are cared for by elderly grandparents.^[196]

By affecting mainly young adults, AIDS reduces the taxable population, in turn reducing the resources available for public expenditures such as education and health services not related to AIDS resulting in increasing pressure for the state's finances and slower growth of the economy. This results in a slower growth of the tax base, an effect that is reinforced if there are growing expenditures on treating the sick, training (to replace sick workers), sick pay and caring for AIDS orphans. This is especially true if the sharp increase in adult mortality shifts the responsibility and blame from the family to the government in caring for these orphans.^[196]

At the household level, AIDS results in both the loss of income but also increased spending on healthcare. A study in Côte d'Ivoire showed that households with an HIV/AIDS patient, spent twice as much on medical expenses as other households. This additional expenditure also leaves less income to spend on education and other personal or family investment.^[197]

Religion and AIDS

The topic of religion and AIDS has become highly controversial in the past twenty years, primarily because some religious authorities have publicly declared their opposition to the use of condoms.^[198]^[199] The religious approach to prevent the spread of AIDS according to a report by American health expert Matthew Hanley titled The Catholic Church and the Global Aids Crisis argues that cultural changes are needed including a re-emphasis on fidelity within marriage and sexual abstinence outside of it.^[199]

Some religious organisations have claimed that prayer can cure HIV/AIDS. In 2011, the BBC reported that some churches in London were claiming that prayer would cure AIDS, and the Hackney-based Centre for the Study of Sexual Health and HIV reported that several people stopped taking their medication, sometimes on the direct advice of their pastor, leading to a number of deaths.^[200] The Synagogue Church Of All Nations advertise an "anointing water" to promote God's healing, although the group deny advising people to stop taking medication.^[200]

Media portrayal

One of the first high profile cases of AIDS was the American Rock Hudson, a gay actor who had been married and divorced earlier in life, who died on 2 October 1985 having announced that he was suffering from the virus on 25 July that year. He had been diagnosed during 1984.^[201] A notable British casualty of AIDS that year was Nicholas Eden, a gay politician and son of the late prime minister Anthony Eden.^[202] On November 24, 1991, the virus claimed the life of British rock star Freddie Mercury, lead singer of the band Queen, who died from an AIDS related illness having only revealed the diagnosis on the previous day.^[203] However he had been diagnosed as HIV positive during 1987.^[204] One of the first high profile heterosexual cases of the virus was Arthur Ashe, the American tennis player. He was diagnosed as HIV positive on 31 August 1988, having contracted the virus from blood transfusions during heart surgery earlier in the 1980s. Further tests within 24 hours of the initial diagnosis revealed that Ashe had AIDS, but he did not tell the public about his diagnosis until April 1992.^[205] He died, aged 49, as a result on 6 February 1993.^[206]

Therese Frare's photograph of gay activist David Kirby, as he lay dying from AIDS while surrounded by family, was taken in April 1990. LIFE magazine said the photo became the one image "most powerfully identified with the HIV/AIDS epidemic." The photo was displayed in LIFE magazine, was the winner of the World Press Photo, and acquired worldwide notoriety after being used in a United Colors of Benetton advertising campaign in 1992.^[207]

Denial, conspiracies, and misconceptions

A small group of individuals continue to dispute the connection between HIV and AIDS,^[208] the existence of HIV itself, or the validity of HIV testing and treatment methods.^[209]^[210] These claims, known as AIDS denialism, have been examined and rejected by the scientific community.^[211] However, they have had a significant political impact, particularly in South Africa, where the government's official embrace of AIDS denialism (1999-2005) was responsible for its ineffective response to that country's AIDS epidemic, and has been blamed for hundreds of thousands of avoidable deaths and HIV infections.^[212]^[213]^[214] Operation INFEKTION was a worldwide Soviet active measures operation to spread information that the United States had created HIV/AIDS. Surveys show that a significant number of people believed – and continue to believe – in such claims.^[215]

There are many misconceptions about HIV and AIDS. Three of the most common are that AIDS can spread through casual contact, that sexual intercourse with a virgin will cure AIDS, and that HIV can infect only homosexual men and drug users. Other misconceptions are that any act of anal intercourse between two uninfected gay men can lead to HIV infection, and that open discussion of homosexuality and HIV in schools will lead to increased rates of homosexuality and AIDS.^[216]^[217]

Research

Research to improve current treatments includes decreasing side effects of current drugs, further simplifying drug regimens to improve adherence, and determining better sequences of regimens to manage drug resistance. However, only a vaccine is thought to be able to halt the pandemic. This is because a vaccine would cost less, thus being affordable for developing countries, and would not require daily treatment.^[218] However, after over 20 years of research, HIV-1 remains a difficult target for a vaccine,^[218]^[219] and there is as yet no cure.

Stem cell transplantation

In 2007, Timothy Ray Brown,^[220] a 40-year-old HIV-positive man, also known as "the Berlin Patient", was given a stem cell transplant as part of his treatment for acute myeloid leukemia (AML).^[221] A second transplant was made a year later after a relapse. The donor was chosen not only for genetic compatibility but also for being homozygous for a CCR5-Δ32 mutation that confers resistance to HIV infection.^[222]^[223] After 20 months without antiretroviral drug treatment, it was reported that HIV levels in Brown's blood, bone marrow, and bowel were below the limit of detection.^[223] The virus remained undetectable over three years after the first transplant.^[221] Although the researchers and some commentators have characterized this result as a cure, others suggest that the virus may remain hidden in tissues^[224] such as the brain (which acts as a viral reservoir).^[225] Stem cell treatment remains investigational because of its anecdotal nature, the disease and mortality risk associated with stem cell transplants, and the difficulty of finding suitable donors.^[224]^[226]

Immunomodulatory agents

Complementing efforts to control viral replication, immunotherapies that may assist in the recovery of the immune system have been explored in past and ongoing trials, including IL-2 and IL-7.^[227]

The failure of vaccine candidates to protect against HIV infection and progression to AIDS has led to a renewed focus on the biological mechanisms responsible for HIV latency. A limited period of therapy combining anti-retrovirals with drugs targeting the latent reservoir may one day allow for total eradication of HIV infection.^[228] Researchers have discovered an abzyme that can destroy the protein gp120 CD4 binding site. This protein is common to all HIV variants as it is the attachment point for B lymphocytes and subsequent compromising of the immune system.^[229]

Notes

^ Sepkowitz KA (2001). "AIDS—the first 20 years". N. Engl. J. Med. 344 (23): 1764–72. doi:10.1056/NEJM200106073442306. PMID 11396444. {{cite journal}}: Unknown parameter |month= ignored (help)
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j Markowitz, edited by William N. Rom ; associate editor, Steven B. (2007). Environmental and occupational medicine (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 745. ISBN 978-0-7817-6299-1. {{cite book}}: |first= has generic name (help)CS1 maint: multiple names: authors list (link)
^ "HIV and Its Transmission". Centers for Disease Control and Prevention. 2003. Archived from the original on February 4, 2005. Retrieved May 23, 2006.
^ ^a ^b Sharp, PM (2011 Sep). "Origins of HIV and the AIDS Pandemic". Cold Spring Harbor perspectives in medicine. 1 (1): a006841. doi:10.1101/cshperspect.a006841. PMC 3234451. PMID 22229120. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Gallo RC (2006). "A reflection on HIV/AIDS research after 25 years". Retrovirology. 3: 72. doi:10.1186/1742-4690-3-72. PMC 1629027. PMID 17054781.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ ^a ^b "Global Report Fact Sheet" (PDF). UNAIDS. 2010.
^ ^a ^b ^c ^d ^e ^f UNAIDS 2011 pg. 1–10
^ ^a ^b Kallings LO (2008). "The first postmodern pandemic: 25 years of HIV/AIDS". J Intern Med. 263 (3): 218–43. doi:10.1111/j.1365-2796.2007.01910.x. PMID 18205765.(subscription required)
^ ^a ^b ^c ^d ^e ^f Mandell, Bennett, and Dolan (2010). Chapter 121.
^ ^a ^b ^c "Stages of HIV". U.S. Department of Health & Human Services. December 2010. Retrieved June 13, 2012.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children (PDF). Geneva: World Health Organization. 2007. pp. 6–16. ISBN 978-92-4-159562-9.
^ Diseases and disorders. Tarrytown, NY: Marshall Cavendish. 2008. p. 25. ISBN 978-0-7614-7771-6.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ Mandell, Bennett, and Dolan (2010). Chapter 118.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s Vogel, M (2010 Jul). "The treatment of patients with HIV". Deutsches Ärzteblatt international. 107 (28–29): 507–15, quiz 516. doi:10.3238/arztebl.2010.0507. PMC 2915483. PMID 20703338. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Evian, Clive (2006). Primary HIV/AIDS care: a practical guide for primary health care personnel in a clinical and supportive setting (Updated 4th ed.). Houghton [South Africa]: Jacana. p. 29. ISBN 978-1-77009-198-6.
^ Radiology of AIDS. Berlin [u.a.]: Springer. 2001. p. 19. ISBN 978-3-540-66510-6. {{cite book}}: |first= missing |last= (help)CS1 maint: multiple names: authors list (link)
^ Elliott, Tom (2012). Lecture Notes: Medical Microbiology and Infection. John Wiley & Sons. p. 273. ISBN 978-1-118-37226-5.
^ ^a ^b Blankson, JN (2010 Mar). "Control of HIV-1 replication in elite suppressors". Discovery medicine. 9 (46): 261–6. PMID 20350494. {{cite journal}}: Check date values in: |date= (help)
^ Walker, BD (2007 Aug-Sep). "Elite control of HIV Infection: implications for vaccines and treatment". Topics in HIV medicine : a publication of the International AIDS Society, USA. 15 (4): 134–6. PMID 17720999. {{cite journal}}: Check date values in: |date= (help)
^ Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA (2003). "Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa". Clin. Infect. Dis. 36 (5): 656–662. doi:10.1086/367655. PMID 12594648.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Chu, C (February 15, 2011). "Complications of HIV infection: a systems-based approach". American family physician. 83 (4): 395–406. PMID 21322514. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b ^c ^d ^e Mandell, Bennett, and Dolan (2010). Chapter 169.
^ "AIDS". MedlinePlus. A.D.A.M. Retrieved June 14, 2012.
^ Sestak K (2005). "Chronic diarrhea and AIDS: insights into studies with non-human primates". Curr. HIV Res. 3 (3): 199–205. doi:10.2174/1570162054368084. PMID 16022653. {{cite journal}}: Unknown parameter |month= ignored (help)
^ ^a ^b ^c Kripke, C (August 1, 2007). "Antiretroviral prophylaxis for occupational exposure to HIV". American family physician. 76 (3): 375–6. PMID 17708137.
^ van der Kuyl, AC (September 24, 2007). "Identifying HIV-1 dual infections". Retrovirology. 4: 67. doi:10.1186/1742-4690-4-67. PMC 2045676. PMID 17892568. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
^ ^a ^b "HIV in the United States: An Overview". Center for Disease Control and Prevention. March 2012.
^ ^a ^b ^c ^d ^e ^f ^g Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M (2009). "Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies". The Lancet Infectious Diseases. 9 (2): 118–129. doi:10.1016/S1473-3099(09)70021-0. PMID 19179227. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Beyrer, C (2012 Jul 28). "Global epidemiology of HIV infection in men who have sex with men". Lancet. 380 (9839): 367–77. doi:10.1016/S0140-6736(12)60821-6. PMID 22819660. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Yu, M (2010 Aug). "Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes". Expert opinion on biological therapy. 10 (8): 1181–95. doi:10.1517/14712598.2010.496776. PMC 2904634. PMID 20624114. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Stürchler, Dieter A. (2006). Exposure a guide to sources of infections. Washington, DC: ASM Press. p. 544. ISBN 9781555813765.
^ al.], edited by Richard Pattman ... [et (2010). Oxford handbook of genitourinary medicine, HIV, and sexual health (2nd ed. ed.). Oxford: Oxford University Press. p. 95. ISBN 9780199571666. {{cite book}}: |edition= has extra text (help); |first= has generic name (help)
^ ^a ^b ^c Dosekun, O (2010 Jul). "An overview of the relative risks of different sexual behaviours on HIV transmission". Current opinion in HIV and AIDS. 5 (4): 291–7. doi:10.1097/COH.0b013e32833a88a3. PMID 20543603. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b Ng, BE (March 16, 2011). Butler, Lisa M (ed.). "Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection". Cochrane database of systematic reviews (Online) (3): CD001220. doi:10.1002/14651858.CD001220.pub3. PMID 21412869. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Anderson, J (2012 Feb). "Women and HIV: motherhood and more". Current opinion in infectious diseases. 25 (1): 58–65. doi:10.1097/QCO.0b013e32834ef514. PMID 22156896. {{cite journal}}: Check date values in: |date= (help)
^ Klimas, N (2008 Jun). "Overview of HIV". Psychosomatic Medicine. 70 (5): 523–30. doi:10.1097/PSY.0b013e31817ae69f. PMID 18541903. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Draughon, JE (2012). "Nonoccupational post exposure prophylaxis following sexual assault in industrialized low-HIV-prevalence countries: a review". Psychology, health & medicine. 17 (2): 235–54. doi:10.1080/13548506.2011.579984. PMID 22372741. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b Baggaley, RF (April 4, 2006). "Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis". AIDS (London, England). 20 (6): 805–12. doi:10.1097/01.aids.0000218543.46963.6d. PMID 16549963. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "Will I need a blood transfusion?" (PDF). NHS patient information. National Health Services. 2011. Retrieved August 29, 2012.
^ UNAIDS 2011 pg. 60–70
^ "Blood safety ... for too few". WHO. 2001. Retrieved January 17, 2006.
^ ^a ^b ^c Reid, SR (August 28, 2009). "Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review". Harm reduction journal. 6: 24. doi:10.1186/1477-7517-6-24. PMC 2741434. PMID 19715601.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ ^a ^b "Basic Information about HIV and AIDS". Center for Disease Control and Prevention. April 2012.
^ "Why Mosquitoes Cannot Transmit AIDS [HIV virus]". Rci.rutgers.edu. Retrieved July 28, 2010.
^ ^a ^b ^c ^d ^e ^f Coutsoudis, A (2010 Oct). "Prevention of vertical transmission of HIV-1 in resource-limited settings". Expert review of anti-infective therapy. 8 (10): 1163–75. doi:10.1586/eri.10.94. PMID 20954881. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "Fluids of transmission". AIDS.gov. United States Department of Health and Human Services. November 1, 2011. Retrieved September 14, 2012.
^ ^a ^b Thorne, C (2007 Jun). "HIV". Seminars in fetal & neonatal medicine. 12 (3): 174–81. doi:10.1016/j.siny.2007.01.009. PMID 17321814. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Alimonti JB, Ball TB, Fowke KR (2003). "Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS". J. Gen. Virol. 84 (7): 1649–1661. doi:10.1099/vir.0.19110-0. PMID 12810858.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ International Committee on Taxonomy of Viruses (2002). "61.0.6. Lentivirus". National Institutes of Health. Archived from the original on April 18, 2006. Retrieved June 25, 2012.
^ International Committee on Taxonomy of Viruses (2002). "61. Retroviridae". National Institutes of Health. Archived from the original on June 29, 2006. Retrieved June 25, 2012.
^ Lévy, J. A. (1993). "HIV pathogenesis and long-term survival". AIDS. 7 (11): 1401–10. doi:10.1097/00002030-199311000-00001. PMID 8280406.
^ Smith, Johanna A.; Daniel, René (Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia) (2006). "Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses". ACS Chem Biol. 1 (4): 217–26. doi:10.1021/cb600131q. PMID 17163676.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Martínez, edited by Miguel Angel (2010). RNA interference and viruses : current innovations and future trends. Norfolk: Caister Academic Press. p. 73. ISBN 9781904455561. {{cite book}}: |first= has generic name (help)
^ Immunology, infection, and immunity. Washington, D.C.: ASM Press. 2004. p. 550. ISBN 9781555812461. {{cite book}}: |first= has generic name (help); |first= missing |last= (help)
^ Gilbert, PB; et al. (February 28, 2003). "Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal". Statistics in Medicine. 22 (4): 573–593. doi:10.1002/sim.1342. PMID 12590415.
^ ^a ^b Reeves, J. D. and Doms, R. W (2002). "Human Immunodeficiency Virus Type 2". J. Gen. Virol. 83 (Pt 6): 1253–65. doi:10.1099/vir.0.18253-0. PMID 12029140.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Piatak, M., Jr, Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. and Lifson, J.D. (1993). "High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR". Science. 259 (5102): 1749–1754. Bibcode:1993Sci...259.1749P. doi:10.1126/science.8096089. PMID 8096089.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS. (1997). "The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia". Proc Natl Acad Sci U S A. 94 (1): 254–258. Bibcode:1997PNAS...94..254P. doi:10.1073/pnas.94.1.254. PMC 19306. PMID 8990195.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Guss DA (1994). "The acquired immune deficiency syndrome: an overview for the emergency physician, Part 1". J Emerg Med. 12 (3): 375–84. doi:10.1016/0736-4679(94)90281-X. PMID 8040596.
^ Hel Z, McGhee JR, Mestecky J (2006). "HIV infection: first battle decides the war". Trends Immunol. 27 (6): 274–81. doi:10.1016/j.it.2006.04.007. PMID 16679064. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Arie J. Zuckerman et al. (eds) (2007). Principles and practice of clinical virology (6th ed.). Hoboken, N.J.: Wiley. p. 905. ISBN 978-0-470-51799-4. {{cite book}}: |author= has generic name (help)
^ Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M (2004). "Primary HIV-1 infection is associated with preferential depletion of CD4⁺ T cells from effector sites in the gastrointestinal tract". J. Exp. Med. 200 (6): 761–70. doi:10.1084/jem.20041196. PMC 2211967. PMID 15365095. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC (2004). "CD4⁺ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract". J. Exp. Med. 200 (6): 749–59. doi:10.1084/jem.20040874. PMC 2211962. PMID 15365096. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ ^a ^b editor, Julio Aliberti, (2011). Control of Innate and Adaptive Immune Responses During Infectious Diseases. New York, NY: Springer Verlag. p. 145. ISBN 978-1-4614-0483-5. {{cite book}}: |last= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
^ Appay V, Sauce D (2008). "Immune activation and inflammation in HIV-1 infection: causes and consequences". J. Pathol. 214 (2): 231–41. doi:10.1002/path.2276. PMID 18161758. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006). "Microbial translocation is a cause of systemic immune activation in chronic HIV infection". Nat. Med. 12 (12): 1365–71. doi:10.1038/nm1511. PMID 17115046. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ ^a ^b Kellerman, S (2010 Jul 20). "HIV testing for children in resource-limited settings: what are we waiting for?". PLoS medicine. 7 (7): e1000285. doi:10.1371/journal.pmed.1000285. PMC 2907270. PMID 20652012. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
^ ^a ^b ^c UNAIDS 2011 pg. 70–80
^ ^a ^b ^c ^d Schneider, E (December 5, 2008). "Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008". MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 57 (RR–10): 1–12. PMID 19052530. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Crosby, R (2012 Mar). "Condom effectiveness: where are we now?". Sexual health. 9 (1): 10–7. doi:10.1071/SH11036. PMID 22348628. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "Condom Facts and Figures". WHO. 2003. Retrieved January 17, 2006. {{cite web}}: Unknown parameter |month= ignored (help)
^ Gallo, MF (2012 Mar). "A review of the effectiveness and acceptability of the female condom for dual protection". Sexual health. 9 (1): 18–26. doi:10.1071/SH11037. PMID 22348629. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b Celum, C (2012 Feb). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current opinion in infectious diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Baptista, M (November 1, 2009). "Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds". Mini reviews in medicinal chemistry. 9 (13): 1556–67. doi:10.2174/138955709790361548. PMID 20205637. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Siegfried, N (April 15, 2009). Siegfried, Nandi (ed.). "Male circumcision for prevention of heterosexual acquisition of HIV in men". Cochrane database of systematic reviews (Online) (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". World Health Organization. March 28, 2007.
^ Larke, N (2010 May 27 – Jun 9). "Male circumcision, HIV and sexually transmitted infections: a review". British journal of nursing (Mark Allen Publishing). 19 (10): 629–34. PMID 20622758. {{cite journal}}: Check date values in: |date= (help)
^ Eaton, L (2009 Nov). "Behavioral aspects of male circumcision for the prevention of HIV infection". Current HIV/AIDS reports. 6 (4): 187–93. doi:10.1007/s11904-009-0025-9. PMID 19849961. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)(subscription required)
^ Kim, HH (2010 Nov). "Male circumcision: Africa and beyond?". Current opinion in urology. 20 (6): 515–9. doi:10.1097/MOU.0b013e32833f1b21. PMID 20844437. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Templeton, DJ (2010 Feb). "Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men". Current opinion in infectious diseases. 23 (1): 45–52. doi:10.1097/QCO.0b013e328334e54d. PMID 19935420. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Wiysonge, CS.; Kongnyuy, EJ.; Shey, M.; Muula, AS.; Navti, OB.; Akl, EA.; Lo, YR. (2011). Wiysonge, Charles Shey (ed.). "Male circumcision for prevention of homosexual acquisition of HIV in men". Cochrane Database Syst Rev (6): CD007496. doi:10.1002/14651858.CD007496.pub2. PMID 21678366. {{cite journal}}: Cite has empty unknown parameter: |month= (help)
^ Eaton LA, Kalichman S (2007). "Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies". Curr HIV/AIDS Rep. 4 (4): 165–72. doi:10.1007/s11904-007-0024-7. PMC 2937204. PMID 18366947. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Utz-Billing I, Kentenich H (2008). "Female genital mutilation: an injury, physical and mental harm". J Psychosom Obstet Gynaecol. 29 (4): 225–9. doi:10.1080/01674820802547087. PMID 19065392. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Underhill K, Operario D, Montgomery P (2008). Operario, Don (ed.). "Abstinence-only programs for HIV infection prevention in high-income countries". Cochrane Database of Systematic Reviews (4): CD005421. doi:10.1002/14651858.CD005421.pub2. PMID 17943855.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Tolli, MV (May 28, 2012). "Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies". Health education research. doi:10.1093/her/cys055. PMID 22641791.
^ Ljubojević, S (2010). "Sexually transmitted infections and adolescence". Acta dermatovenerologica Croatica : ADC. 18 (4): 305–10. PMID 21251451. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Patel VL, Yoskowitz NA, Kaufman DR, Shortliffe EH (2008). "Discerning patterns of human immunodeficiency virus risk in healthy young adults". Am J Med. 121 (4): 758–764. doi:10.1016/j.amjmed.2008.04.022. PMC 2597652. PMID 18724961.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Anglemyer, A (August 10, 2011). Rutherford, George W (ed.). "Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples". Cochrane database of systematic reviews (Online) (8): CD009153. doi:10.1002/14651858.CD009153.pub2. PMID 21833973. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Centers for Disease Control (CDC) (1987). "Recommendations for prevention of HIV transmission in health-care settings". MMWR. 36 (Suppl 2): 1S–18S. PMID 3112554. {{cite journal}}: Unknown parameter |month= ignored (help)
^ ^a ^b Kurth, AE (2011 Mar). "Combination HIV prevention: significance, challenges, and opportunities". Current HIV/AIDS reports. 8 (1): 62–72. doi:10.1007/s11904-010-0063-3. PMC 3036787. PMID 20941553. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ MacArthur, G. J. (October 4, 2012). "Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis". BMJ. 345 (oct03 3): e5945–e5945. doi:10.1136/bmj.e5945. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b ^c [No authors listed] (2012). "HIV exposure through contact with body fluids". Prescrire Int. 21 (126): 100–1, 103–5. PMID 22515138. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Linden, JA (September 1, 2011). "Clinical practice. Care of the adult patient after sexual assault". The New England Journal of Medicine. 365 (9): 834–41. doi:10.1056/NEJMcp1102869. PMID 21879901.
^ Young, TN (January 24, 2007). Young, Taryn (ed.). "Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure". Cochrane database of systematic reviews (Online) (1): CD002835. doi:10.1002/14651858.CD002835.pub3. PMID 17253483. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Siegfried, N (July 6, 2011). Siegfried, Nandi (ed.). "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection". Cochrane database of systematic reviews (Online) (7): CD003510. doi:10.1002/14651858.CD003510.pub3. PMID 21735394. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV – Infections in Pregnant Women, Mothers and their Infants – Consensus statement" (PDF). October 25–27, 2006. Archived from the original (PDF) on April 9, 2008. Retrieved March 12, 2008. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)CS1 maint: date and year (link)
^ Horvath, T (January 21, 2009). Horvath, Tara (ed.). "Interventions for preventing late postnatal mother-to-child transmission of HIV". Cochrane database of systematic reviews (Online) (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMID 19160297. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ UNAIDS (May 18, 2012). "The quest for an HIV vaccine".
^ Reynell, L (March 2, 2012). "HIV vaccines: an attainable goal?". Swiss medical weekly. 142: w13535. doi:10.4414/smw.2012.13535. PMID 22389197. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ U.S. Army Office of the Surgeon General (March 21, 2011). "HIV Vaccine Trial in Thai Adults". ClinicalTrials.gov. Retrieved June 28, 2011.
^ U.S. Army Office of the Surgeon General (June 2, 2010). "Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial". ClinicalTrials.gov.
^ May, MT (2011 Dec). "Life expectancy of HIV-positive adults: a review". Sexual health. 8 (4): 526–33. doi:10.1071/SH11046. PMID 22127039. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "First documented case of child cured of HIV". Science Daily. March 3, 2013. Retrieved March 4, 2013.
^ ^a ^b ^c ^d ^e ^f ^g ^h Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (PDF). World Health Organization. 2010. pp. 19–20. ISBN 978-92-4-159976-4.
^ Sax, PE (April 30, 2009). "When to start antiretroviral therapy—ready when you are?". The New England Journal of Medicine. 360 (18): 1897–9. doi:10.1056/NEJMe0902713. PMID 19339713. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Siegfried, N (March 17, 2010). Siegfried, Nandi (ed.). "Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults". Cochrane database of systematic reviews (Online) (3): CD008272. doi:10.1002/14651858.CD008272.pub2. PMID 20238364. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Panel on Antiretroviral Guidelines for Adults and Adolescents (December 1, 2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (PDF). United States Department of Health and Human Services. p. i.
^ When To Start, Consortium (April 18, 2009). "Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies". Lancet. 373 (9672): 1352–63. doi:10.1016/S0140-6736(09)60612-7. PMC 2670965. PMID 19361855. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Beard, J (2009 Nov). "Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review". AIDS care. 21 (11): 1343–56. doi:10.1080/09540120902889926. PMID 20024710. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Orrell, C (2005 Nov). "Antiretroviral adherence in a resource-poor setting". Current HIV/AIDS reports. 2 (4): 171–6. doi:10.1007/s11904-005-0012-8. PMID 16343374. {{cite journal}}: Check date values in: |date= (help)
^ Malta, M (2008 Aug). "Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review". Addiction (Abingdon, England). 103 (8): 1242–57. doi:10.1111/j.1360-0443.2008.02269.x. PMID 18855813. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Nachega, JB (2011 Apr). "HIV treatment adherence, drug resistance, virologic failure: evolving concepts". Infectious disorders drug targets. 11 (2): 167–74. PMID 21406048. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Nachega, JB (2010 Jan). "Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities". Current opinion in HIV and AIDS. 5 (1): 70–7. doi:10.1097/COH.0b013e328333ad61. PMID 20046150. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b ^c Montessori, V., Press, N., Harris, M., Akagi, L., Montaner, J. S. (2004). "Adverse effects of antiretroviral therapy for HIV infection". CMAJ. 170 (2): 229–238. PMC 315530. PMID 14734438.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ ^a ^b Burgoyne RW, Tan DH (2008). "Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act". J. Antimicrob. Chemother. 61 (3): 469–73. doi:10.1093/jac/dkm499. PMID 18174196. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Barbaro, G (2011 Dec). "Human immunodeficiency virus & cardiovascular risk". The Indian journal of medical research. 134 (6): 898–903. doi:10.4103/0971-5916.92634. PMC 3284097. PMID 22310821. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
^ Orsi, F (2010 May). "Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries". Current opinion in HIV and AIDS. 5 (3): 237–41. doi:10.1097/COH.0b013e32833860ba. PMID 20539080. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b ^c UNAIDS 2011 pg. 150–160
^ ^a ^b "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (PDF). The Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Aug 11,2011. {{cite web}}: Check date values in: |date= (help)
^ Antiretroviral therapy for HIV infection in infants and children (PDF). World Health Organization. 2010. p. 2. ISBN 978-92-4-159980-1.
^ Laurence J (2006). "Hepatitis A and B virus immunization in HIV-infected persons". AIDS Reader. 16 (1): 15–17. PMID 16433468.
^ Huang, L (2011 Jun). "HIV-associated Pneumocystis pneumonia". Proceedings of the American Thoracic Society. 8 (3): 294–300. doi:10.1513/pats.201009-062WR. PMC 3132788. PMID 21653531. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ "Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America". United States Department of Health and Human Services. February 2, 2007.
^ ^a ^b Smith, [edited by] Blaine T. (2008). Concepts in immunology and immunotherapeutics (4th ed.). Bethesda, Md.: American Society of Health-System Pharmacists. p. 143. ISBN 978-1-58528-127-5. {{cite book}}: |first= has generic name (help)
^ Littlewood RA, Vanable PA (2008). "Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care". AIDS Care. 20 (8): 1002–18. doi:10.1080/09540120701767216. PMC 2570227. PMID 18608078. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Mills E, Wu P, Ernst E (2005). "Complementary therapies for the treatment of HIV: in search of the evidence". Int J STD AIDS. 16 (6): 395–403. doi:10.1258/0956462054093962. PMID 15969772. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ ^a ^b ^c Irlam, JH (December 8, 2010). Irlam, James H (ed.). "Micronutrient supplementation in children and adults with HIV infection". Cochrane database of systematic reviews (Online) (12): CD003650. doi:10.1002/14651858.CD003650.pub3. PMID 21154354. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Stone, CA (2010 Nov). "Role of selenium in HIV infection". Nutrition Reviews. 68 (11): 671–81. doi:10.1111/j.1753-4887.2010.00337.x. PMC 3066516. PMID 20961297. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Forrester, JE (2011 Dec). "Micronutrients in HIV/AIDS: is there evidence to change the WHO 2003 recommendations?". The American journal of clinical nutrition. 94 (6): 1683S–1689S. doi:10.3945/ajcn.111.011999. PMC 3226021. PMID 22089440. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b World Health Organization (2003-05). Nutrient requirements for people living with HIV/AIDS: Report of a technical consultation (PDF). Geneva. Archived from the original (PDF) on March 25, 2009. Retrieved March 31, 2009. {{cite book}}: Check date values in: |date= (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Liu JP, Manheimer E, Yang M (2005). Liu, Jian Ping (ed.). "Herbal medicines for treating HIV infection and AIDS". Cochrane Database Syst Rev (3): CD003937. doi:10.1002/14651858.CD003937.pub2. PMID 16034917.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ ^a ^b ^c Knoll B, Lassmann B, Temesgen Z (2007). "Current status of HIV infection: a review for non-HIV-treating physicians". Int J Dermatol. 46 (12): 1219–28. doi:10.1111/j.1365-4632.2007.03520.x. PMID 18173512.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Joint United Nations Programme on HIV/AIDS, World Health Organization (2007). "2007 AIDS epidemic update" (PDF). Retrieved March 12, 2008. {{cite web}}: Unknown parameter |month= ignored (help)
^ ^a ^b Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA (2002). "HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?". AIDS. 16 (4): 597–632. doi:10.1097/00002030-200203080-00011. PMID 11873003.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Zwahlen M, Egger M (2006). "Progression and mortality of untreated HIV-positive individuals living in resource-limited settings: update of literature review and evidence synthesis" (PDF). UNAIDS Obligation HQ/05/422204. Archived from the original (PDF) on April 9, 2008. Retrieved March 19, 2008. {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ ^a ^b Antiretroviral Therapy Cohort Collaboration (2008). "Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies". Lancet. 372 (9635): 293–9. doi:10.1016/S0140-6736(08)61113-7. PMC 3130543. PMID 18657708.
^ Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. (2006). "The lifetime cost of current HIV care in the United States". Med Care. 44 (11): 990–997. doi:10.1097/01.mlr.0000228021.89490.2a. PMID 17063130.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
^ van Sighem, AI (June 19, 2010). "Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals". AIDS (London, England). 24 (10): 1527–35. doi:10.1097/QAD.0b013e32833a3946. PMID 20467289. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b Cheung, MC (2005 Jun–Jul). "AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy". The oncologist. 10 (6): 412–26. doi:10.1634/theoncologist.10-6-412. PMID 15967835. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Tang J, Kaslow RA (2003). "The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy". AIDS. 17 (Suppl 4): S51–S60. doi:10.1097/00002030-200317004-00006. PMID 15080180.
^ Lawn SD (2004). "AIDS in Africa: the impact of co-infections on the pathogenesis of HIV-1 infection". J. Infect. Dis. 48 (1): 1–12. doi:10.1016/j.jinf.2003.09.001. PMID 14667787.
^ Campbell GR; Pasquier E; Watkins J; et al. (2004). "The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis". J. Biol. Chem. 279 (46): 48197–48204. doi:10.1074/jbc.M406195200. PMID 15331610. {{cite journal}}: Unknown parameter |author-separator= ignored (help)CS1 maint: unflagged free DOI (link)
^ Campbell GR, Watkins JD, Esquieu D, Pasquier E, Loret EP, Spector SA (2005). "The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells". J. Biol. Chem. 280 (46): 38376–39382. doi:10.1074/jbc.M506630200. PMID 16155003.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
^ "Tuberculosis". Fact sheet 104. World Health Organization. March 2012. Retrieved August 29, 2012.
^ World Health Organization (2011). "Global tuberculosis control 2011" (PDF). ISBN 978 92 4 156438 0. Retrieved August 29, 2012.
^ Pennsylvania, Editors, Raphael Rubin, M.D., Professor of Pathology, David S. Strayer, M.D., Ph.D., Professor of Pathology, Department of Pathology and Cell Biology, Jefferson Medical College of Thomas Jefferson University Philadelphia, Pennsylvania ; Founder and Consulting Editor, Emanuel Rubin, M.D., Gonzalo Aponte Distinguished Professor of Pathology, Chairman Emeritus of the Department of Pathology and Cell Biology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, (2011). Rubin's pathology : clinicopathologic foundations of medicine (Sixth ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 154. ISBN 978-1-60547-968-2. {{cite book}}: |first= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19462243 , please use {{cite journal}} with |pmid=19462243 instead.
^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17086056, please use {{cite journal}} with |pmid=17086056 instead.
^ Nicholas PK; Kemppainen JK; Canaval GE; et al. (2007). "Symptom management and self-care for peripheral neuropathy in HIV/AIDS". AIDS Care. 19 (2): 179–89. doi:10.1080/09540120600971083. PMID 17364396. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
^ Boshoff C, Weiss R (2002). "AIDS-related malignancies". Nat. Rev. Cancer. 2 (5): 373–382. doi:10.1038/nrc797. PMID 12044013.
^ Yarchoan R, Tosato G, Little RF (2005). "Therapy insight: AIDS-related malignancies – the influence of antiviral therapy on pathogenesis and management". Nat. Clin. Pract. Oncol. 2 (8): 406–415. doi:10.1038/ncponc0253. PMID 16130937.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19106702, please use {{cite journal}} with |pmid=19106702 instead.
^ [1]
^ Cohen, MS (2008 Apr). "The spread, treatment, and prevention of HIV-1: evolution of a global pandemic". The Journal of Clinical Investigation. 118 (4): 1244–54. doi:10.1172/JCI34706. PMC 2276790. PMID 18382737. Retrieved 17 September 2012. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ ^a ^b ^c ^d UNAIDS 2011 pg. 20–30
^ ^a ^b ^c UNAIDS 2011 pg. 40–50
^ ^a ^b ^c ^d Mandell, Bennett, and Dolan (2010). Chapter 117.
^ Centers for Disease Control and Prevention, (CDC) (June 3, 2011). "HIV surveillance—United States, 1981–2008". MMWR. Morbidity and mortality weekly report. 60 (21): 689–93. PMID 21637182.
^ Health Protection Agency (2010). HIV in the United Kingdom: 2010 Report.
^ Surveillance (2010). HIV and AIDS in Canada : surveillance report to December 31, 2009 (PDF). Ottawa: Public Health Agency of Canada, Centre for Communicable Diseases and Infection Control, Surveillance and Risk Assessment Division. ISBN 978-1-100-52141-1. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Gottlieb MS (2006). "Pneumocystis pneumonia—Los Angeles. 1981". Am J Public Health. 96 (6): 980–1, discussion 982–3. doi:10.2105/AJPH.96.6.980. PMC 1470612. PMID 16714472. Archived from the original on April 22, 2009. Retrieved March 31, 2009. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Friedman-Kien AE (1981). "Disseminated Kaposi's sarcoma syndrome in young homosexual men". J. Am. Acad. Dermatol. 5 (4): 468–71. doi:10.1016/S0190-9622(81)80010-2. PMID 7287964. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Hymes KB; Cheung T; Greene JB; et al. (1981). "Kaposi's sarcoma in homosexual men-a report of eight cases". Lancet. 2 (8247): 598–600. doi:10.1016/S0140-6736(81)92740-9. PMID 6116083. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
^ ^a ^b Basavapathruni, A; Anderson, KS (2007). "Reverse transcription of the HIV-1 pandemic". The FASEB Journal. 21 (14): 3795–3808. doi:10.1096/fj.07-8697rev. PMID 17639073. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)
^ Centers for Disease Control (CDC) (1982). "Persistent, generalized lymphadenopathy among homosexual males". MMWR Morb Mortal Wkly Rep. 31 (19): 249–251. PMID 6808340. Retrieved August 31, 2011.
^ Barré-Sinoussi F; Chermann JC; Rey F; et al. (1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–871. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. PMID 6189183. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
^ ^a ^b Centers for Disease Control (CDC) (1982). "Opportunistic infections and Kaposi's sarcoma among Haitians in the United States". MMWR Morb Mortal Wkly Rep. 31 (26): 353–354, 360–361. PMID 6811853. Retrieved August 31, 2011.
^ "Making Headway Under Hellacious Circumstances" (PDF). American Association for the Advancement of Science. July 28, 2006. Retrieved June 23, 2008.
^ Altman LK (May 11, 1982). "New homosexual disorder worries health officials". The New York Times. Retrieved August 31, 2011.
^ Kher U (July 27, 1982). "A Name for the Plague". Time. Archived from the original on March 7, 2008. Retrieved March 10, 2008. {{cite news}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Centers for Disease Control (CDC) (1982). "Update on acquired immune deficiency syndrome (AIDS)—United States". MMWR Morb Mortal Wkly Rep. 31 (37): 507–508, 513–514. PMID 6815471.
^ RC Gallo, PS Sarin, EP Gelmann, M Robert-Guroff, E Richardson, VS Kalyanaraman, D Mann, GD Sidhu, RE Stahl, S Zolla-Pazner, J Leibowitch, and M Popovic (1983). "Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 865–867. Bibcode:1983Sci...220..865G. doi:10.1126/science.6601823. PMID 6601823.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1126/science.6189183, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1126/science.6189183 instead.
^ Aldrich, ed. by Robert (2001). Who's who in gay and lesbian history. London: Routledge. p. 154. ISBN 9780415229746. {{cite book}}: |first= has generic name (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Gao F; Bailes E; Robertson DL; et al. (1999). "Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes". Nature. 397 (6718): 436–41. Bibcode:1999Natur.397..436G. doi:10.1038/17130. PMID 9989410. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
^ Keele, B. F., van Heuverswyn, F., Li, Y. Y., Bailes, E., Takehisa, J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V., Liegois, F., Loul, S., Mpoudi Ngole, E., Bienvenue, Y., Delaporte, E., Brookfield, J. F. Y., Sharp, P. M., Shaw, G. M., Peeters, M., and Hahn, B. H. (July 28, 2006). "Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1". Science. 313 (5786): 523–6. Bibcode:2006Sci...313..523K. doi:10.1126/science.1126531. PMC 2442710. PMID 16728595.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Goodier, J., and Kazazian, H. (2008). "Retrotransposons Revisited: The Restraint and Rehabilitation of Parasites". Cell. 135 (1): 23–35. doi:10.1016/j.cell.2008.09.022. PMID 18854152.{{cite journal}}: CS1 maint: multiple names: authors list (link)(subscription required)
^ Sharp, P. M.; Bailes, E.; Chaudhuri, R. R.; Rodenburg, C. M.; Santiago, M. O.; Hahn, B. H. (2001). "The origins of acquired immune deficiency syndrome viruses: where and when?" (PDF). Philosophical Transactions of the Royal Society B: Biological Sciences. 356 (1410): 867–76. doi:10.1098/rstb.2001.0863. PMC 1088480. PMID 11405934.
^ Kalish ML; Wolfe ND; Ndongmo CD; McNicholl J; Robbins KE; et al. (2005). "Central African hunters exposed to simian immunodeficiency virus". Emerg Infect Dis. 11 (12): 1928–30. doi:10.3201/eid1112.050394. PMC 3367631. PMID 16485481. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
^ ^a ^b Marx PA, Alcabes PG, Drucker E (2001). "Serial human passage of simian immunodeficiency virus by unsterile injections and the emergence of epidemic human immunodeficiency virus in Africa" (PDF). Philos Trans R Soc Lond B Biol Sci. 356 (1410): 911–20. doi:10.1098/rstb.2001.0867. PMC 1088484. PMID 11405938.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Worobey, Michael; Gemmel, Marlea; Teuwen, Dirk E.; Haselkorn, Tamara; Kunstman, Kevin; Bunce, Michael; Muyembe, Jean-Jacques; Kabongo, Jean-Marie M.; Kalengayi, Raphaël M. (2008). "Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960" (PDF). Nature. 455 (7213): 661–4. Bibcode:2008Natur.455..661W. doi:10.1038/nature07390. PMID 18833279. (subscription required)
^ ^a ^b Sousa, João Dinis de; Müller, Viktor; Lemey, Philippe; Vandamme, Anne-Mieke; Vandamme, Anne-Mieke (2010). Martin, Darren P. (ed.). "High GUD Incidence in the Early 20th Century Created a Particularly Permissive Time Window for the Origin and Initial Spread of Epidemic HIV Strains". PLoS ONE. 5 (4): e9936. doi:10.1371/journal.pone.0009936. PMC 2848574. PMID 20376191.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Chitnis, Amit; Rawls, Diana; Moore, Jim (2000). "Origin of HIV Type 1 in Colonial French Equatorial Africa?". AIDS Research and Human Retroviruses. 16 (1): 5–8. doi:10.1089/088922200309548. PMID 10628811.(subscription required)
^ Donald G. McNeil, Jr. (September 16, 2010). "Precursor to H.I.V. Was in Monkeys for Millennia". New York Times. Retrieved September 17, 2010. Dr. Marx believes that the crucial event was the introduction into Africa of millions of inexpensive, mass-produced syringes in the 1950s. ... suspect that the growth of colonial cities is to blame. Before 1910, no Central African town had more than 10,000 people. But urban migration rose, increasing sexual contacts and leading to red-light districts. {{cite news}}: Cite has empty unknown parameter: |coauthors= (help)
^ Zhu, T., Korber, B. T., Nahmias, A. J., Hooper, E., Sharp, P. M. and Ho, D. D. (1998). "An African HIV-1 Sequence from 1959 and Implications for the Origin of the epidemic". Nature. 391 (6667): 594–7. Bibcode:1998Natur.391..594Z. doi:10.1038/35400. PMID 9468138.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Kolata, Gina (October 28, 1987). "Boy's 1969 Death Suggests AIDS Invaded U.S. Several Times". The New York Times. Retrieved February 11, 2009.
^ ^a ^b Gilbert, M. Thomas P.; Rambaut, Andrew; Wlasiuk, Gabriela; Spira, Thomas J.; Pitchenik, Arthur E.; Worobey, Michael (November 20, 2007). "The emergence of HIV/AIDS in the Americas and beyond" (PDF). PNAS. 104 (47): 18566–18570. Bibcode:2007PNAS..10418566G. doi:10.1073/pnas.0705329104. PMC 2141817. PMID 17978186.
^ "The impact of AIDS on people and societies". 2006 Report on the global AIDS epidemic. UNAIDS. 2006. ISBN 92-9173-479-9. {{cite book}}: |access-date= requires |url= (help); |format= requires |url= (help); External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
^ Ogden J, Nyblade L (2005). "Common at its core: HIV-related stigma across contexts" (PDF). International Center for Research on Women. Retrieved February 15, 2007.
^ ^a ^b ^c Herek GM, Capitanio JP (1999). "AIDS Stigma and sexual prejudice" (PDF). American Behavioral Scientist. 42 (7): 1130–1147. doi:10.1177/0002764299042007006. Retrieved March 27, 2006.
^ Snyder M, Omoto AM, Crain AL (1999). "Punished for their good deeds: stigmatization for AIDS volunteers". American Behavioral Scientist. 42 (7): 1175–1192. doi:10.1177/0002764299042007009.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Sharma, A.K. Population and society. New Delhi: Concept Pub. Co. p. 242. ISBN 9788180698187.
^ Herek, GM (2002 Mar). "HIV-related stigma and knowledge in the United States: prevalence and trends, 1991–1999". American journal of public health. 92 (3): 371–7. doi:10.2105/AJPH.92.3.371. PMC 1447082. PMID 11867313. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ De Cock, KM (2012 Jun 19). "The evolving epidemiology of HIV/AIDS". AIDS (London, England). 26 (10): 1205–13. doi:10.1097/QAD.0b013e328354622a. PMID 22706007. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Bell C, Devarajan S, Gersbach H (2003). "The long-run economic costs of AIDS: theory and an application to South Africa" (PDF). World Bank Policy Research Working Paper No. 3152. Retrieved April 28, 2008. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
^ ^a ^b Greener R (2002). "AIDS and macroeconomic impact". In S, Forsyth (ed.) (ed.). State of The Art: AIDS and Economics (PDF). IAEN. pp. 49–55. {{cite book}}: |editor= has generic name (help)
^ Over M (1992). "The macroeconomic impact of AIDS in Sub-Saharan Africa, Population and Human Resources Department" (PDF). The World Bank. Archived from the original (PDF) on May 27, 2008. Retrieved May 3, 2008. {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ "AIDS Stigma". News-medical.net. Retrieved November 1, 2011.
^ ^a ^b "Thirty years after AIDS discovery, appreciation growing for Catholic approach". Catholicnewsagency.com. June 5, 2011. Retrieved November 1, 2011.
^ ^a ^b "Church HIV prayer cure claims 'cause three deaths'". BBC News. October 18, 2011. Retrieved October 18, 2011.
^ "Rock Hudson announces he has AIDS – History.com This Day in History – 7/25/1985". History.com. Retrieved November 1, 2011.
^ Coleman, Brian (June 25, 2007). "Thatcher the gay icon". New Statesman. Retrieved November 1, 2011.
^ "November 24, 1991: Giant of rock dies". BBC On This Day. BBC News. Retrieved November 1, 2011.
^ "Freddie Mercury". Nndb.com. Retrieved November 1, 2011.
^ Bliss, Dominic. "Frozen In Time: Arthur Ashe". iTENNISstore.com. Retrieved June 25, 2012.
^ "Tributes to Arthur Ashe". The Independent. London. February 8, 1993. Retrieved July 24, 2012.
^ Cosgrove, Ben. "Behind the Picture: The Photo That Changed the Face of AIDS". LIFE magazine. Retrieved August 16, 2012.
^ Duesberg, P. H. (1988). "HIV is not the cause of AIDS". Science. 241 (4865): 514, 517. Bibcode:1988Sci...241..514D. doi:10.1126/science.3399880. PMID 3399880.Cohen, J. (1994). "The Controversy over HIV and AIDS" (PDF). Science. 266 (5191): 1642–1649. Bibcode:1994Sci...266.1642C. doi:10.1126/science.7992043. PMID 7992043. Retrieved March 31, 2009.
^ Kalichman, Seth (2009). Denying AIDS: Conspiracy Theories, Pseudoscience, and Human Tragedy. New York: Copernicus Books (Springer Science+Business Media). ISBN 978-0-387-79475-4.
^ Smith TC, Novella SP (2007). "HIV Denial in the Internet Era". PLoS Med. 4 (8): e256. doi:10.1371/journal.pmed.0040256. PMC 1949841. PMID 17713982. Retrieved November 7, 2009. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)
^ Various (Last updated January 14, 2010). "Resources and Links, HIV-AIDS Connection". National Institute of Allergy and Infectious Diseases. Retrieved 2009-02-22. {{cite web}}: Check date values in: |date= (help)
^ Watson J (2006). "Scientists, activists sue South Africa's AIDS 'denialists'". Nat. Med. 12 (1): 6. doi:10.1038/nm0106-6a. PMID 16397537.
^ Baleta A (2003). "S Africa's AIDS activists accuse government of murder". Lancet. 361 (9363): 1105. doi:10.1016/S0140-6736(03)12909-1. PMID 12672319.
^ Cohen J (2000). "South Africa's new enemy". Science. 288 (5474): 2168–70. doi:10.1126/science.288.5474.2168. PMID 10896606.
^ Operation INFEKTION – Soviet Bloc Intelligence and Its AIDS Disinformation Campaign. Thomas Boghardt. 2009
^ Blechner MJ (1997). Hope and mortality: psychodynamic approaches to AIDS and HIV. Hillsdale, NJ: Analytic Press. ISBN 0-88163-223-6. {{cite book}}: Unknown parameter |unused_data= ignored (help)
^ Kirby DB, Laris BA, Rolleri LA (2007). "Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world". J Adolesc Health. 40 (3): 206–17. doi:10.1016/j.jadohealth.2006.11.143. PMID 17321420. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ ^a ^b Ferrantelli F, Cafaro A, Ensoli B (2004). "Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccine". Curr. Opin. Biotechnol. 15 (6): 543–56. doi:10.1016/j.copbio.2004.10.008. PMID 15560981. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT (2008). "The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus". Nat. Rev. Microbiol. 6 (2): 143–55. doi:10.1038/nrmicro1819. PMID 18197170. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ "German HIV patient cured after stem cell transplant". Belfast Telegraph. December 15, 2010. Retrieved December 15, 2010.
^ ^a ^b Allers, K (March 10, 2011). "Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation". Blood. 117 (10): 2791–9. doi:10.1182/blood-2010-09-309591. PMID 21148083. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Mark Schoofs (November 7, 2008). "A Doctor, a Mutation and a Potential Cure for AIDS". The Wall Street Journal. Retrieved November 9, 2008.
^ ^a ^b Hütter G, Nowak D, Mossner M, Ganepola S, Ganepola A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E (2009). "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation". N Engl J Med. 360 (7): 692–698. doi:10.1056/NEJMoa0802905. PMID 19213682. Retrieved March 31, 2009.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ ^a ^b Levy JA (2009). "Not an HIV Cure, but Encouraging New Directions". N Engl J Med. 360 (7): 724–725. doi:10.1056/NEJMe0810248. PMID 19213687. Retrieved March 31, 2009.
^ Nath, A (March 13, 2011). "Eradication of HIV from the brain: reasons for pause". AIDS (London, England). 25 (5): 577–80. doi:10.1097/QAD.0b013e3283437d2f. PMID 21160414. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)(subscription required)
^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 21331536, please use {{cite journal}} with |pmid=21331536 instead.(subscription required)
^ Tincati, C (2009 Jan). "Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease". Current molecular pharmacology. 2 (1): 40–5. doi:10.2174/1874467210902010040. PMID 20021444. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Bowman MC, Archin NM, Margolis DM. (2009). "Pharmaceutical approaches to eradication of persistent HIV infection". Expert Reviews in Molecular Medicine. 11 (e6): e6. doi:10.1017/S1462399409000970. PMID 19208267.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S (2008). "Catalytic antibodies to HIV: Physiological role and potential clinical utility". Autoimmun Rev. 7 (6): 473–9. doi:10.1016/j.autrev.2008.04.002. PMC 2527403. PMID 18558365. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

References

Mandell, Gerald L.; Bennett, John E.; Dolin, Raphael, eds. (2010). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (7th ed.). Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 978-0-443-06839-3.
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2011). Global HIV/AIDS Response, Epidemic update and health sector progress towards universal access (PDF). Joint United Nations Programme on HIV/AIDS.

External links

HIV/AIDS at Curlie
Joint United Nations Program on HIV/AIDS
AIDSinfo – HIV/AIDS Treatment Information, U.S. Department of Health and Human Services

Template:Link FA Template:Link FA Template:Link FA Template:Link FA Template:Link FA Template:Link FA Template:Link FA Template:Link GA Template:Link FA

[pmid11396444-1] Sepkowitz KA (2001). "AIDS—the first 20 years". N. Engl. J. Med. 344 (23): 1764–72. doi:10.1056/NEJM200106073442306. PMID 11396444. {{cite journal}}: Unknown parameter |month= ignored (help)

[TransmissionM2007-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j Markowitz, edited by William N. Rom ; associate editor, Steven B. (2007). Environmental and occupational medicine (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 745. ISBN 978-0-7817-6299-1. {{cite book}}: |first= has generic name (help)CS1 maint: multiple names: authors list (link)

[CDCtransmission-3] "HIV and Its Transmission". Centers for Disease Control and Prevention. 2003. Archived from the original on February 4, 2005. Retrieved May 23, 2006.

[Orgin2011-4] Sharp, PM (2011 Sep). "Origins of HIV and the AIDS Pandemic". Cold Spring Harbor perspectives in medicine. 1 (1): a006841. doi:10.1101/cshperspect.a006841. PMC 3234451. PMID 22229120. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[5] Gallo RC (2006). "A reflection on HIV/AIDS research after 25 years". Retrovirology. 3: 72. doi:10.1186/1742-4690-3-72. PMC 1629027. PMID 17054781.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[TotalDeath2010-6] "Global Report Fact Sheet" (PDF). UNAIDS. 2010.

[UN2011Ten-7] ^ ^a ^b ^c ^d ^e ^f UNAIDS 2011 pg. 1–10

[Kallings-8] Kallings LO (2008). "The first postmodern pandemic: 25 years of HIV/AIDS". J Intern Med. 263 (3): 218–43. doi:10.1111/j.1365-2796.2007.01910.x. PMID 18205765.(subscription required)

[M121-9] ^ ^a ^b ^c ^d ^e ^f Mandell, Bennett, and Dolan (2010). Chapter 121.

[AIDS2010GOV-10] "Stages of HIV". U.S. Department of Health & Human Services. December 2010. Retrieved June 13, 2012.

[WHOCase2007-11] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children (PDF). Geneva: World Health Organization. 2007. pp. 6–16. ISBN 978-92-4-159562-9.

[12] Diseases and disorders. Tarrytown, NY: Marshall Cavendish. 2008. p. 25. ISBN 978-0-7614-7771-6.

[M118-13] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ Mandell, Bennett, and Dolan (2010). Chapter 118.

[Deut2010-14] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s Vogel, M (2010 Jul). "The treatment of patients with HIV". Deutsches Ärzteblatt international. 107 (28–29): 507–15, quiz 516. doi:10.3238/arztebl.2010.0507. PMC 2915483. PMID 20703338. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[15] Evian, Clive (2006). Primary HIV/AIDS care: a practical guide for primary health care personnel in a clinical and supportive setting (Updated 4th ed.). Houghton [South Africa]: Jacana. p. 29. ISBN 978-1-77009-198-6.

[16] Radiology of AIDS. Berlin [u.a.]: Springer. 2001. p. 19. ISBN 978-3-540-66510-6. {{cite book}}: |first= missing |last= (help)CS1 maint: multiple names: authors list (link)

[17] Elliott, Tom (2012). Lecture Notes: Medical Microbiology and Infection. John Wiley & Sons. p. 273. ISBN 978-1-118-37226-5.

[LT2010-18] Blankson, JN (2010 Mar). "Control of HIV-1 replication in elite suppressors". Discovery medicine. 9 (46): 261–6. PMID 20350494. {{cite journal}}: Check date values in: |date= (help)

[Walker2007-19] Walker, BD (2007 Aug-Sep). "Elite control of HIV Infection: implications for vaccines and treatment". Topics in HIV medicine : a publication of the International AIDS Society, USA. 15 (4): 134–6. PMID 17720999. {{cite journal}}: Check date values in: |date= (help)

[Holmes-20] Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA (2003). "Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa". Clin. Infect. Dis. 36 (5): 656–662. doi:10.1086/367655. PMID 12594648.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Complications2011-21] Chu, C (February 15, 2011). "Complications of HIV infection: a systems-based approach". American family physician. 83 (4): 395–406. PMID 21322514. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[M169-22] Mandell, Bennett, and Dolan (2010). Chapter 169.

[23] "AIDS". MedlinePlus. A.D.A.M. Retrieved June 14, 2012.

[24] Sestak K (2005). "Chronic diarrhea and AIDS: insights into studies with non-human primates". Curr. HIV Res. 3 (3): 199–205. doi:10.2174/1570162054368084. PMID 16022653. {{cite journal}}: Unknown parameter |month= ignored (help)

[AFP2007-25] Kripke, C (August 1, 2007). "Antiretroviral prophylaxis for occupational exposure to HIV". American family physician. 76 (3): 375–6. PMID 17708137.

[26] van der Kuyl, AC (September 24, 2007). "Identifying HIV-1 dual infections". Retrovirology. 4: 67. doi:10.1186/1742-4690-4-67. PMC 2045676. PMID 17892568. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)

[TransmissionCDC2012-27] "HIV in the United States: An Overview". Center for Disease Control and Prevention. March 2012.

[Boily2009-28] ^ ^a ^b ^c ^d ^e ^f ^g Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M (2009). "Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies". The Lancet Infectious Diseases. 9 (2): 118–129. doi:10.1016/S1473-3099(09)70021-0. PMID 19179227. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[29] Beyrer, C (2012 Jul 28). "Global epidemiology of HIV infection in men who have sex with men". Lancet. 380 (9839): 367–77. doi:10.1016/S0140-6736(12)60821-6. PMID 22819660. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[30] Yu, M (2010 Aug). "Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes". Expert opinion on biological therapy. 10 (8): 1181–95. doi:10.1517/14712598.2010.496776. PMC 2904634. PMID 20624114. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[31] Stürchler, Dieter A. (2006). Exposure a guide to sources of infections. Washington, DC: ASM Press. p. 544. ISBN 9781555813765.

[32] .], edited by Richard Pattman ... [et (2010). Oxford handbook of genitourinary medicine, HIV, and sexual health (2nd ed. ed.). Oxford: Oxford University Press. p. 95. ISBN 9780199571666. {{cite book}}: |edition= has extra text (help); |first= has generic name (help)

[Dosekun2010-33] Dosekun, O (2010 Jul). "An overview of the relative risks of different sexual behaviours on HIV transmission". Current opinion in HIV and AIDS. 5 (4): 291–7. doi:10.1097/COH.0b013e32833a88a3. PMID 20543603. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[CochraneSTI2012-34] Ng, BE (March 16, 2011). Butler, Lisa M (ed.). "Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection". Cochrane database of systematic reviews (Online) (3): CD001220. doi:10.1002/14651858.CD001220.pub3. PMID 21412869. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[35] Anderson, J (2012 Feb). "Women and HIV: motherhood and more". Current opinion in infectious diseases. 25 (1): 58–65. doi:10.1097/QCO.0b013e32834ef514. PMID 22156896. {{cite journal}}: Check date values in: |date= (help)

[36] Klimas, N (2008 Jun). "Overview of HIV". Psychosomatic Medicine. 70 (5): 523–30. doi:10.1097/PSY.0b013e31817ae69f. PMID 18541903. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[37] Draughon, JE (2012). "Nonoccupational post exposure prophylaxis following sexual assault in industrialized low-HIV-prevalence countries: a review". Psychology, health & medicine. 17 (2): 235–54. doi:10.1080/13548506.2011.579984. PMID 22372741. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Risk2006-38] Baggaley, RF (April 4, 2006). "Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis". AIDS (London, England). 20 (6): 805–12. doi:10.1097/01.aids.0000218543.46963.6d. PMID 16549963. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[39] "Will I need a blood transfusion?" (PDF). NHS patient information. National Health Services. 2011. Retrieved August 29, 2012.

[UN2011Seventy-40] UNAIDS 2011 pg. 60–70

[WHO070401-41] "Blood safety ... for too few". WHO. 2001. Retrieved January 17, 2006.

[UnsafeInjection2009-42] Reid, SR (August 28, 2009). "Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review". Harm reduction journal. 6: 24. doi:10.1186/1477-7517-6-24. PMC 2741434. PMID 19715601.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[CDCBasics2012-43] "Basic Information about HIV and AIDS". Center for Disease Control and Prevention. April 2012.

[44] "Why Mosquitoes Cannot Transmit AIDS [HIV virus]". Rci.rutgers.edu. Retrieved July 28, 2010.

[Mother2010-45] ^ ^a ^b ^c ^d ^e ^f Coutsoudis, A (2010 Oct). "Prevention of vertical transmission of HIV-1 in resource-limited settings". Expert review of anti-infective therapy. 8 (10): 1163–75. doi:10.1586/eri.10.94. PMID 20954881. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[fluids_of_transmission-46] "Fluids of transmission". AIDS.gov. United States Department of Health and Human Services. November 1, 2011. Retrieved September 14, 2012.

[MTC2007-47] Thorne, C (2007 Jun). "HIV". Seminars in fetal & neonatal medicine. 12 (3): 174–81. doi:10.1016/j.siny.2007.01.009. PMID 17321814. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Alimonti-48] Alimonti JB, Ball TB, Fowke KR (2003). "Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS". J. Gen. Virol. 84 (7): 1649–1661. doi:10.1099/vir.0.19110-0. PMID 12810858.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[ICTV61.0.6-49] International Committee on Taxonomy of Viruses (2002). "61.0.6. Lentivirus". National Institutes of Health. Archived from the original on April 18, 2006. Retrieved June 25, 2012.

[ICTV61.-50] International Committee on Taxonomy of Viruses (2002). "61. Retroviridae". National Institutes of Health. Archived from the original on June 29, 2006. Retrieved June 25, 2012.

[Levy-51] Lévy, J. A. (1993). "HIV pathogenesis and long-term survival". AIDS. 7 (11): 1401–10. doi:10.1097/00002030-199311000-00001. PMID 8280406.

[JASmith-52] Smith, Johanna A.; Daniel, René (Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia) (2006). "Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses". ACS Chem Biol. 1 (4): 217–26. doi:10.1021/cb600131q. PMID 17163676.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[53] Martínez, edited by Miguel Angel (2010). RNA interference and viruses : current innovations and future trends. Norfolk: Caister Academic Press. p. 73. ISBN 9781904455561. {{cite book}}: |first= has generic name (help)

[54] Immunology, infection, and immunity. Washington, D.C.: ASM Press. 2004. p. 550. ISBN 9781555812461. {{cite book}}: |first= has generic name (help); |first= missing |last= (help)

[55] Gilbert, PB; et al. (February 28, 2003). "Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal". Statistics in Medicine. 22 (4): 573–593. doi:10.1002/sim.1342. PMID 12590415.

[Reeves-56] Reeves, J. D. and Doms, R. W (2002). "Human Immunodeficiency Virus Type 2". J. Gen. Virol. 83 (Pt 6): 1253–65. doi:10.1099/vir.0.18253-0. PMID 12029140.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Piatak-57] Piatak, M., Jr, Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. and Lifson, J.D. (1993). "High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR". Science. 259 (5102): 1749–1754. Bibcode:1993Sci...259.1749P. doi:10.1126/science.8096089. PMID 8096089.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Pantaleo1998-58] Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS. (1997). "The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia". Proc Natl Acad Sci U S A. 94 (1): 254–258. Bibcode:1997PNAS...94..254P. doi:10.1073/pnas.94.1.254. PMC 19306. PMID 8990195.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[pmid8040596-59] Guss DA (1994). "The acquired immune deficiency syndrome: an overview for the emergency physician, Part 1". J Emerg Med. 12 (3): 375–84. doi:10.1016/0736-4679(94)90281-X. PMID 8040596.

[pmid16679064-60] Hel Z, McGhee JR, Mestecky J (2006). "HIV infection: first battle decides the war". Trends Immunol. 27 (6): 274–81. doi:10.1016/j.it.2006.04.007. PMID 16679064. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[61] Arie J. Zuckerman et al. (eds) (2007). Principles and practice of clinical virology (6th ed.). Hoboken, N.J.: Wiley. p. 905. ISBN 978-0-470-51799-4. {{cite book}}: |author= has generic name (help)

[pmid15365095-62] Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M (2004). "Primary HIV-1 infection is associated with preferential depletion of CD4⁺ T cells from effector sites in the gastrointestinal tract". J. Exp. Med. 200 (6): 761–70. doi:10.1084/jem.20041196. PMC 2211967. PMID 15365095. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[pmid15365096-63] Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC (2004). "CD4⁺ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract". J. Exp. Med. 200 (6): 749–59. doi:10.1084/jem.20040874. PMC 2211962. PMID 15365096. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[Julio2011-64] tor, Julio Aliberti, (2011). Control of Innate and Adaptive Immune Responses During Infectious Diseases. New York, NY: Springer Verlag. p. 145. ISBN 978-1-4614-0483-5. {{cite book}}: |last= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)

[pmid18161758-65] Appay V, Sauce D (2008). "Immune activation and inflammation in HIV-1 infection: causes and consequences". J. Pathol. 214 (2): 231–41. doi:10.1002/path.2276. PMID 18161758. {{cite journal}}: Unknown parameter |month= ignored (help)

[pmid17115046-66] Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006). "Microbial translocation is a cause of systemic immune activation in chronic HIV infection". Nat. Med. 12 (12): 1365–71. doi:10.1038/nm1511. PMID 17115046. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[ChildDiag2010-67] Kellerman, S (2010 Jul 20). "HIV testing for children in resource-limited settings: what are we waiting for?". PLoS medicine. 7 (7): e1000285. doi:10.1371/journal.pmed.1000285. PMC 2907270. PMID 20652012. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)

[UN2011Eighty-68] UNAIDS 2011 pg. 70–80

[CDCCase2008-69] Schneider, E (December 5, 2008). "Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008". MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 57 (RR–10): 1–12. PMID 19052530. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[70] Crosby, R (2012 Mar). "Condom effectiveness: where are we now?". Sexual health. 9 (1): 10–7. doi:10.1071/SH11036. PMID 22348628. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[WHOCondoms-71] "Condom Facts and Figures". WHO. 2003. Retrieved January 17, 2006. {{cite web}}: Unknown parameter |month= ignored (help)

[72] Gallo, MF (2012 Mar). "A review of the effectiveness and acceptability of the female condom for dual protection". Sexual health. 9 (1): 18–26. doi:10.1071/SH11037. PMID 22348629. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[VagGel2012-73] Celum, C (2012 Feb). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current opinion in infectious diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[74] Baptista, M (November 1, 2009). "Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds". Mini reviews in medicinal chemistry. 9 (13): 1556–67. doi:10.2174/138955709790361548. PMID 20205637. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[75] Siegfried, N (April 15, 2009). Siegfried, Nandi (ed.). "Male circumcision for prevention of heterosexual acquisition of HIV in men". Cochrane database of systematic reviews (Online) (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID 19370585. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[76] "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". World Health Organization. March 28, 2007.

[77] Larke, N (2010 May 27 – Jun 9). "Male circumcision, HIV and sexually transmitted infections: a review". British journal of nursing (Mark Allen Publishing). 19 (10): 629–34. PMID 20622758. {{cite journal}}: Check date values in: |date= (help)

[78] Eaton, L (2009 Nov). "Behavioral aspects of male circumcision for the prevention of HIV infection". Current HIV/AIDS reports. 6 (4): 187–93. doi:10.1007/s11904-009-0025-9. PMID 19849961. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)(subscription required)

[79] Kim, HH (2010 Nov). "Male circumcision: Africa and beyond?". Current opinion in urology. 20 (6): 515–9. doi:10.1097/MOU.0b013e32833f1b21. PMID 20844437. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[80] Templeton, DJ (2010 Feb). "Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men". Current opinion in infectious diseases. 23 (1): 45–52. doi:10.1097/QCO.0b013e328334e54d. PMID 19935420. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[81] Wiysonge, CS.; Kongnyuy, EJ.; Shey, M.; Muula, AS.; Navti, OB.; Akl, EA.; Lo, YR. (2011). Wiysonge, Charles Shey (ed.). "Male circumcision for prevention of homosexual acquisition of HIV in men". Cochrane Database Syst Rev (6): CD007496. doi:10.1002/14651858.CD007496.pub2. PMID 21678366. {{cite journal}}: Cite has empty unknown parameter: |month= (help)

[82] Eaton LA, Kalichman S (2007). "Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies". Curr HIV/AIDS Rep. 4 (4): 165–72. doi:10.1007/s11904-007-0024-7. PMC 2937204. PMID 18366947. {{cite journal}}: Unknown parameter |month= ignored (help)

[83] Utz-Billing I, Kentenich H (2008). "Female genital mutilation: an injury, physical and mental harm". J Psychosom Obstet Gynaecol. 29 (4): 225–9. doi:10.1080/01674820802547087. PMID 19065392. {{cite journal}}: Unknown parameter |month= ignored (help)

[84] Underhill K, Operario D, Montgomery P (2008). Operario, Don (ed.). "Abstinence-only programs for HIV infection prevention in high-income countries". Cochrane Database of Systematic Reviews (4): CD005421. doi:10.1002/14651858.CD005421.pub2. PMID 17943855.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[85] Tolli, MV (May 28, 2012). "Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies". Health education research. doi:10.1093/her/cys055. PMID 22641791.

[86] Ljubojević, S (2010). "Sexually transmitted infections and adolescence". Acta dermatovenerologica Croatica : ADC. 18 (4): 305–10. PMID 21251451. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Patel2008-87] Patel VL, Yoskowitz NA, Kaufman DR, Shortliffe EH (2008). "Discerning patterns of human immunodeficiency virus risk in healthy young adults". Am J Med. 121 (4): 758–764. doi:10.1016/j.amjmed.2008.04.022. PMC 2597652. PMID 18724961.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[88] Anglemyer, A (August 10, 2011). Rutherford, George W (ed.). "Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples". Cochrane database of systematic reviews (Online) (8): CD009153. doi:10.1002/14651858.CD009153.pub2. PMID 21833973. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[89] Centers for Disease Control (CDC) (1987). "Recommendations for prevention of HIV transmission in health-care settings". MMWR. 36 (Suppl 2): 1S–18S. PMID 3112554. {{cite journal}}: Unknown parameter |month= ignored (help)

[Kurth2011-90] Kurth, AE (2011 Mar). "Combination HIV prevention: significance, challenges, and opportunities". Current HIV/AIDS reports. 8 (1): 62–72. doi:10.1007/s11904-010-0063-3. PMC 3036787. PMID 20941553. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[91] MacArthur, G. J. (October 4, 2012). "Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis". BMJ. 345 (oct03 3): e5945–e5945. doi:10.1136/bmj.e5945. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Prevention2012-92] [No authors listed] (2012). "HIV exposure through contact with body fluids". Prescrire Int. 21 (126): 100–1, 103–5. PMID 22515138. {{cite journal}}: Unknown parameter |month= ignored (help)

[NEJM2011Sex-93] Linden, JA (September 1, 2011). "Clinical practice. Care of the adult patient after sexual assault". The New England Journal of Medicine. 365 (9): 834–41. doi:10.1056/NEJMcp1102869. PMID 21879901.

[CochranePEP2007-94] Young, TN (January 24, 2007). Young, Taryn (ed.). "Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure". Cochrane database of systematic reviews (Online) (1): CD002835. doi:10.1002/14651858.CD002835.pub3. PMID 17253483. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[95] Siegfried, N (July 6, 2011). Siegfried, Nandi (ed.). "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection". Cochrane database of systematic reviews (Online) (7): CD003510. doi:10.1002/14651858.CD003510.pub3. PMID 21735394. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[96] "WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV – Infections in Pregnant Women, Mothers and their Infants – Consensus statement" (PDF). October 25–27, 2006. Archived from the original (PDF) on April 9, 2008. Retrieved March 12, 2008. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)CS1 maint: date and year (link)

[97] Horvath, T (January 21, 2009). Horvath, Tara (ed.). "Interventions for preventing late postnatal mother-to-child transmission of HIV". Cochrane database of systematic reviews (Online) (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMID 19160297. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[98] UNAIDS (May 18, 2012). "The quest for an HIV vaccine".

[99] Reynell, L (March 2, 2012). "HIV vaccines: an attainable goal?". Swiss medical weekly. 142: w13535. doi:10.4414/smw.2012.13535. PMID 22389197. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[100] U.S. Army Office of the Surgeon General (March 21, 2011). "HIV Vaccine Trial in Thai Adults". ClinicalTrials.gov. Retrieved June 28, 2011.

[101] U.S. Army Office of the Surgeon General (June 2, 2010). "Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial". ClinicalTrials.gov.

[LE2011-102] May, MT (2011 Dec). "Life expectancy of HIV-positive adults: a review". Sexual health. 8 (4): 526–33. doi:10.1071/SH11046. PMID 22127039. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[103] "First documented case of child cured of HIV". Science Daily. March 3, 2013. Retrieved March 4, 2013.

[WHOTx2010Pg19-104] ^ ^a ^b ^c ^d ^e ^f ^g ^h Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (PDF). World Health Organization. 2010. pp. 19–20. ISBN 978-92-4-159976-4.

[105] Sax, PE (April 30, 2009). "When to start antiretroviral therapy—ready when you are?". The New England Journal of Medicine. 360 (18): 1897–9. doi:10.1056/NEJMe0902713. PMID 19339713. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[CochraneART2010-106] Siegfried, N (March 17, 2010). Siegfried, Nandi (ed.). "Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults". Cochrane database of systematic reviews (Online) (3): CD008272. doi:10.1002/14651858.CD008272.pub2. PMID 20238364. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Guidelines2009-107] Panel on Antiretroviral Guidelines for Adults and Adolescents (December 1, 2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (PDF). United States Department of Health and Human Services. p. i.

[108] When To Start, Consortium (April 18, 2009). "Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies". Lancet. 373 (9672): 1352–63. doi:10.1016/S0140-6736(09)60612-7. PMC 2670965. PMID 19361855. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[109] Beard, J (2009 Nov). "Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review". AIDS care. 21 (11): 1343–56. doi:10.1080/09540120902889926. PMID 20024710. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[110] Orrell, C (2005 Nov). "Antiretroviral adherence in a resource-poor setting". Current HIV/AIDS reports. 2 (4): 171–6. doi:10.1007/s11904-005-0012-8. PMID 16343374. {{cite journal}}: Check date values in: |date= (help)

[111] Malta, M (2008 Aug). "Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review". Addiction (Abingdon, England). 103 (8): 1242–57. doi:10.1111/j.1360-0443.2008.02269.x. PMID 18855813. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[112] Nachega, JB (2011 Apr). "HIV treatment adherence, drug resistance, virologic failure: evolving concepts". Infectious disorders drug targets. 11 (2): 167–74. PMID 21406048. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[113] Nachega, JB (2010 Jan). "Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities". Current opinion in HIV and AIDS. 5 (1): 70–7. doi:10.1097/COH.0b013e328333ad61. PMID 20046150. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Montessori2004-114] Montessori, V., Press, N., Harris, M., Akagi, L., Montaner, J. S. (2004). "Adverse effects of antiretroviral therapy for HIV infection". CMAJ. 170 (2): 229–238. PMC 315530. PMID 14734438.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Burgoyne2008-115] Burgoyne RW, Tan DH (2008). "Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act". J. Antimicrob. Chemother. 61 (3): 469–73. doi:10.1093/jac/dkm499. PMID 18174196. {{cite journal}}: Unknown parameter |month= ignored (help)

[116] Barbaro, G (2011 Dec). "Human immunodeficiency virus & cardiovascular risk". The Indian journal of medical research. 134 (6): 898–903. doi:10.4103/0971-5916.92634. PMC 3284097. PMID 22310821. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)

[117] Orsi, F (2010 May). "Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries". Current opinion in HIV and AIDS. 5 (3): 237–41. doi:10.1097/COH.0b013e32833860ba. PMID 20539080. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[UN2011ONESIXTY-118] UNAIDS 2011 pg. 150–160

[USKID2011-119] "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (PDF). The Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Aug 11,2011. {{cite web}}: Check date values in: |date= (help)

[WHOKID2010-120] Antiretroviral therapy for HIV infection in infants and children (PDF). World Health Organization. 2010. p. 2. ISBN 978-92-4-159980-1.

[Laurence-121] Laurence J (2006). "Hepatitis A and B virus immunization in HIV-infected persons". AIDS Reader. 16 (1): 15–17. PMID 16433468.

[PCP2011-122] Huang, L (2011 Jun). "HIV-associated Pneumocystis pneumonia". Proceedings of the American Thoracic Society. 8 (3): 294–300. doi:10.1513/pats.201009-062WR. PMC 3132788. PMID 21653531. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[PEPpocketguide-123] "Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America". United States Department of Health and Human Services. February 2, 2007.

[InfectionBook2008-124] Smith, [edited by] Blaine T. (2008). Concepts in immunology and immunotherapeutics (4th ed.). Bethesda, Md.: American Society of Health-System Pharmacists. p. 143. ISBN 978-1-58528-127-5. {{cite book}}: |first= has generic name (help)

[pmid18608078-125] Littlewood RA, Vanable PA (2008). "Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care". AIDS Care. 20 (8): 1002–18. doi:10.1080/09540120701767216. PMC 2570227. PMID 18608078. {{cite journal}}: Unknown parameter |month= ignored (help)

[pmid15969772-126] Mills E, Wu P, Ernst E (2005). "Complementary therapies for the treatment of HIV: in search of the evidence". Int J STD AIDS. 16 (6): 395–403. doi:10.1258/0956462054093962. PMID 15969772. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[Irlam-127] Irlam, JH (December 8, 2010). Irlam, James H (ed.). "Micronutrient supplementation in children and adults with HIV infection". Cochrane database of systematic reviews (Online) (12): CD003650. doi:10.1002/14651858.CD003650.pub3. PMID 21154354. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[128] Stone, CA (2010 Nov). "Role of selenium in HIV infection". Nutrition Reviews. 68 (11): 671–81. doi:10.1111/j.1753-4887.2010.00337.x. PMC 3066516. PMID 20961297. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[129] Forrester, JE (2011 Dec). "Micronutrients in HIV/AIDS: is there evidence to change the WHO 2003 recommendations?". The American journal of clinical nutrition. 94 (6): 1683S–1689S. doi:10.3945/ajcn.111.011999. PMC 3226021. PMID 22089440. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[WHO_nutrients-130] World Health Organization (2003-05). Nutrient requirements for people living with HIV/AIDS: Report of a technical consultation (PDF). Geneva. Archived from the original (PDF) on March 25, 2009. Retrieved March 31, 2009. {{cite book}}: Check date values in: |date= (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[131] Liu JP, Manheimer E, Yang M (2005). Liu, Jian Ping (ed.). "Herbal medicines for treating HIV infection and AIDS". Cochrane Database Syst Rev (3): CD003937. doi:10.1002/14651858.CD003937.pub2. PMID 16034917.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Knoll2007-132] Knoll B, Lassmann B, Temesgen Z (2007). "Current status of HIV infection: a review for non-HIV-treating physicians". Int J Dermatol. 46 (12): 1219–28. doi:10.1111/j.1365-4632.2007.03520.x. PMID 18173512.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[UNAIDS2007-133] Joint United Nations Programme on HIV/AIDS, World Health Organization (2007). "2007 AIDS epidemic update" (PDF). Retrieved March 12, 2008. {{cite web}}: Unknown parameter |month= ignored (help)

[Morgan2-134] Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA (2002). "HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?". AIDS. 16 (4): 597–632. doi:10.1097/00002030-200203080-00011. PMID 11873003.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[135] Zwahlen M, Egger M (2006). "Progression and mortality of untreated HIV-positive individuals living in resource-limited settings: update of literature review and evidence synthesis" (PDF). UNAIDS Obligation HQ/05/422204. Archived from the original (PDF) on April 9, 2008. Retrieved March 19, 2008. {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[LifeExpecr2008-136] Antiretroviral Therapy Cohort Collaboration (2008). "Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies". Lancet. 372 (9635): 293–9. doi:10.1016/S0140-6736(08)61113-7. PMC 3130543. PMID 18657708.

[Schack2006-137] Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. (2006). "The lifetime cost of current HIV care in the United States". Med Care. 44 (11): 990–997. doi:10.1097/01.mlr.0000228021.89490.2a. PMID 17063130.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)

[138] van Sighem, AI (June 19, 2010). "Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals". AIDS (London, England). 24 (10): 1527–35. doi:10.1097/QAD.0b013e32833a3946. PMID 20467289. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Cancer2005-139] Cheung, MC (2005 Jun–Jul). "AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy". The oncologist. 10 (6): 412–26. doi:10.1634/theoncologist.10-6-412. PMID 15967835. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Tang-140] Tang J, Kaslow RA (2003). "The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy". AIDS. 17 (Suppl 4): S51–S60. doi:10.1097/00002030-200317004-00006. PMID 15080180.

[Lawn-141] Lawn SD (2004). "AIDS in Africa: the impact of co-infections on the pathogenesis of HIV-1 infection". J. Infect. Dis. 48 (1): 1–12. doi:10.1016/j.jinf.2003.09.001. PMID 14667787.

[Campbell-142] Campbell GR; Pasquier E; Watkins J; et al. (2004). "The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis". J. Biol. Chem. 279 (46): 48197–48204. doi:10.1074/jbc.M406195200. PMID 15331610. {{cite journal}}: Unknown parameter |author-separator= ignored (help)CS1 maint: unflagged free DOI (link)

[Campbell2-143] Campbell GR, Watkins JD, Esquieu D, Pasquier E, Loret EP, Spector SA (2005). "The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells". J. Biol. Chem. 280 (46): 38376–39382. doi:10.1074/jbc.M506630200. PMID 16155003.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)

[144] "Tuberculosis". Fact sheet 104. World Health Organization. March 2012. Retrieved August 29, 2012.

[WHO2011-145] World Health Organization (2011). "Global tuberculosis control 2011" (PDF). ISBN 978 92 4 156438 0. Retrieved August 29, 2012.

[146] Pennsylvania, Editors, Raphael Rubin, M.D., Professor of Pathology, David S. Strayer, M.D., Ph.D., Professor of Pathology, Department of Pathology and Cell Biology, Jefferson Medical College of Thomas Jefferson University Philadelphia, Pennsylvania ; Founder and Consulting Editor, Emanuel Rubin, M.D., Gonzalo Aponte Distinguished Professor of Pathology, Chairman Emeritus of the Department of Pathology and Cell Biology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, (2011). Rubin's pathology : clinicopathologic foundations of medicine (Sixth ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 154. ISBN 978-1-60547-968-2. {{cite book}}: |first= has generic name (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)

[Woods2009-147] Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19462243 , please use {{cite journal}} with |pmid=19462243 instead.

[Brown2006-148] Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17086056, please use {{cite journal}} with |pmid=17086056 instead.

[Nicholas2007-149] Nicholas PK; Kemppainen JK; Canaval GE; et al. (2007). "Symptom management and self-care for peripheral neuropathy in HIV/AIDS". AIDS Care. 19 (2): 179–89. doi:10.1080/09540120600971083. PMID 17364396. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)

[Boshoff2002-150] Boshoff C, Weiss R (2002). "AIDS-related malignancies". Nat. Rev. Cancer. 2 (5): 373–382. doi:10.1038/nrc797. PMID 12044013.

[Yarchoan2005-151] Yarchoan R, Tosato G, Little RF (2005). "Therapy insight: AIDS-related malignancies – the influence of antiviral therapy on pathogenesis and management". Nat. Clin. Pract. Oncol. 2 (8): 406–415. doi:10.1038/ncponc0253. PMID 16130937.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Post2009-152] Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19106702, please use {{cite journal}} with |pmid=19106702 instead.

[153] [1]

[Cohen2008-154] Cohen, MS (2008 Apr). "The spread, treatment, and prevention of HIV-1: evolution of a global pandemic". The Journal of Clinical Investigation. 118 (4): 1244–54. doi:10.1172/JCI34706. PMC 2276790. PMID 18382737. Retrieved 17 September 2012. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[UN2011Thirty-155] UNAIDS 2011 pg. 20–30

[UN2011Fifty-156] UNAIDS 2011 pg. 40–50

[M117-157] Mandell, Bennett, and Dolan (2010). Chapter 117.

[USAEPI2011-158] Centers for Disease Control and Prevention, (CDC) (June 3, 2011). "HIV surveillance—United States, 1981–2008". MMWR. Morbidity and mortality weekly report. 60 (21): 689–93. PMID 21637182.

[159] Health Protection Agency (2010). HIV in the United Kingdom: 2010 Report.

[160] Surveillance (2010). HIV and AIDS in Canada : surveillance report to December 31, 2009 (PDF). Ottawa: Public Health Agency of Canada, Centre for Communicable Diseases and Infection Control, Surveillance and Risk Assessment Division. ISBN 978-1-100-52141-1. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[MMWR2-161] Gottlieb MS (2006). "Pneumocystis pneumonia—Los Angeles. 1981". Am J Public Health. 96 (6): 980–1, discussion 982–3. doi:10.2105/AJPH.96.6.980. PMC 1470612. PMID 16714472. Archived from the original on April 22, 2009. Retrieved March 31, 2009. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[pmid7287964-162] Friedman-Kien AE (1981). "Disseminated Kaposi's sarcoma syndrome in young homosexual men". J. Am. Acad. Dermatol. 5 (4): 468–71. doi:10.1016/S0190-9622(81)80010-2. PMID 7287964. {{cite journal}}: Unknown parameter |month= ignored (help)

[pmid6116083-163] Hymes KB; Cheung T; Greene JB; et al. (1981). "Kaposi's sarcoma in homosexual men-a report of eight cases". Lancet. 2 (8247): 598–600. doi:10.1016/S0140-6736(81)92740-9. PMID 6116083. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)

[Basavapathruni_2007-164] Basavapathruni, A; Anderson, KS (2007). "Reverse transcription of the HIV-1 pandemic". The FASEB Journal. 21 (14): 3795–3808. doi:10.1096/fj.07-8697rev. PMID 17639073. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)

[MMWR1982a-165] Centers for Disease Control (CDC) (1982). "Persistent, generalized lymphadenopathy among homosexual males". MMWR Morb Mortal Wkly Rep. 31 (19): 249–251. PMID 6808340. Retrieved August 31, 2011.

[Barre-166] Barré-Sinoussi F; Chermann JC; Rey F; et al. (1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–871. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. PMID 6189183. {{cite journal}}: Unknown parameter |author-separator= ignored (help)

[MMWR1982b-167] Centers for Disease Control (CDC) (1982). "Opportunistic infections and Kaposi's sarcoma among Haitians in the United States". MMWR Morb Mortal Wkly Rep. 31 (26): 353–354, 360–361. PMID 6811853. Retrieved August 31, 2011.

[SciRep470b-168] "Making Headway Under Hellacious Circumstances" (PDF). American Association for the Advancement of Science. July 28, 2006. Retrieved June 23, 2008.

[Altman-169] Altman LK (May 11, 1982). "New homosexual disorder worries health officials". The New York Times. Retrieved August 31, 2011.

[Kher-170] Kher U (July 27, 1982). "A Name for the Plague". Time. Archived from the original on March 7, 2008. Retrieved March 10, 2008. {{cite news}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[MMWR1982c-171] Centers for Disease Control (CDC) (1982). "Update on acquired immune deficiency syndrome (AIDS)—United States". MMWR Morb Mortal Wkly Rep. 31 (37): 507–508, 513–514. PMID 6815471.

[Gallo-172] RC Gallo, PS Sarin, EP Gelmann, M Robert-Guroff, E Richardson, VS Kalyanaraman, D Mann, GD Sidhu, RE Stahl, S Zolla-Pazner, J Leibowitch, and M Popovic (1983). "Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 865–867. Bibcode:1983Sci...220..865G. doi:10.1126/science.6601823. PMID 6601823.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Montagnier-173] Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1126/science.6189183, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1126/science.6189183 instead.

[174] Aldrich, ed. by Robert (2001). Who's who in gay and lesbian history. London: Routledge. p. 154. ISBN 9780415229746. {{cite book}}: |first= has generic name (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[pmid9989410-175] Gao F; Bailes E; Robertson DL; et al. (1999). "Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes". Nature. 397 (6718): 436–41. Bibcode:1999Natur.397..436G. doi:10.1038/17130. PMID 9989410. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)

[Keele-176] Keele, B. F., van Heuverswyn, F., Li, Y. Y., Bailes, E., Takehisa, J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V., Liegois, F., Loul, S., Mpoudi Ngole, E., Bienvenue, Y., Delaporte, E., Brookfield, J. F. Y., Sharp, P. M., Shaw, G. M., Peeters, M., and Hahn, B. H. (July 28, 2006). "Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1". Science. 313 (5786): 523–6. Bibcode:2006Sci...313..523K. doi:10.1126/science.1126531. PMC 2442710. PMID 16728595.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Goodier-177] Goodier, J., and Kazazian, H. (2008). "Retrotransposons Revisited: The Restraint and Rehabilitation of Parasites". Cell. 135 (1): 23–35. doi:10.1016/j.cell.2008.09.022. PMID 18854152.{{cite journal}}: CS1 maint: multiple names: authors list (link)(subscription required)

[Sharp2001-178] Sharp, P. M.; Bailes, E.; Chaudhuri, R. R.; Rodenburg, C. M.; Santiago, M. O.; Hahn, B. H. (2001). "The origins of acquired immune deficiency syndrome viruses: where and when?" (PDF). Philosophical Transactions of the Royal Society B: Biological Sciences. 356 (1410): 867–76. doi:10.1098/rstb.2001.0863. PMC 1088480. PMID 11405934.

[Kalish2005-179] Kalish ML; Wolfe ND; Ndongmo CD; McNicholl J; Robbins KE; et al. (2005). "Central African hunters exposed to simian immunodeficiency virus". Emerg Infect Dis. 11 (12): 1928–30. doi:10.3201/eid1112.050394. PMC 3367631. PMID 16485481. {{cite journal}}: Unknown parameter |author-separator= ignored (help)

[Marx2001-180] Marx PA, Alcabes PG, Drucker E (2001). "Serial human passage of simian immunodeficiency virus by unsterile injections and the emergence of epidemic human immunodeficiency virus in Africa" (PDF). Philos Trans R Soc Lond B Biol Sci. 356 (1410): 911–20. doi:10.1098/rstb.2001.0867. PMC 1088484. PMID 11405938.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[Worobey2008-181] Worobey, Michael; Gemmel, Marlea; Teuwen, Dirk E.; Haselkorn, Tamara; Kunstman, Kevin; Bunce, Michael; Muyembe, Jean-Jacques; Kabongo, Jean-Marie M.; Kalengayi, Raphaël M. (2008). "Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960" (PDF). Nature. 455 (7213): 661–4. Bibcode:2008Natur.455..661W. doi:10.1038/nature07390. PMID 18833279. (subscription required)

[Sousa2010-182] Sousa, João Dinis de; Müller, Viktor; Lemey, Philippe; Vandamme, Anne-Mieke; Vandamme, Anne-Mieke (2010). Martin, Darren P. (ed.). "High GUD Incidence in the Early 20th Century Created a Particularly Permissive Time Window for the Origin and Initial Spread of Epidemic HIV Strains". PLoS ONE. 5 (4): e9936. doi:10.1371/journal.pone.0009936. PMC 2848574. PMID 20376191.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[Chitnis2000-183] Chitnis, Amit; Rawls, Diana; Moore, Jim (2000). "Origin of HIV Type 1 in Colonial French Equatorial Africa?". AIDS Research and Human Retroviruses. 16 (1): 5–8. doi:10.1089/088922200309548. PMID 10628811.(subscription required)

[McNeil-184] Donald G. McNeil, Jr. (September 16, 2010). "Precursor to H.I.V. Was in Monkeys for Millennia". New York Times. Retrieved September 17, 2010. Dr. Marx believes that the crucial event was the introduction into Africa of millions of inexpensive, mass-produced syringes in the 1950s. ... suspect that the growth of colonial cities is to blame. Before 1910, no Central African town had more than 10,000 people. But urban migration rose, increasing sexual contacts and leading to red-light districts. {{cite news}}: Cite has empty unknown parameter: |coauthors= (help)

[Zhu-185] Zhu, T., Korber, B. T., Nahmias, A. J., Hooper, E., Sharp, P. M. and Ho, D. D. (1998). "An African HIV-1 Sequence from 1959 and Implications for the Origin of the epidemic". Nature. 391 (6667): 594–7. Bibcode:1998Natur.391..594Z. doi:10.1038/35400. PMID 9468138.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[186] Kolata, Gina (October 28, 1987). "Boy's 1969 Death Suggests AIDS Invaded U.S. Several Times". The New York Times. Retrieved February 11, 2009.

[Thomas_Gilbert-187] Gilbert, M. Thomas P.; Rambaut, Andrew; Wlasiuk, Gabriela; Spira, Thomas J.; Pitchenik, Arthur E.; Worobey, Michael (November 20, 2007). "The emergence of HIV/AIDS in the Americas and beyond" (PDF). PNAS. 104 (47): 18566–18570. Bibcode:2007PNAS..10418566G. doi:10.1073/pnas.0705329104. PMC 2141817. PMID 17978186.

[UNAIDS2006Ch4-188] "The impact of AIDS on people and societies". 2006 Report on the global AIDS epidemic. UNAIDS. 2006. ISBN 92-9173-479-9. {{cite book}}: |access-date= requires |url= (help); |format= requires |url= (help); External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)

[Ogden-189] Ogden J, Nyblade L (2005). "Common at its core: HIV-related stigma across contexts" (PDF). International Center for Research on Women. Retrieved February 15, 2007.

[Herek1999-190] Herek GM, Capitanio JP (1999). "AIDS Stigma and sexual prejudice" (PDF). American Behavioral Scientist. 42 (7): 1130–1147. doi:10.1177/0002764299042007006. Retrieved March 27, 2006.

[Snyder-191] Snyder M, Omoto AM, Crain AL (1999). "Punished for their good deeds: stigmatization for AIDS volunteers". American Behavioral Scientist. 42 (7): 1175–1192. doi:10.1177/0002764299042007009.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[192] Sharma, A.K. Population and society. New Delhi: Concept Pub. Co. p. 242. ISBN 9788180698187.

[Herek2002-193] Herek, GM (2002 Mar). "HIV-related stigma and knowledge in the United States: prevalence and trends, 1991–1999". American journal of public health. 92 (3): 371–7. doi:10.2105/AJPH.92.3.371. PMC 1447082. PMID 11867313. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[194] De Cock, KM (2012 Jun 19). "The evolving epidemiology of HIV/AIDS". AIDS (London, England). 26 (10): 1205–13. doi:10.1097/QAD.0b013e328354622a. PMID 22706007. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Bell-et-al-2003-195] Bell C, Devarajan S, Gersbach H (2003). "The long-run economic costs of AIDS: theory and an application to South Africa" (PDF). World Bank Policy Research Working Paper No. 3152. Retrieved April 28, 2008. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)

[Greener-196] Greener R (2002). "AIDS and macroeconomic impact". In S, Forsyth (ed.) (ed.). State of The Art: AIDS and Economics (PDF). IAEN. pp. 49–55. {{cite book}}: |editor= has generic name (help)

[WBank-197] Over M (1992). "The macroeconomic impact of AIDS in Sub-Saharan Africa, Population and Human Resources Department" (PDF). The World Bank. Archived from the original (PDF) on May 27, 2008. Retrieved May 3, 2008. {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[198] "AIDS Stigma". News-medical.net. Retrieved November 1, 2011.

[Thirty_years_after_AIDS_discovery,_appreciation_growing_for_Catholic_approach-199] "Thirty years after AIDS discovery, appreciation growing for Catholic approach". Catholicnewsagency.com. June 5, 2011. Retrieved November 1, 2011.

[BBC18102011-200] "Church HIV prayer cure claims 'cause three deaths'". BBC News. October 18, 2011. Retrieved October 18, 2011.

[201] "Rock Hudson announces he has AIDS – History.com This Day in History – 7/25/1985". History.com. Retrieved November 1, 2011.

[202] Coleman, Brian (June 25, 2007). "Thatcher the gay icon". New Statesman. Retrieved November 1, 2011.

[203] "November 24, 1991: Giant of rock dies". BBC On This Day. BBC News. Retrieved November 1, 2011.

[204] "Freddie Mercury". Nndb.com. Retrieved November 1, 2011.

[205] Bliss, Dominic. "Frozen In Time: Arthur Ashe". iTENNISstore.com. Retrieved June 25, 2012.

[206] "Tributes to Arthur Ashe". The Independent. London. February 8, 1993. Retrieved July 24, 2012.

[207] Cosgrove, Ben. "Behind the Picture: The Photo That Changed the Face of AIDS". LIFE magazine. Retrieved August 16, 2012.

[Duesberg-208] Duesberg, P. H. (1988). "HIV is not the cause of AIDS". Science. 241 (4865): 514, 517. Bibcode:1988Sci...241..514D. doi:10.1126/science.3399880. PMID 3399880.Cohen, J. (1994). "The Controversy over HIV and AIDS" (PDF). Science. 266 (5191): 1642–1649. Bibcode:1994Sci...266.1642C. doi:10.1126/science.7992043. PMID 7992043. Retrieved March 31, 2009.

[Kalichman-209] Kalichman, Seth (2009). Denying AIDS: Conspiracy Theories, Pseudoscience, and Human Tragedy. New York: Copernicus Books (Springer Science+Business Media). ISBN 978-0-387-79475-4.

[SmithNovella-210] Smith TC, Novella SP (2007). "HIV Denial in the Internet Era". PLoS Med. 4 (8): e256. doi:10.1371/journal.pmed.0040256. PMC 1949841. PMID 17713982. Retrieved November 7, 2009. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)

[consensus-211] Various (Last updated January 14, 2010). "Resources and Links, HIV-AIDS Connection". National Institute of Allergy and Infectious Diseases. Retrieved 2009-02-22. {{cite web}}: Check date values in: |date= (help)

[212] Watson J (2006). "Scientists, activists sue South Africa's AIDS 'denialists'". Nat. Med. 12 (1): 6. doi:10.1038/nm0106-6a. PMID 16397537.

[213] Baleta A (2003). "S Africa's AIDS activists accuse government of murder". Lancet. 361 (9363): 1105. doi:10.1016/S0140-6736(03)12909-1. PMID 12672319.

[214] Cohen J (2000). "South Africa's new enemy". Science. 288 (5474): 2168–70. doi:10.1126/science.288.5474.2168. PMID 10896606.

[infektion-215] Operation INFEKTION – Soviet Bloc Intelligence and Its AIDS Disinformation Campaign. Thomas Boghardt. 2009

[216] Blechner MJ (1997). Hope and mortality: psychodynamic approaches to AIDS and HIV. Hillsdale, NJ: Analytic Press. ISBN 0-88163-223-6. {{cite book}}: Unknown parameter |unused_data= ignored (help)

[217] Kirby DB, Laris BA, Rolleri LA (2007). "Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world". J Adolesc Health. 40 (3): 206–17. doi:10.1016/j.jadohealth.2006.11.143. PMID 17321420. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[Ferrantelli-218] Ferrantelli F, Cafaro A, Ensoli B (2004). "Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccine". Curr. Opin. Biotechnol. 15 (6): 543–56. doi:10.1016/j.copbio.2004.10.008. PMID 15560981. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[219] Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT (2008). "The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus". Nat. Rev. Microbiol. 6 (2): 143–55. doi:10.1038/nrmicro1819. PMID 18197170. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[ghivberlin-220] "German HIV patient cured after stem cell transplant". Belfast Telegraph. December 15, 2010. Retrieved December 15, 2010.

[Blood-221] Allers, K (March 10, 2011). "Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation". Blood. 117 (10): 2791–9. doi:10.1182/blood-2010-09-309591. PMID 21148083. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Wall_Street_Journal_2008-222] Mark Schoofs (November 7, 2008). "A Doctor, a Mutation and a Potential Cure for AIDS". The Wall Street Journal. Retrieved November 9, 2008.

[Huetter2009-223] Hütter G, Nowak D, Mossner M, Ganepola S, Ganepola A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E (2009). "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation". N Engl J Med. 360 (7): 692–698. doi:10.1056/NEJMoa0802905. PMID 19213682. Retrieved March 31, 2009.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[NEJMLevy-224] Levy JA (2009). "Not an HIV Cure, but Encouraging New Directions". N Engl J Med. 360 (7): 724–725. doi:10.1056/NEJMe0810248. PMID 19213687. Retrieved March 31, 2009.

[225] Nath, A (March 13, 2011). "Eradication of HIV from the brain: reasons for pause". AIDS (London, England). 25 (5): 577–80. doi:10.1097/QAD.0b013e3283437d2f. PMID 21160414. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)(subscription required)

[226] Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 21331536, please use {{cite journal}} with |pmid=21331536 instead.(subscription required)

[Tincati-2009-227] Tincati, C (2009 Jan). "Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease". Current molecular pharmacology. 2 (1): 40–5. doi:10.2174/1874467210902010040. PMID 20021444. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[Bowman-228] Bowman MC, Archin NM, Margolis DM. (2009). "Pharmaceutical approaches to eradication of persistent HIV infection". Expert Reviews in Molecular Medicine. 11 (e6): e6. doi:10.1017/S1462399409000970. PMID 19208267.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[229] Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S (2008). "Catalytic antibodies to HIV: Physiological role and potential clinical utility". Autoimmun Rev. 7 (6): 473–9. doi:10.1016/j.autrev.2008.04.002. PMC 2527403. PMID 18558365. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

[67]

[68]

[69]

[70]

[71]

[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]

@@ Line 6: / Line 6: @@
 | Name =HIV/AIDS
 | Image = Red_Ribbon.svg
-| Caption = The [[Red ribbon#Awareness symbol|red ribbon]] is a symbol for [[solidarity]] with HIV-positive people and those living with AIDS.
+| Caption = The [[red ribbon]] is a symbol for [[solidarity]] with HIV-positive people and those living with AIDS.
 | Alt         = A red ribbon in the shape of a bow
 | Width = 120
@@ Line 20: / Line 20: @@
 }}
 <!--Signs and symptoms -->
-'''Human immunodeficiency virus infection''' / '''acquired immunodeficiency syndrome''' ('''HIV/AIDS''') is a [[disease]] of the human [[immune system]] caused by infection with [[HIV|human immunodeficiency virus]] (HIV).<ref name="pmid11396444">{{Cite journal|author=Sepkowitz KA|title=AIDS—the first 20 years|journal=N. Engl. J. Med.|volume=344|issue=23|pages=1764–72|year=2001|month=June|pmid=11396444|doi=10.1056/NEJM200106073442306}}</ref> During the initial infection, a person may experience a brief period of [[influenza-like illness]]. This is typically followed by a prolonged period without symptoms. As the illness progresses, it interferes more and more with the immune system, making the person much more likely to get infections, including [[opportunistic infection]]s and [[tumors]] that do not usually affect people who have working immune systems.
+'''Human immunodeficiency virus infection''' / '''acquired immunodeficiency syndrome''' ('''HIV/AIDS''') is a [[disease]] of the human [[immune system]] caused by infection with [[human immunodeficiency virus]] (HIV).<ref name="pmid11396444">{{Cite journal|author=Sepkowitz KA|title=AIDS—the first 20 years|journal=N. Engl. J. Med.|volume=344|issue=23|pages=1764–72|year=2001|month=June|pmid=11396444|doi=10.1056/NEJM200106073442306}}</ref> During the initial infection, a person may experience a brief period of [[influenza-like illness]]. This is typically followed by a prolonged period without symptoms. As the illness progresses, it interferes more and more with the immune system, making the person much more likely to get infections, including [[opportunistic infection]]s and [[tumors]] that do not usually affect people who have working immune systems.
 <!--Transmission and prevention -->
@@ Line 26: / Line 26: @@
 <!--Treatment -->
-There is no cure or [[HIV vaccine|vaccine]]; however, [[antiretroviral|antiretroviral treatment]] can slow the course of the disease and may lead to a near-normal life expectancy. While antiretroviral treatment reduces the risk of death and complications from the disease, these medications are expensive and may be associated with side effects.
+There is no cure or [[HIV vaccine|vaccine]]; however, [[antiretroviral treatment]] can slow the course of the disease and may lead to a near-normal life expectancy. While antiretroviral treatment reduces the risk of death and complications from the disease, these medications are expensive and may be associated with side effects.
 <!--History and Epidemiology -->
 [[Molecular phylogenetics|Genetic research]] indicates that HIV originated in west-central Africa during the early twentieth century.<ref name=Orgin2011>{{cite journal|last=Sharp|first=PM|coauthors=Hahn, BH|title=Origins of HIV and the AIDS Pandemic|journal=Cold Spring Harbor perspectives in medicine|date=2011 Sep|volume=1|issue=1|pages=a006841|pmid=22229120|doi=10.1101/cshperspect.a006841|pmc=3234451}}</ref> AIDS was first recognized by the [[Centers for Disease Control and Prevention]] (CDC) in 1981 and its cause—HIV infection—was identified in the early part of the decade.<ref>{{Cite journal|author=Gallo RC|title=A reflection on HIV/AIDS research after 25 years|journal= Retrovirology|volume=3|page=72|year=2006|pmid=17054781|doi=10.1186/1742-4690-3-72|url=http://www.retrovirology.com/content/3//72|pmc=1629027}}</ref> Since its discovery, AIDS has caused nearly 30&nbsp;million deaths (as of 2009).<ref name=TotalDeath2010>{{cite web|title=Global Report Fact Sheet|url=http://www.unaids.org/documents/20101123_FS_Global_em_en.pdf|work=UNAIDS|year=2010}}</ref> As of 2010, approximately 34&nbsp;million people have contracted HIV globally.<ref name=UN2011Ten/> AIDS is considered a [[pandemic]]—a disease outbreak which is present over a large area and is actively spreading.<ref name=Kallings/>
-HIV/AIDS has had a great impact on society, both as an illness and as a source of [[Discrimination_against_people_with_HIV/AIDS|discrimination]]. The disease also has significant [[Economic impact of HIV/AIDS|economic impacts]]. There are many [[Misconceptions_about_HIV_and_AIDS|misconceptions about HIV/AIDS]] such as the belief that it can be transmitted by casual non-sexual contact. The disease has also become subject to many [[Religion and HIV/AIDS|controversies involving religion]].
+HIV/AIDS has had a great impact on society, both as an illness and as a source of [[Discrimination_against_people_with_HIV/AIDS|discrimination]]. The disease also has significant [[Economic impact of HIV/AIDS|economic impact]]. There are many [[misconceptions about HIV/AIDS]] such as the belief that it can be transmitted by casual non-sexual contact. The disease has also become subject to many [[Religion and HIV/AIDS|controversies involving religion]].
 {{TOC limit|3}}
@@ Line 55: / Line 55: @@
 <!--Opportunistic infections  -->
-[[Opportunistic infections]] may be caused by [[bacteria]], [[virus]]es, [[fungus|fungi]] and [[parasitism|parasite]]s that are normally controlled by the immune system.<ref name=Holmes>{{Cite journal|author=Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA|title= Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa|journal=Clin. Infect. Dis.|year=2003|pages=656–662|volume=36|issue=5| pmid=12594648|doi=10.1086/367655}}</ref> Which infections occur partly depends on what organisms are common in the person's environment.<ref name=M118/> These infections may affect nearly every [[biological system|organ system]].<ref name=Complications2011>{{cite journal|last=Chu|first=C|coauthors=Selwyn, PA|title=Complications of HIV infection: a systems-based approach|journal=American family physician|date=2011-02-15|volume=83|issue=4|pages=395–406|pmid=21322514}}</ref>
+[[Opportunistic infections]] may be caused by [[bacteria]], [[virus]]es, [[fungi]] and [[parasite]]s that are normally controlled by the immune system.<ref name=Holmes>{{Cite journal|author=Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA|title= Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa|journal=Clin. Infect. Dis.|year=2003|pages=656–662|volume=36|issue=5| pmid=12594648|doi=10.1086/367655}}</ref> Which infections occur partly depends on what organisms are common in the person's environment.<ref name=M118/> These infections may affect nearly every [[biological system|organ system]].<ref name=Complications2011>{{cite journal|last=Chu|first=C|coauthors=Selwyn, PA|title=Complications of HIV infection: a systems-based approach|journal=American family physician|date=2011-02-15|volume=83|issue=4|pages=395–406|pmid=21322514}}</ref>
 <!--AIDS related cancers  -->
-People with AIDS have an increased risk of developing various viral induced cancers including: [[Kaposi's sarcoma]], [[Burkitt's lymphoma]], [[primary central nervous system lymphoma]], and [[cervical cancer]].<ref name=Deut2010/> Kaposi's sarcoma is the most common cancer occurring in 10 to 20% of people with HIV.<ref name=M169>Mandell, Bennett, and Dolan (2010). Chapter 169.</ref> The second most common cancer is lymphoma which is the cause of death of nearly 16% of people with AIDS and is the initial sign of AIDS in 3 to 4%.<ref name=M169/> Both these cancers are associated with [[Kaposi's sarcoma-associated herpesvirus|human herpesvirus 8]].<ref name=M169/> Cervical cancer occurs more frequently in those with AIDS due to its association with [[human papillomavirus]] (HPV).<ref name=M169/>
+People with AIDS have an increased risk of developing various viral induced cancers including: [[Kaposi's sarcoma]], [[Burkitt's lymphoma]], [[primary central nervous system lymphoma]], and [[cervical cancer]].<ref name=Deut2010/> Kaposi's sarcoma is the most common cancer occurring in 10 to 20% of people with HIV.<ref name=M169>Mandell, Bennett, and Dolan (2010). Chapter 169.</ref> The second most common cancer is lymphoma which is the cause of death of nearly 16% of people with AIDS and is the initial sign of AIDS in 3 to 4%.<ref name=M169/> Both these cancers are associated with [[human herpesvirus 8]].<ref name=M169/> Cervical cancer occurs more frequently in those with AIDS due to its association with [[human papillomavirus]] (HPV).<ref name=M169/>
 <!--Systemic symptoms  -->
@@ Line 72: / Line 72: @@
 <!--Per act risk  -->
-As regards [[safe sex|unprotected]] heterosexual contacts, estimates of the risk of HIV transmission per sexual act appear to be four to ten times higher in low-income countries than in high-income countries.<ref name=Boily2009/> In low-income countries, the risk of female-to-male transmission is estimated as 0.38% per act, and of male-to-female transmission as 0.30% per act; the equivalent estimates for high-income countries are 0.04% per act for female-to-male transmission, and 0.08% per act for male-to-female transmission.<ref name=Boily2009/> The risk of transmission from anal intercourse is especially high, estimated as 1.4{{ndash}}1.7% per act in heterosexual as well as homosexual contacts.<ref name=Boily2009/><ref>{{cite journal|last=Beyrer|first=C|coauthors=Baral, SD; van Griensven, F; Goodreau, SM; Chariyalertsak, S; Wirtz, AL; Brookmeyer, R|title=Global epidemiology of HIV infection in men who have sex with men.|journal=Lancet|date=2012 Jul 28|volume=380|issue=9839|pages=367–77|pmid=22819660|doi=10.1016/S0140-6736(12)60821-6}}</ref> While the risk of transmission from [[oral sex]] is relatively low, it is still present.<ref>{{cite journal|last=Yu|first=M|coauthors=Vajdy, M|title=Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes|journal=Expert opinion on biological therapy|date=2010 Aug|volume=10|issue=8|pages=1181–95|pmid=20624114|doi=10.1517/14712598.2010.496776|pmc=2904634}}</ref> The risk from receiving oral sex has been described as "nearly nil"<ref>{{cite book|last=Stürchler|first=Dieter A.|title=Exposure a guide to sources of infections|year=2006|publisher=ASM Press|location=Washington, DC|isbn=9781555813765|pages=544|url=http://books.google.ca/books?id=MWa5or3Xa9EC&pg=PA544}}</ref> however a few cases have been reported.<ref>{{cite book|last=al.]|first=edited by Richard Pattman ... [et|title=Oxford handbook of genitourinary medicine, HIV, and sexual health|year=2010|publisher=Oxford University Press|location=Oxford|isbn=9780199571666|pages=95|url=http://books.google.ca/books?id=Jm1H4EeULmYC&pg=PA95|edition=2nd ed.}}</ref> The per act risk is estimated at 0{{ndash}}0.04% for receptive oral intercourse.<ref name=Dosekun2010>{{cite journal|last=Dosekun|first=O|coauthors=Fox, J|title=An overview of the relative risks of different sexual behaviours on HIV transmission|journal=Current opinion in HIV and AIDS|date=2010 Jul|volume=5|issue=4|pages=291–7|pmid=20543603|doi=10.1097/COH.0b013e32833a88a3}}</ref> In settings involving [[Prostitution|commercial sex]] in low income countries, risk of female-to-male transmission has been estimated as 2.4% per act and male-to-female transmission as 0.05% per act.<ref name=Boily2009>{{cite journal|author=Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M |title=Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies|journal=The Lancet Infectious Diseases|volume=9 |issue=2|pages=118–129|year=2009|month=February|pmid=19179227|doi=10.1016/S1473-3099(09)70021-0}}</ref>
+As regards [[safe sex|unprotected]] heterosexual contacts, estimates of the risk of HIV transmission per sexual act appear to be four to ten times higher in low-income countries than in high-income countries.<ref name=Boily2009/> In low-income countries, the risk of female-to-male transmission is estimated as 0.38% per act, and of male-to-female transmission as 0.30% per act; the equivalent estimates for high-income countries are 0.04% per act for female-to-male transmission, and 0.08% per act for male-to-female transmission.<ref name=Boily2009/> The risk of transmission from anal intercourse is especially high, estimated as 1.4{{ndash}}1.7% per act in heterosexual as well as homosexual contacts.<ref name=Boily2009/><ref>{{cite journal|last=Beyrer|first=C|coauthors=Baral, SD; van Griensven, F; Goodreau, SM; Chariyalertsak, S; Wirtz, AL; Brookmeyer, R|title=Global epidemiology of HIV infection in men who have sex with men.|journal=Lancet|date=2012 Jul 28|volume=380|issue=9839|pages=367–77|pmid=22819660|doi=10.1016/S0140-6736(12)60821-6}}</ref> While the risk of transmission from [[oral sex]] is relatively low, it is still present.<ref>{{cite journal|last=Yu|first=M|coauthors=Vajdy, M|title=Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes|journal=Expert opinion on biological therapy|date=2010 Aug|volume=10|issue=8|pages=1181–95|pmid=20624114|doi=10.1517/14712598.2010.496776|pmc=2904634}}</ref> The risk from receiving oral sex has been described as "nearly nil"<ref>{{cite book|last=Stürchler|first=Dieter A.|title=Exposure a guide to sources of infections|year=2006|publisher=ASM Press|location=Washington, DC|isbn=9781555813765|pages=544|url=http://books.google.ca/books?id=MWa5or3Xa9EC&pg=PA544}}</ref> however a few cases have been reported.<ref>{{cite book|last=al.]|first=edited by Richard Pattman ... [et|title=Oxford handbook of genitourinary medicine, HIV, and sexual health|year=2010|publisher=Oxford University Press|location=Oxford|isbn=9780199571666|pages=95|url=http://books.google.ca/books?id=Jm1H4EeULmYC&pg=PA95|edition=2nd ed.}}</ref> The per act risk is estimated at 0{{ndash}}0.04% for receptive oral intercourse.<ref name=Dosekun2010>{{cite journal|last=Dosekun|first=O|coauthors=Fox, J|title=An overview of the relative risks of different sexual behaviours on HIV transmission|journal=Current opinion in HIV and AIDS|date=2010 Jul|volume=5|issue=4|pages=291–7|pmid=20543603|doi=10.1097/COH.0b013e32833a88a3}}</ref> In settings involving [[commercial sex]] in low income countries, risk of female-to-male transmission has been estimated as 2.4% per act and male-to-female transmission as 0.05% per act.<ref name=Boily2009>{{cite journal|author=Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M |title=Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies|journal=The Lancet Infectious Diseases|volume=9 |issue=2|pages=118–129|year=2009|month=February|pmid=19179227|doi=10.1016/S1473-3099(09)70021-0}}</ref>
 <!--Factors that increase the risk  -->
@@ Line 86: / Line 86: @@
 <!--Blood transfusion  -->
-[[Blood transfusion]]s with infected blood result in transmission of infection in about 93% of cases.<ref name=Risk2006/> In developed countries the risk of acquiring HIV from a blood transfusion is extremely low (less than one in half a million) where improved donor selection and HIV screening is performed.<ref name=TransmissionM2007/> In the UK the risk is reported at one in five million.<ref>{{cite web|title=Will I need a blood transfusion?|work=NHS patient information|year=2011|url=http://hospital.blood.co.uk/library/pdf/2011_Will_I_Need_English_v3.pdf|publisher=National Health Services|accessdate=August 29, 2012}}</ref> However, in low income countries only half of the blood used for transfusions may be appropriately screened (as of 2008).<ref name=UN2011Seventy>UNAIDS 2011 pg. 60–70</ref> It is estimated that up to 15% of HIV infections in these areas come from transfusion of infected blood and blood products, representing between 5% and 10% of global infections.<ref name=TransmissionM2007/><ref name=WHO070401>{{cite web| publisher=[[World Health Organization|WHO]] | year= 2001| url=http://www.who.int/inf-pr-2000/en/pr2000-25.html| title=Blood safety&nbsp;... for too few|accessdate =January 17, 2006}}</ref>
+[[Blood transfusion]]s with infected blood result in transmission of infection in about 93% of cases.<ref name=Risk2006/> In developed countries the risk of acquiring HIV from a blood transfusion is extremely low (less than one in half a million) where improved donor selection and HIV screening is performed.<ref name=TransmissionM2007/> In the UK the risk is reported at one in five million.<ref>{{cite web|title=Will I need a blood transfusion?|work=NHS patient information|year=2011|url=http://hospital.blood.co.uk/library/pdf/2011_Will_I_Need_English_v3.pdf|publisher=National Health Services|accessdate=August 29, 2012}}</ref> However, in low income countries only half of the blood used for transfusions may be appropriately screened (as of 2008).<ref name=UN2011Seventy>UNAIDS 2011 pg. 60–70</ref> It is estimated that up to 15% of HIV infections in these areas come from transfusion of infected blood and blood products, representing between 5% and 10% of global infections.<ref name=TransmissionM2007/><ref name=WHO070401>{{cite web| publisher=[[WHO]] | year= 2001| url=http://www.who.int/inf-pr-2000/en/pr2000-25.html| title=Blood safety&nbsp;... for too few|accessdate =January 17, 2006}}</ref>
 <!--Non-sanitary health practices - this is about medical injections in particular -->
 Unsafe medical injections play a significant role in HIV spread in sub-Saharan Africa. In 2007, between 12 and 17% of infections in this region were attributed to medical syringe use.<ref name=UnsafeInjection2009>{{cite journal|last=Reid|first=SR|title=Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review|journal=Harm reduction journal|date=2009-08-28|volume=6|page=24|pmid=19715601|doi=10.1186/1477-7517-6-24|pmc=2741434}}</ref> The World Health Organisation estimates the risk of transmission as a result of a medical injection in Africa at 1.2%.<ref name=UnsafeInjection2009/> Significant risks are also associated with invasive procedures, assisted delivery, and dental care in this area of the world.<ref name=UnsafeInjection2009/>
-People giving or receiving [[tattoo]]s, [[body piercing|piercings]], and [[scarification]] are theoretically at risk of infection but no confirmed cases have been documented.<ref name=CDCBasics2012>{{cite web|title=Basic Information about HIV and AIDS|url=http://www.cdc.gov/hiv/topics/basic/|work=Center for Disease Control and Prevention|date=April 2012}}</ref> It is not possible for [[mosquito]]es or other insects to transmit HIV.<ref>{{cite web|url=http://www.rci.rutgers.edu/%7Einsects/aids.htm|title=Why Mosquitoes Cannot Transmit AIDS [HIV virus&#93;|publisher=Rci.rutgers.edu |date= |accessdate=2010-07-28}}</ref>
+People giving or receiving [[tattoo]]s, [[piercings]], and [[scarification]] are theoretically at risk of infection but no confirmed cases have been documented.<ref name=CDCBasics2012>{{cite web|title=Basic Information about HIV and AIDS|url=http://www.cdc.gov/hiv/topics/basic/|work=Center for Disease Control and Prevention|date=April 2012}}</ref> It is not possible for [[mosquito]]es or other insects to transmit HIV.<ref>{{cite web|url=http://www.rci.rutgers.edu/%7Einsects/aids.htm|title=Why Mosquitoes Cannot Transmit AIDS [HIV virus&#93;|publisher=Rci.rutgers.edu |date= |accessdate=2010-07-28}}</ref>
 === Mother-to-child ===
@@ Line 101: / Line 101: @@
 [[HIV]] is the cause of the spectrum of disease known as HIV/AIDS. HIV is a [[retrovirus]] that primarily infects components of the human [[immune system]] such as CD4<SUP>+</SUP> T cells, [[macrophage]]s and [[dendritic cell]]s. It directly and indirectly destroys CD4<SUP>+</SUP> T cells.<ref name=Alimonti>{{Cite journal | author=Alimonti JB, Ball TB, Fowke KR | title=Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS | journal=J. Gen. Virol. | year=2003 | pages=1649–1661 | volume=84 | issue=7 | pmid=12810858 | doi=10.1099/vir.0.19110-0}}</ref>
-HIV is a member of the [[genus]] ''[[Lentivirus]]'',<ref name=ICTV61.0.6>{{cite web | author=[[International Committee on Taxonomy of Viruses]] | publisher=[[National Institutes of Health]] | year=2002 | url=http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61060000.htm |archiveurl=http://web.archive.org/web/20060418135608/http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61060000.htm | title=61.0.6. Lentivirus | accessdate=2012-06-25 |archivedate=2006-04-18}}</ref> part of the family of [[Retroviridae]].<ref name=ICTV61.>{{cite web | author=International Committee on Taxonomy of Viruses | publisher=National Institutes of Health | year=2002 | url=http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61000000.htm | title=61. Retroviridae | archiveurl=http://web.archive.org/web/20060629180810/http://ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61000000.htm | accessdate=2012-06-25 | archivedate=2006-06-29}}</ref> Lentiviruses share many [[morphology (biology)|morphological]] and [[biology|biological]] characteristics. Many species of mammals are infected by lentiviruses, which are characteristically responsible for long-duration illnesses with a long [[incubation period]].<ref name=Levy>{{cite journal | author=Lévy, J. A. | title=HIV pathogenesis and long-term survival | journal=AIDS | year=1993 | pages=1401–10 | volume=7 | issue=11 | pmid=8280406 | doi=10.1097/00002030-199311000-00001}}</ref> Lentiviruses are transmitted as single-stranded, positive-[[Sense (molecular biology)|sense]], enveloped [[RNA virus]]es. Upon entry into the target cell, the viral [[RNA]] [[genome]] is converted (reverse transcribed) into double-stranded [[DNA]] by a virally encoded [[reverse transcriptase]] that is transported along with the viral genome in the virus particle. The resulting viral DNA is then imported into the cell nucleus and integrated into the cellular DNA by a virally encoded [[integrase]] and host co-factors.<ref name="JASmith">{{cite journal  | author= Smith, Johanna A.; Daniel, René (Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia)|title= Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses |journal=ACS Chem Biol|volume=1|issue=4 |pages= 217–26 | year= 2006 |pmid= 17163676 |doi=10.1021/cb600131q   |url= }}</ref> Once integrated, the virus may become [[Incubation period|latent]], allowing the virus and its host cell to avoid detection by the immune system.<ref>{{cite book|last=Martínez|first=edited by Miguel Angel|title=RNA interference and viruses : current innovations and future trends|year=2010|publisher=Caister Academic Press|location=Norfolk|isbn=9781904455561|pages=73|url=http://books.google.ca/books?id=C5TY8W74scIC&pg=PA73}}</ref> Alternatively, the virus may be [[Transcription (genetics)|transcribed]], producing new RNA genomes and viral proteins that are packaged and released from the cell as new virus particles that begin the replication cycle anew.<ref>{{cite book|first=ed. by Gerald B. Pier|title=Immunology, infection, and immunity|year=2004|publisher=ASM Press|location=Washington, D.C.|isbn=9781555812461|pages=550|url=http://books.google.ca/books?id=kBb-wYsMHEAC&pg=PA550&lpg=PA550}}</ref>
+HIV is a member of the [[genus]] ''[[Lentivirus]]'',<ref name=ICTV61.0.6>{{cite web | author=[[International Committee on Taxonomy of Viruses]] | publisher=[[National Institutes of Health]] | year=2002 | url=http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61060000.htm |archiveurl=http://web.archive.org/web/20060418135608/http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61060000.htm | title=61.0.6. Lentivirus | accessdate=2012-06-25 |archivedate=2006-04-18}}</ref> part of the family of [[Retroviridae]].<ref name=ICTV61.>{{cite web | author=International Committee on Taxonomy of Viruses | publisher=National Institutes of Health | year=2002 | url=http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61000000.htm | title=61. Retroviridae | archiveurl=http://web.archive.org/web/20060629180810/http://ncbi.nlm.nih.gov/ICTVdb/ICTVdB/61000000.htm | accessdate=2012-06-25 | archivedate=2006-06-29}}</ref> Lentiviruses share many [[morphology (biology)|morphological]] and [[biological]] characteristics. Many species of mammals are infected by lentiviruses, which are characteristically responsible for long-duration illnesses with a long [[incubation period]].<ref name=Levy>{{cite journal | author=Lévy, J. A. | title=HIV pathogenesis and long-term survival | journal=AIDS | year=1993 | pages=1401–10 | volume=7 | issue=11 | pmid=8280406 | doi=10.1097/00002030-199311000-00001}}</ref> Lentiviruses are transmitted as single-stranded, positive-[[Sense (molecular biology)|sense]], enveloped [[RNA virus]]es. Upon entry into the target cell, the viral [[RNA]] [[genome]] is converted (reverse transcribed) into double-stranded [[DNA]] by a virally encoded [[reverse transcriptase]] that is transported along with the viral genome in the virus particle. The resulting viral DNA is then imported into the cell nucleus and integrated into the cellular DNA by a virally encoded [[integrase]] and host co-factors.<ref name="JASmith">{{cite journal  | author= Smith, Johanna A.; Daniel, René (Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia)|title= Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses |journal=ACS Chem Biol|volume=1|issue=4 |pages= 217–26 | year= 2006 |pmid= 17163676 |doi=10.1021/cb600131q   |url= }}</ref> Once integrated, the virus may become [[Incubation period|latent]], allowing the virus and its host cell to avoid detection by the immune system.<ref>{{cite book|last=Martínez|first=edited by Miguel Angel|title=RNA interference and viruses : current innovations and future trends|year=2010|publisher=Caister Academic Press|location=Norfolk|isbn=9781904455561|pages=73|url=http://books.google.ca/books?id=C5TY8W74scIC&pg=PA73}}</ref> Alternatively, the virus may be [[Transcription (genetics)|transcribed]], producing new RNA genomes and viral proteins that are packaged and released from the cell as new virus particles that begin the replication cycle anew.<ref>{{cite book|first=ed. by Gerald B. Pier|title=Immunology, infection, and immunity|year=2004|publisher=ASM Press|location=Washington, D.C.|isbn=9781555812461|pages=550|url=http://books.google.ca/books?id=kBb-wYsMHEAC&pg=PA550&lpg=PA550}}</ref>
-Two [[Subtypes of HIV|types of HIV]] have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that was originally discovered (and initially referred to also as LAV or HTLV-III). It is more [[virulence|virulent]], more [[infectivity|infective]],<ref>{{cite journal | title=Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal | last=Gilbert | first=PB |journal=Statistics in Medicine | date=28 February 2003| volume=22 | issue=4 | pages=573–593 | pmid=12590415 |doi=10.1002/sim.1342 | last2=McKeague | first2=IW | last3=Eisen | first3=G | last4=Mullins | first4=C | last5=Guéye-Ndiaye| first5=A | last6=Mboup | first6=S | last7=Kanki | first7=PJ | display-authors=1}}</ref> and is the cause of the majority of HIV infections globally. The lower infectivity of HIV-2 as compared with HIV-1 implies that fewer people exposed to HIV-2 will be infected per exposure. Because of its relatively poor capacity for transmission, HIV-2 is largely confined to [[West Africa]].<ref name="Reeves">{{cite journal | author=Reeves, J. D. and Doms, R. W | title=Human Immunodeficiency Virus Type 2 | journal=J. Gen. Virol. | year=2002 | pages=1253–65 | volume=83 | issue=Pt 6 | pmid=12029140 | doi=10.1099/vir.0.18253-0}}</ref>
+Two [[Subtypes of HIV|types of HIV]] have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that was originally discovered (and initially referred to also as LAV or HTLV-III). It is more [[virulent]], more [[infectivity|infective]],<ref>{{cite journal | title=Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal | last=Gilbert | first=PB |journal=Statistics in Medicine | date=28 February 2003| volume=22 | issue=4 | pages=573–593 | pmid=12590415 |doi=10.1002/sim.1342 | last2=McKeague | first2=IW | last3=Eisen | first3=G | last4=Mullins | first4=C | last5=Guéye-Ndiaye| first5=A | last6=Mboup | first6=S | last7=Kanki | first7=PJ | display-authors=1}}</ref> and is the cause of the majority of HIV infections globally. The lower infectivity of HIV-2 as compared with HIV-1 implies that fewer people exposed to HIV-2 will be infected per exposure. Because of its relatively poor capacity for transmission, HIV-2 is largely confined to [[West Africa]].<ref name="Reeves">{{cite journal | author=Reeves, J. D. and Doms, R. W | title=Human Immunodeficiency Virus Type 2 | journal=J. Gen. Virol. | year=2002 | pages=1253–65 | volume=83 | issue=Pt 6 | pmid=12029140 | doi=10.1099/vir.0.18253-0}}</ref>
 == Pathophysiology ==
 {{Main|Pathophysiology of HIV/AIDS}}
-[[File:HIV-budding-Color.jpg|thumb|alt= A large round blue object with a smaller red object attached to it. Multiple small green spots are speckled over both.|[[Scanning electron microscope|Scanning electron micrograph]] of HIV-1, colored green, budding from a cultured [[lymphocyte]].]]
+[[File:HIV-budding-Color.jpg|thumb|alt= A large round blue object with a smaller red object attached to it. Multiple small green spots are speckled over both.|[[Scanning electron micrograph]] of HIV-1, colored green, budding from a cultured [[lymphocyte]].]]
 After the virus enters the body there is a period of rapid [[viral replication]], leading to an abundance of virus in the peripheral blood. During primary infection, the level of HIV may reach several million virus particles per milliliter of blood.<ref name=Piatak>{{cite journal | author=Piatak, M., Jr, Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. and Lifson, J.D. | title=High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR |journal=Science | year=1993 |pages=1749–1754 |volume=259 | issue=5102 | pmid=8096089 | doi=10.1126/science.8096089|bibcode = 1993Sci...259.1749P }}</ref> This response is accompanied by a marked drop in the number of circulating CD4<sup>+</sup> T cells. The acute [[viremia]] is almost invariably associated with activation of [[cytotoxic T cell|CD8<sup>+</sup> T cells]], which kill HIV-infected cells, and subsequently with antibody production, or [[seroconversion]]. The CD8<sup>+</sup> T cell response is thought to be important in controlling virus levels, which peak and then decline, as the CD4<sup>+</sup> T cell counts recover. A good CD8<sup>+</sup> T cell response has been linked to slower disease progression and a better prognosis, though it does not eliminate the virus.<ref name=Pantaleo1998>{{cite journal| author=Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS. | title=The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia | journal=Proc Natl Acad Sci U S A. | year=1997 |pages=254–258 | volume=94 | issue=1 | pmid=8990195 | doi=10.1073/pnas.94.1.254| pmc=19306|bibcode = 1997PNAS...94..254P }}</ref>
@@ Line 122: / Line 122: @@
 === HIV testing ===
-Most people infected with HIV develop specific [[antibodies]] (i.e. [[seroconversion|seroconvert]]) within three to twelve weeks of the initial infection.<ref name=M118/> Diagnosis of primary HIV before seroconversion is done by measuring HIV-[[RNA]] or [[P24 antigen#Antigen tests|p24 antigen]].<ref name=M118/> Positive results obtained by antibody or [[Polymerase chain reaction|PCR]] testing are confirmed either by a different antibody or by PCR.<ref name=WHOCase2007/>
+Most people infected with HIV develop specific [[antibodies]] (i.e. [[seroconvert]]) within three to twelve weeks of the initial infection.<ref name=M118/> Diagnosis of primary HIV before seroconversion is done by measuring HIV-[[RNA]] or [[p24 antigen]].<ref name=M118/> Positive results obtained by antibody or [[PCR]] testing are confirmed either by a different antibody or by PCR.<ref name=WHOCase2007/>
-Antibody tests in children younger than 18&nbsp;months are typically inaccurate due to the continued presence of [[Maternal Passive Immunity#Naturally acquired passive immunity|maternal antibodies]].<ref name=ChildDiag2010>{{cite journal|last=Kellerman|first=S|coauthors=Essajee, S|title=HIV testing for children in resource-limited settings: what are we waiting for?|journal=PLoS medicine|date=2010 Jul 20|volume=7|issue=7|pages=e1000285|pmid=20652012|doi=10.1371/journal.pmed.1000285|pmc=2907270}}</ref> Thus HIV infection can only be diagnosed by PCR testing for HIV RNA or DNA, or via testing for the p24 antigen.<ref name=WHOCase2007/> Much of the world lacks access to reliable PCR testing and many places simply wait until either symptoms develop or the child is old enough for accurate antibody testing.<ref name=ChildDiag2010/> In sub-Saharan Africa as of 2007–2009 between 30–70% of the population was aware of their HIV status.<ref name=UN2011Eighty>UNAIDS 2011 pg. 70–80</ref> In 2009 between four and 42% of the population was tested.<ref name=UN2011Eighty/> These figures represent substantial increases from ten years previous.<ref name=UN2011Eighty/>
+Antibody tests in children younger than 18&nbsp;months are typically inaccurate due to the continued presence of [[maternal antibodies]].<ref name=ChildDiag2010>{{cite journal|last=Kellerman|first=S|coauthors=Essajee, S|title=HIV testing for children in resource-limited settings: what are we waiting for?|journal=PLoS medicine|date=2010 Jul 20|volume=7|issue=7|pages=e1000285|pmid=20652012|doi=10.1371/journal.pmed.1000285|pmc=2907270}}</ref> Thus HIV infection can only be diagnosed by PCR testing for HIV RNA or DNA, or via testing for the p24 antigen.<ref name=WHOCase2007/> Much of the world lacks access to reliable PCR testing and many places simply wait until either symptoms develop or the child is old enough for accurate antibody testing.<ref name=ChildDiag2010/> In sub-Saharan Africa as of 2007–2009 between 30–70% of the population was aware of their HIV status.<ref name=UN2011Eighty>UNAIDS 2011 pg. 70–80</ref> In 2009 between four and 42% of the population was tested.<ref name=UN2011Eighty/> These figures represent substantial increases from ten years previous.<ref name=UN2011Eighty/>
 ===Classifications of HIV infection===
-Two main clinical staging systems are used to classify HIV and HIV-related disease for [[Disease surveillance|surveillance]] purposes: the [[WHO disease staging system for HIV infection and disease]],<ref name=WHOCase2007/> and the [[CDC classification system for HIV infection]].<ref name=CDCCase2008/> The [[Centers for Disease Control and Prevention|CDC]]'s classification system is more frequently adopted in developed countries. Since the [[World Health Organization|WHO]]'s staging system does not require laboratory tests, it is suited to the resource-restricted conditions encountered in developing countries, where it can also be used to help guide clinical management. Despite their differences, the two systems allow comparison for statistical purposes.<ref name=M121/><ref name=WHOCase2007/><ref name=CDCCase2008/>
+Two main clinical staging systems are used to classify HIV and HIV-related disease for [[Disease surveillance|surveillance]] purposes: the [[WHO disease staging system for HIV infection and disease]],<ref name=WHOCase2007/> and the [[CDC classification system for HIV infection]].<ref name=CDCCase2008/> The [[Centers for Disease Control and Prevention|CDC]]'s classification system is more frequently adopted in developed countries. Since the [[World Health WHO]]'s staging system does not require laboratory tests, it is suited to the resource-restricted conditions encountered in developing countries, where it can also be used to help guide clinical management. Despite their differences, the two systems allow comparison for statistical purposes.<ref name=M121/><ref name=WHOCase2007/><ref name=CDCCase2008/>
 The World Health Organization first proposed a definition for AIDS in 1986.<ref name=WHOCase2007/> Since then, the WHO classification has been updated and expanded several times, with the most recent version being published in 2007.<ref name=WHOCase2007>{{cite book|title=WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children.|pages=6–16|url=http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf|format=PDF|year=2007|publisher=World Health Organization|location=Geneva|isbn=978-92-4-159562-9}}</ref> The WHO system uses the following categories:
@@ Line 134: / Line 134: @@
 * Stage II: Mild symptoms which may include minor [[Mucous membrane|mucocutaneous]] manifestations and recurrent [[upper respiratory tract]] infections. A CD4 count of less than 500/uL.<ref name=WHOCase2007/>
 * Stage III: Advanced symptoms which may include unexplained [[Chronic (medical)|chronic]] [[diarrhea]] for longer than a month, severe bacterial infections including tuberculosis of the lung as well as a CD4 count of less than 350/uL.<ref name=WHOCase2007/>
-* Stage IV or AIDS: severe symptoms which includes [[toxoplasmosis]] of the brain, [[candidiasis]] of the [[esophagus]], [[Vertebrate trachea|trachea]], [[bronchus|bronchi]] or [[lung]]s and [[Kaposi's sarcoma]]. A CD4 count of less than 200/uL.<ref name=WHOCase2007/>
+* Stage IV or AIDS: severe symptoms which includes [[toxoplasmosis]] of the brain, [[candidiasis]] of the [[esophagus]], [[Vertebrate trachea]], [[bronchi]] or [[lung]]s and [[Kaposi's sarcoma]]. A CD4 count of less than 200/uL.<ref name=WHOCase2007/>
 The United States [[Center for Disease Control and Prevention]] also created a classification system for HIV, and updated it in 2008.<ref name=CDCCase2008>{{cite journal|last=Schneider|first=E|coauthors=Whitmore, S; Glynn, KM; Dominguez, K; Mitsch, A; McKenna, MT; Centers for Disease Control and Prevention, (CDC)|title=Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008|journal=MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control|date=2008-12-05|volume=57|issue=RR–10|pages=1–12|pmid=19052530}}</ref> In this system HIV infections are classified based on CD4 count and clinical symptoms,<ref name=CDCCase2008/> and describes the infection in three stages:
@@ Line 150: / Line 150: @@
 === Sexual contact ===
 <!--Condoms  -->
-Consistent [[condom]] use reduces the risk of HIV transmission by approximately 80% over the long term.<ref>{{cite journal|last=Crosby|first=R|coauthors=Bounse, S|title=Condom effectiveness: where are we now?|journal=Sexual health|date=2012 Mar|volume=9|issue=1|pages=10–7|pmid=22348628|doi=10.1071/SH11036}}</ref> When one partner of a couple is infected, consistent condom use results in rates of HIV infection for the uninfected person of below 1% per year.<ref name=WHOCondoms>{{cite web| publisher=[[World Health Organization|WHO]]| month=August | year=2003|url=http://www.wpro.who.int/mediacentre/factsheets/fs_200308_Condoms/en/index.html  | title=Condom Facts and Figures|accessdate=January 17, 2006 }}</ref> There is some evidence to suggest that [[female condom]]s may provide an equivalent level of protection.<ref>{{cite journal|last=Gallo|first=MF|coauthors=Kilbourne-Brook, M; Coffey, PS|title=A review of the effectiveness and acceptability of the female condom for dual protection|journal=Sexual health|date=2012 Mar|volume=9|issue=1|pages=18–26|pmid=22348629|doi=10.1071/SH11037}}</ref> Application of a vaginal gel containing [[tenofovir]] (a [[reverse transcriptase inhibitor]]) immediately before sex seems to reduce infection rates by approximately 40% among African women.<ref name=VagGel2012>{{cite journal|last=Celum|first=C|coauthors=Baeten, JM|title=Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence|journal=Current opinion in infectious diseases|date=2012 Feb|volume=25|issue=1|pages=51–7|pmid=22156901|doi=10.1097/QCO.0b013e32834ef5ef|pmc=3266126}}</ref> By contrast, use of the [[spermicide]] [[nonoxynol-9]] may increase the risk of transmission due to its tendency to cause vaginal and rectal irritation.<ref>{{cite journal|last=Baptista|first=M|coauthors=Ramalho-Santos, J|title=Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds|journal=Mini reviews in medicinal chemistry|date=2009-11-01|volume=9|issue=13|pages=1556–67|pmid=20205637|doi=10.2174/138955709790361548}}</ref>
+Consistent [[condom]] use reduces the risk of HIV transmission by approximately 80% over the long term.<ref>{{cite journal|last=Crosby|first=R|coauthors=Bounse, S|title=Condom effectiveness: where are we now?|journal=Sexual health|date=2012 Mar|volume=9|issue=1|pages=10–7|pmid=22348628|doi=10.1071/SH11036}}</ref> When one partner of a couple is infected, consistent condom use results in rates of HIV infection for the uninfected person of below 1% per year.<ref name=WHOCondoms>{{cite web| publisher=[[WHO]]| month=August | year=2003|url=http://www.wpro.who.int/mediacentre/factsheets/fs_200308_Condoms/en/index.html  | title=Condom Facts and Figures|accessdate=January 17, 2006 }}</ref> There is some evidence to suggest that [[female condom]]s may provide an equivalent level of protection.<ref>{{cite journal|last=Gallo|first=MF|coauthors=Kilbourne-Brook, M; Coffey, PS|title=A review of the effectiveness and acceptability of the female condom for dual protection|journal=Sexual health|date=2012 Mar|volume=9|issue=1|pages=18–26|pmid=22348629|doi=10.1071/SH11037}}</ref> Application of a vaginal gel containing [[tenofovir]] (a [[reverse transcriptase inhibitor]]) immediately before sex seems to reduce infection rates by approximately 40% among African women.<ref name=VagGel2012>{{cite journal|last=Celum|first=C|coauthors=Baeten, JM|title=Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence|journal=Current opinion in infectious diseases|date=2012 Feb|volume=25|issue=1|pages=51–7|pmid=22156901|doi=10.1097/QCO.0b013e32834ef5ef|pmc=3266126}}</ref> By contrast, use of the [[spermicide]] [[nonoxynol-9]] may increase the risk of transmission due to its tendency to cause vaginal and rectal irritation.<ref>{{cite journal|last=Baptista|first=M|coauthors=Ramalho-Santos, J|title=Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds|journal=Mini reviews in medicinal chemistry|date=2009-11-01|volume=9|issue=13|pages=1556–67|pmid=20205637|doi=10.2174/138955709790361548}}</ref>
 <!--Circumcision  -->
 [[Circumcision]] in [[Sub-Saharan Africa]] "reduces the acquisition of HIV by heterosexual men by between 38% and 66% over 24 months".<ref>{{cite journal|last=Siegfried|first=N|coauthors=Muller, M; Deeks, JJ; Volmink, J|title=Male circumcision for prevention of heterosexual acquisition of HIV in men|journal=Cochrane database of systematic reviews (Online)|date=2009-04-15|issue=2|pages=CD003362|pmid=19370585|doi=10.1002/14651858.CD003362.pub2|editor1-last=Siegfried|editor1-first=Nandi}}</ref> Based on these studies, the World Health Organization and UNAIDS both recommended male circumcision as a method of preventing female-to-male HIV transmission in 2007.<ref>{{cite web |title=WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention |publisher=World Health Organization |date=Mar 28, 2007|url=http://www.who.int/mediacentre/news/releases/2007/pr10/en/index.html}}</ref>  Whether it protects against male-to-female transmission is disputed<ref>{{cite journal|last=Larke|first=N|title=Male circumcision, HIV and sexually transmitted infections: a review|journal=British journal of nursing (Mark Allen Publishing)|date=2010 May 27 – Jun 9|volume=19|issue=10|pages=629–34|pmid=20622758}}</ref><ref>{{cite journal|last=Eaton|first=L|coauthors=Kalichman, SC|title=Behavioral aspects of male circumcision for the prevention of HIV infection|journal=Current HIV/AIDS reports|date=2009 Nov|volume=6|issue=4|pages=187–93|pmid=19849961|doi=10.1007/s11904-009-0025-9}}(subscription required)</ref> and whether it is of benefit in [[developed countries]] and among [[men who have sex with men]] is undetermined.<ref>{{cite journal|last=Kim|first=HH|coauthors=Li, PS, Goldstein, M|title=Male circumcision: Africa and beyond?|journal=Current opinion in urology|date=2010 Nov|volume=20|issue=6|pages=515–9|pmid=20844437|doi=10.1097/MOU.0b013e32833f1b21}}</ref><ref>{{cite journal|last=Templeton|first=DJ|coauthors=Millett, GA, Grulich, AE|title=Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men|journal=Current opinion in infectious diseases|date=2010 Feb|volume=23|issue=1|pages=45–52|pmid=19935420|doi=10.1097/QCO.0b013e328334e54d}}</ref><ref>{{Cite journal  | last1 = Wiysonge | first1 = CS. | last2 = Kongnyuy | first2 = EJ. | last3 = Shey | first3 = M. | last4 = Muula | first4 = AS.|last5 = Navti | first5 = OB. | last6 = Akl | first6 = EA. | last7 = Lo | first7 = YR. | title = Male circumcision for prevention of homosexual acquisition of HIV in men | journal = Cochrane Database Syst Rev | volume =  | issue = 6 | pages = CD007496 | month =  | year = 2011 | doi = 10.1002/14651858.CD007496.pub2 | pmid = 21678366  | editor1-last = Wiysonge  |editor1-first = Charles Shey }}</ref> Some experts fear that a lower perception of vulnerability among circumcised men may result in more sexual risk-taking behavior, thus negating its preventive effects.<ref>{{Cite journal|author=Eaton LA, Kalichman S |title=Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies |journal=Curr HIV/AIDS Rep |volume=4 |issue=4 |pages=165–72 |year=2007|month=December|pmid=18366947|pmc=2937204 |doi=10.1007/s11904-007-0024-7}}</ref> Women who have undergone [[female genital cutting]] have an increased risk of HIV.<ref>{{Cite journal|author=Utz-Billing I, Kentenich H|title=Female genital mutilation: an injury, physical and mental harm |journal=J Psychosom Obstet Gynaecol |volume=29|issue=4 |pages=225–9|year=2008 |month=December |pmid=19065392 |doi=10.1080/01674820802547087 |url=}}</ref>
@@ Line 160: / Line 160: @@
 Treating people with HIV whose CD4 count ≥ 350cells/µL with antiretrovirals protects 96% of their partners from infection.<ref>{{cite journal|last=Anglemyer|first=A|coauthors=Rutherford, GW; Baggaley, RC; Egger, M; Siegfried, N|title=Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples|journal=Cochrane database of systematic reviews (Online)|date=2011-08-10|issue=8|pages=CD009153|pmid=21833973|doi=10.1002/14651858.CD009153.pub2|editor1-last=Rutherford|editor1-first=George W}}</ref> [[Pre-exposure prophylaxis]] with a daily dose of the medications [[tenofovir]], with or without [[emtricitabine]], is effective in a number of groups including: men who have sex with men, couples where one is HIV positive, and young heterosexuals in Africa.<ref name=VagGel2012/>
-[[Universal precautions]] within the health care environment are believed to be effective in decreasing the risk of HIV.<ref>{{Cite journal|title=Recommendations for prevention of HIV transmission in health-care settings|journal=MMWR|volume=36 |issue=Suppl 2 |pages=1S–18S |year=1987 |month=August|pmid=3112554|url=http://www.cdc.gov/MMWR/PREVIEW/MMWRHTML/00023587.htm |author1= Centers for Disease Control (CDC)}}</ref> [[Intravenous drug use]] is an important risk factor and [[harm reduction]] strategies such as [[needle-exchange programme]]s and [[Opioid replacement therapy|opioid substitution therapy]] appear effective in decreasing this risk.<ref name=Kurth2011>{{cite journal|last=Kurth|first=AE|coauthors=Celum, C; Baeten, JM; Vermund, SH; Wasserheit, JN|title=Combination HIV prevention: significance, challenges, and opportunities|journal=Current HIV/AIDS reports|date=2011 Mar|volume=8|issue=1|pages=62–72|pmid=20941553|doi=10.1007/s11904-010-0063-3|pmc=3036787}}</ref><ref>{{cite journal|last=MacArthur|first=G. J.|coauthors=Minozzi, S.; Martin, N.; Vickerman, P.; Deren, S.; Bruneau, J.; Degenhardt, L.; Hickman, M.|title=Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis|journal=BMJ|date=4 October 2012|volume=345|issue=oct03 3|pages=e5945–e5945|doi=10.1136/bmj.e5945}}</ref>
+[[Universal precautions]] within the health care environment are believed to be effective in decreasing the risk of HIV.<ref>{{Cite journal|title=Recommendations for prevention of HIV transmission in health-care settings|journal=MMWR|volume=36 |issue=Suppl 2 |pages=1S–18S |year=1987 |month=August|pmid=3112554|url=http://www.cdc.gov/MMWR/PREVIEW/MMWRHTML/00023587.htm |author1= Centers for Disease Control (CDC)}}</ref> [[Intravenous drug use]] is an important risk factor and [[harm reduction]] strategies such as [[needle-exchange programme]]s and [[opioid substitution therapy]] appear effective in decreasing this risk.<ref name=Kurth2011>{{cite journal|last=Kurth|first=AE|coauthors=Celum, C; Baeten, JM; Vermund, SH; Wasserheit, JN|title=Combination HIV prevention: significance, challenges, and opportunities|journal=Current HIV/AIDS reports|date=2011 Mar|volume=8|issue=1|pages=62–72|pmid=20941553|doi=10.1007/s11904-010-0063-3|pmc=3036787}}</ref><ref>{{cite journal|last=MacArthur|first=G. J.|coauthors=Minozzi, S.; Martin, N.; Vickerman, P.; Deren, S.; Bruneau, J.; Degenhardt, L.; Hickman, M.|title=Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis|journal=BMJ|date=4 October 2012|volume=345|issue=oct03 3|pages=e5945–e5945|doi=10.1136/bmj.e5945}}</ref>
 === Post-exposure ===
@@ Line 169: / Line 169: @@
 === Vaccination ===
+{{Maine|HIV Vaccine}}
-As of 2012 there is no effective [[HIV vaccine|vaccine]] for HIV or AIDS.<ref>{{cite news|title=The quest for an HIV vaccine|url=http://www.unaids.org/en/resources/presscentre/featurestories/2012/may/20120518vaccinesday/|date=May 18, 2012|author=UNAIDS}}</ref> A single trial of the vaccine [[RV 144]] published in 2009 found a partial reduction in the risk of transmission of roughly 30%, stimulating some hope in the research community of developing a truly effective vaccine.<ref>{{cite journal|last=Reynell|first=L|coauthors=Trkola, A|title=HIV vaccines: an attainable goal?|journal=Swiss medical weekly|date=2012-03-02|volume=142|pages=w13535|pmid=22389197|doi=10.4414/smw.2012.13535}}</ref> Further trials of the RV 144 vaccine are ongoing.<ref>{{cite web| author = U.S. Army Office of the Surgeon General| title = HIV Vaccine Trial in Thai Adults| publisher = ClinicalTrials.gov| date = March 21, 2011| accessdate = June 28, 2011| url =http://clinicaltrials.gov/ct2/show/NCT00223080}}</ref><ref>{{cite web| author = U.S. Army Office of the Surgeon General|title = Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial| publisher = ClinicalTrials.gov| date = June 2, 2010| url =http://www.clinicaltrials.gov/ct2/show/NCT00337181}}</ref>
+As of 2012 there is no effective [[vaccine]] for HIV or AIDS.<ref>{{cite news|title=The quest for an HIV vaccine|url=http://www.unaids.org/en/resources/presscentre/featurestories/2012/may/20120518vaccinesday/|date=May 18, 2012|author=UNAIDS}}</ref> A single trial of the vaccine [[RV 144]] published in 2009 found a partial reduction in the risk of transmission of roughly 30%, stimulating some hope in the research community of developing a truly effective vaccine.<ref>{{cite journal|last=Reynell|first=L|coauthors=Trkola, A|title=HIV vaccines: an attainable goal?|journal=Swiss medical weekly|date=2012-03-02|volume=142|pages=w13535|pmid=22389197|doi=10.4414/smw.2012.13535}}</ref> Further trials of the RV 144 vaccine are ongoing.<ref>{{cite web| author = U.S. Army Office of the Surgeon General| title = HIV Vaccine Trial in Thai Adults| publisher = ClinicalTrials.gov| date = March 21, 2011| accessdate = June 28, 2011| url =http://clinicaltrials.gov/ct2/show/NCT00223080}}</ref><ref>{{cite web| author = U.S. Army Office of the Surgeon General|title = Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial| publisher = ClinicalTrials.gov| date = June 2, 2010| url =http://www.clinicaltrials.gov/ct2/show/NCT00337181}}</ref>
 == Management ==
@@ Line 192: / Line 193: @@
 === Opportunistic infections ===
-Measures to prevent opportunistic infections are effective in many people with HIV/AIDS. Treatment with antivirals often improves current, as well as decreases the risk of future, opportunistic infections.<ref name=Montessori2004/> [[Vaccination]] against [[hepatitis]] A and B is advised for all people at risk of HIV before they become infected however may also be given after infection.<ref name=Laurence>{{Cite journal | author=Laurence J | title=Hepatitis A and B virus immunization in HIV-infected persons | journal=AIDS Reader | year=2006 | pages=15–17 | volume=16 | issue=1 |pmid=16433468}}</ref> [[Trimethoprim/sulfamethoxazole]] prophylaxis between four to six weeks of age and finishing breastfeeding in infants born to HIV positive mothers is recommended in resource limited settings.<ref name=UN2011ONESIXTY/> It is also recommended to prevent PCP when peoples' CD4 count is below 200&nbsp;cells/uL and in those who have or have previously had PCP.<ref name=PCP2011>{{cite journal|last=Huang|first=L|coauthors=Cattamanchi, A; Davis, JL; den Boon, S; Kovacs, J; Meshnick, S; Miller, RF; Walzer, PD; Worodria, W; Masur, H; International HIV-associated Opportunistic Pneumonias (IHOP), Study; Lung HIV, Study|title=HIV-associated Pneumocystis pneumonia|journal=Proceedings of the American Thoracic Society|date=2011 Jun|volume=8|issue=3|pages=294–300|pmid=21653531|doi=10.1513/pats.201009-062WR|pmc=3132788}}</ref> People with substantial immunosuppression are also advised to receive prophylactic therapy for [[toxoplasmosis]] and [[Cryptococcus|Cryptococcus meningitis]].<ref name=PEPpocketguide>{{cite web | publisher=[[United States Department of Health and Human Services|Department of Health and Human Services]] | date = February 2, 2007 |url=http://www.guideline.gov/summary/summary.aspx?ss=14&doc_id=6223&string=infected+AND+patients | title=Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.}}</ref> Appropriate preventive measures have reduced the rate of these infections by 50% between 1992 and 1997.<ref name=InfectionBook2008/>
+Measures to prevent opportunistic infections are effective in many people with HIV/AIDS. Treatment with antivirals often improves current, as well as decreases the risk of future, opportunistic infections.<ref name=Montessori2004/> [[Vaccination]] against [[hepatitis]] A and B is advised for all people at risk of HIV before they become infected however may also be given after infection.<ref name=Laurence>{{Cite journal | author=Laurence J | title=Hepatitis A and B virus immunization in HIV-infected persons | journal=AIDS Reader | year=2006 | pages=15–17 | volume=16 | issue=1 |pmid=16433468}}</ref> [[Trimethoprim/sulfamethoxazole]] prophylaxis between four to six weeks of age and finishing breastfeeding in infants born to HIV positive mothers is recommended in resource limited settings.<ref name=UN2011ONESIXTY/> It is also recommended to prevent PCP when peoples' CD4 count is below 200&nbsp;cells/uL and in those who have or have previously had PCP.<ref name=PCP2011>{{cite journal|last=Huang|first=L|coauthors=Cattamanchi, A; Davis, JL; den Boon, S; Kovacs, J; Meshnick, S; Miller, RF; Walzer, PD; Worodria, W; Masur, H; International HIV-associated Opportunistic Pneumonias (IHOP), Study; Lung HIV, Study|title=HIV-associated Pneumocystis pneumonia|journal=Proceedings of the American Thoracic Society|date=2011 Jun|volume=8|issue=3|pages=294–300|pmid=21653531|doi=10.1513/pats.201009-062WR|pmc=3132788}}</ref> People with substantial immunosuppression are also advised to receive prophylactic therapy for [[toxoplasmosis]] and [[Cryptococcus|Cryptococcus meningitis]].<ref name=PEPpocketguide>{{cite web | publisher=[[United States Department of Health and Human Services]] | date = February 2, 2007 |url=http://www.guideline.gov/summary/summary.aspx?ss=14&doc_id=6223&string=infected+AND+patients | title=Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.}}</ref> Appropriate preventive measures have reduced the rate of these infections by 50% between 1992 and 1997.<ref name=InfectionBook2008/>
 === Alternative medicine ===
@@ Line 215: / Line 216: @@
 {{legend|#cb0000|<small>≥&nbsp;50000</small>}}
 {{Multicol-end}}]]
-HIV/AIDS has become a [[chronic disease|chronic]] rather than an acutely fatal disease in many areas of the world.<ref name=Knoll2007/> Prognosis varies between people, and both the CD4 count and viral load are useful for predicted outcomes.<ref name=M118/> Without treatment, average survival time after infection with HIV is estimated to be 9 to 11&nbsp;years, depending on the HIV subtype.<ref name=UNAIDS2007>{{cite web| author =[[Joint United Nations Programme on HIV/AIDS|UNAIDS]], [[World Health Organization|WHO]]| month = December | year = 2007| title = 2007 AIDS epidemic update| url= http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf| accessdate = 2008-03-12| format= PDF}}</ref> After the diagnosis of AIDS, if treatment is not available, survival ranges between 6 and 19&nbsp;months.<ref name=Morgan2>{{Cite journal | author=Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA | title=HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? | journal=AIDS | year=2002 | pages=597–632 | volume=16 | issue=4 | pmid=11873003 | doi=10.1097/00002030-200203080-00011}}</ref><ref>{{Cite journal|title= Progression and mortality of untreated HIV-positive individuals living in resource-limited settings: update of literature review and evidence synthesis |author= Zwahlen M, Egger M | url=http://data.unaids.org/pub/Periodical/2006/zwahlen_unaids_hq_05_422204_2007_en.pdf |format=PDF |year=2006|accessdate=March 19, 2008 |version= UNAIDS Obligation HQ/05/422204| archiveurl=http://web.archive.org/web/20080409065844/http://data.unaids.org/pub/Periodical/2006/zwahlen_unaids_hq_05_422204_2007_en.pdf|archivedate=April 9, 2008| deadurl= no}}</ref> [[HAART]] and appropriate prevention of opportunistic infections reduces the death rate by 80%, and raises the life expectancy for a newly diagnosed young adult to 20–50 years.<ref name=Knoll2007>{{cite journal |journal= Int J Dermatol |year=2007 |volume=46 |issue=12 |pages=1219–28 |title= Current status of HIV infection: a review for non-HIV-treating physicians |author= Knoll B, Lassmann B, Temesgen Z |pmid=18173512|doi=10.1111/j.1365-4632.2007.03520.x}}</ref><ref name=LifeExpecr2008>{{cite journal |journal= Lancet|year=2008 |volume=372|issue=9635 |pages=293–9 |title=Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | author= Antiretroviral Therapy Cohort Collaboration |pmid=18657708  |doi=10.1016/S0140-6736(08)61113-7 |pmc= 3130543 }}</ref><ref name=Schack2006>{{cite journal | author=Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. |title=The lifetime cost of current HIV care in the United States | journal=Med Care | year=2006 |pages=990–997 | volume=44 | issue=11 | pmid=17063130 |doi=10.1097/01.mlr.0000228021.89490.2a}}</ref> This is between two thirds<ref name=LifeExpecr2008/> and nearly that of the general population.<ref name=Deut2010/><ref>{{cite journal|last=van Sighem|first=AI|coauthors=Gras, LA; Reiss, P; Brinkman, K; de Wolf, F; ATHENA national observational cohort, study|title=Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals|journal=AIDS (London, England)|date=2010-06-19|volume=24|issue=10|pages=1527–35|pmid=20467289|doi=10.1097/QAD.0b013e32833a3946}}</ref> If treatment is started late in the infection, prognosis is not as good:<ref name=Deut2010/> for example, if treatment is begun following the diagnosis of AIDS, life expectancy is ~10–40&nbsp;years.<ref name=Deut2010/><ref name=Knoll2007/> Half of infants born with HIV die before two years of age without treatment.<ref name=UN2011ONESIXTY/>
+HIV/AIDS has become a [[chronic disease|chronic]] rather than an acutely fatal disease in many areas of the world.<ref name=Knoll2007/> Prognosis varies between people, and both the CD4 count and viral load are useful for predicted outcomes.<ref name=M118/> Without treatment, average survival time after infection with HIV is estimated to be 9 to 11&nbsp;years, depending on the HIV subtype.<ref name=UNAIDS2007>{{cite web| author =[[Joint United Nations Programme on HIV/AIDS]], [[World Health Organization]]| month = December | year = 2007| title = 2007 AIDS epidemic update| url= http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf| accessdate = 2008-03-12| format= PDF}}</ref> After the diagnosis of AIDS, if treatment is not available, survival ranges between 6 and 19&nbsp;months.<ref name=Morgan2>{{Cite journal | author=Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA | title=HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? | journal=AIDS | year=2002 | pages=597–632 | volume=16 | issue=4 | pmid=11873003 | doi=10.1097/00002030-200203080-00011}}</ref><ref>{{Cite journal|title= Progression and mortality of untreated HIV-positive individuals living in resource-limited settings: update of literature review and evidence synthesis |author= Zwahlen M, Egger M | url=http://data.unaids.org/pub/Periodical/2006/zwahlen_unaids_hq_05_422204_2007_en.pdf |format=PDF |year=2006|accessdate=March 19, 2008 |version= UNAIDS Obligation HQ/05/422204| archiveurl=http://web.archive.org/web/20080409065844/http://data.unaids.org/pub/Periodical/2006/zwahlen_unaids_hq_05_422204_2007_en.pdf|archivedate=April 9, 2008| deadurl= no}}</ref> [[HAART]] and appropriate prevention of opportunistic infections reduces the death rate by 80%, and raises the life expectancy for a newly diagnosed young adult to 20–50 years.<ref name=Knoll2007>{{cite journal |journal= Int J Dermatol |year=2007 |volume=46 |issue=12 |pages=1219–28 |title= Current status of HIV infection: a review for non-HIV-treating physicians |author= Knoll B, Lassmann B, Temesgen Z |pmid=18173512|doi=10.1111/j.1365-4632.2007.03520.x}}</ref><ref name=LifeExpecr2008>{{cite journal |journal= Lancet|year=2008 |volume=372|issue=9635 |pages=293–9 |title=Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | author= Antiretroviral Therapy Cohort Collaboration |pmid=18657708  |doi=10.1016/S0140-6736(08)61113-7 |pmc= 3130543 }}</ref><ref name=Schack2006>{{cite journal | author=Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA. |title=The lifetime cost of current HIV care in the United States | journal=Med Care | year=2006 |pages=990–997 | volume=44 | issue=11 | pmid=17063130 |doi=10.1097/01.mlr.0000228021.89490.2a}}</ref> This is between two thirds<ref name=LifeExpecr2008/> and nearly that of the general population.<ref name=Deut2010/><ref>{{cite journal|last=van Sighem|first=AI|coauthors=Gras, LA; Reiss, P; Brinkman, K; de Wolf, F; ATHENA national observational cohort, study|title=Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals|journal=AIDS (London, England)|date=2010-06-19|volume=24|issue=10|pages=1527–35|pmid=20467289|doi=10.1097/QAD.0b013e32833a3946}}</ref> If treatment is started late in the infection, prognosis is not as good:<ref name=Deut2010/> for example, if treatment is begun following the diagnosis of AIDS, life expectancy is ~10–40&nbsp;years.<ref name=Deut2010/><ref name=Knoll2007/> Half of infants born with HIV die before two years of age without treatment.<ref name=UN2011ONESIXTY/>
 The primary causes of death from HIV/AIDS are [[opportunistic infections]] and [[cancer]], both of which are frequently the result of the progressive failure of the immune system.<ref name=InfectionBook2008>{{cite book|last=Smith|first=[edited by] Blaine T.|title=Concepts in immunology and immunotherapeutics|year=2008|publisher=American Society of Health-System Pharmacists|location=Bethesda, Md.|isbn=978-1-58528-127-5|page=143|url=http://books.google.ca/books?id=G46DrdlxNJAC&pg=PA143|edition=4th}}</ref><ref name=Cancer2005>{{cite journal|last=Cheung|first=MC|coauthors=Pantanowitz, L; Dezube, BJ|title=AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy|journal=The oncologist|date=2005 Jun–Jul|volume=10|issue=6|pages=412–26|pmid=15967835|doi=10.1634/theoncologist.10-6-412}}</ref> Risk of cancer appears to increase once the CD 4 count gets below 500/uL.<ref name=Deut2010/> The rate of clinical disease progression varies widely between individuals and has been shown to be affected by a number of factors such as a person's susceptibility and immune function;<ref name=Tang>{{Cite journal | author=Tang J, Kaslow RA | title=The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy | journal=AIDS | year=2003 | pages=S51–S60 | volume=17 | issue=Suppl 4 | pmid=15080180 | doi=10.1097/00002030-200317004-00006}}</ref> their access to health care and the presence of co-infections;<ref name=Morgan2 /><ref name=Lawn>{{cite journal | author=Lawn SD | title=AIDS in Africa: the impact of co-infections on the pathogenesis of HIV-1 infection | journal=J. Infect. Dis. | year=2004 | pages=1–12 |volume=48 | issue=1| pmid=14667787 | doi=10.1016/j.jinf.2003.09.001}}</ref> as well as the particular strain (or strains) of the virus involved.<ref name=Campbell>{{cite journal | author=Campbell GR |title=The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis | journal=J. Biol. Chem. | year=2004 | pages=48197–48204 | volume=279 | issue=46 | pmid=15331610 |doi=10.1074/jbc.M406195200 | author-separator=, | author2=Pasquier E | author3=Watkins J | display-authors=3 | last4=Bourgarel-Rey | first4=V | last5=Peyrot | first5=V | last6=Esquieu | first6=D | last7=Barbier | first7=P | last8=De Mareuil | first8=J | last9=Braguer | first9=D}}</ref><ref name=Campbell2>{{cite journal | author=Campbell GR, Watkins JD, Esquieu D, Pasquier E, Loret EP, Spector SA | title=The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells | journal=J. Biol. Chem. | year=2005 | pages=38376–39382 | volume=280 | issue=46 |pmid=16155003 | doi=10.1074/jbc.M506630200}}</ref>
@@ Line 243: / Line 244: @@
 In the early days, the CDC did not have an official name for the disease, often referring to it by way of the diseases that were associated with it, for example, [[lymphadenopathy]], the disease after which the discoverers of HIV originally named the virus.<ref name=MMWR1982a>{{Cite journal | author=Centers for Disease Control (CDC) | title=Persistent, generalized lymphadenopathy among homosexual males |url=http://www.cdc.gov/mmwr/preview/mmwrhtml/00001096.htm | journal=MMWR Morb Mortal Wkly Rep. | year=1982 | pages=249–251 | volume=31| issue=19 | pmid=6808340 | accessdate =August 31, 2011}}</ref><ref name=Barre>{{Cite journal| author=Barré-Sinoussi F | title=Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) | journal=Science | year=1983 | pages=868–871 | volume=220 | issue=4599 | pmid=6189183 | doi=10.1126/science.6189183 | bibcode=1983Sci...220..868B| author-separator=,| author2=Chermann JC| author3=Rey F| display-authors=3| last4=Nugeyre| first4=M.| last5=Chamaret| first5=S| last6=Gruest| first6=J| last7=Dauguet| first7=C| last8=Axler-Blin| first8=C| last9=Vezinet-Brun| first9=F
-}}</ref> They also used ''Kaposi's Sarcoma and Opportunistic Infections'', the name by which a task force had been set up in 1981.<ref name=MMWR1982b>{{Cite journal | author=Centers for Disease Control (CDC) | title=Opportunistic infections and Kaposi's sarcoma among Haitians in the United States | url=http://www.cdc.gov/mmwr/preview/mmwrhtml/00001123.htm | journal=MMWR Morb Mortal Wkly Rep. | year=1982 | pages=353–354; 360–361 | volume=31 | issue=26 | pmid=6811853 | accessdate =August 31, 2011}}</ref> At one point, the CDC coined the phrase "the 4H disease", since the syndrome seemed to affect [[Haiti]]ans, homosexuals, [[haemophilia|hemophilia]]cs, and heroin users.<ref name=SciRep470b>{{cite web| publisher=[[American Association for the Advancement of Science]]| date= July 28, 2006
+}}</ref> They also used ''Kaposi's Sarcoma and Opportunistic Infections'', the name by which a task force had been set up in 1981.<ref name=MMWR1982b>{{Cite journal | author=Centers for Disease Control (CDC) | title=Opportunistic infections and Kaposi's sarcoma among Haitians in the United States | url=http://www.cdc.gov/mmwr/preview/mmwrhtml/00001123.htm | journal=MMWR Morb Mortal Wkly Rep. | year=1982 | pages=353–354; 360–361 | volume=31 | issue=26 | pmid=6811853 | accessdate =August 31, 2011}}</ref> At one point, the CDC coined the phrase "the 4H disease", since the syndrome seemed to affect [[Haiti]]ans, homosexuals, [[hemophilia]]cs, and heroin users.<ref name=SciRep470b>{{cite web| publisher=[[American Association for the Advancement of Science]]| date= July 28, 2006
 | url=http://www.scienceonline.org/cgi/reprint/313/5786/470b.pdf| title= Making Headway Under Hellacious Circumstances| accessdate =June 23, 2008| format=PDF}}</ref> In the general press, the term "GRID", which stood for [[gay-related immune deficiency]], had been coined.<ref name=Altman>{{Cite news
 |author=Altman LK | url=http://www.nytimes.com/1982/05/11/science/new-homosexual-disorder-worries-health-officials.html?scp=1&sq=New%20homosexual%20disorder%20worries%20officials&st=cse | title=New homosexual disorder worries health officials | work=The New York Times | date=May 11, 1982 | accessdate =August 31, 2011}}</ref> However, after determining that AIDS was not isolated to the [[gay community]],<ref name=MMWR1982b/> it was realized that the term GRID was misleading and the term AIDS was introduced at a meeting in July 1982.<ref name=Kher>{{Cite news | author=Kher U
@@ Line 253: / Line 254: @@
 ===Origins===
-Both HIV-1 and HIV-2 are believed to have originated in non-human [[primate]]s in West-central Africa and were [[zoonosis|transferred to humans]] in the early 20th century.<ref name=Orgin2011/> HIV-1 appears to have originated in southern [[Cameroon]] through the evolution of SIV(cpz), a [[simian immunodeficiency virus]] (SIV) that infects wild [[chimpanzee]]s (HIV-1 descends from the SIVcpz endemic in the chimpanzee subspecies ''Pan troglodytes troglodytes'').<ref name="pmid9989410">{{cite journal |author=Gao F |title=Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes |journal=Nature |volume=397 |issue=6718|pages=436–41 |year=1999 |month=February |pmid=9989410 |doi=10.1038/17130 |url=|bibcode = 1999Natur.397..436G |author-separator=, |author2=Bailes E |author3=Robertson DL |display-authors=3 |last4=Chen |first4=Yalu |last5=Rodenburg |first5=Cynthia M. |last6=Michael |first6=Scott F. |last7=Cummins |first7=Larry B. |last8=Arthur |first8=Larry O. |last9=Peeters |first9=Martine }}</ref><ref name=Keele>{{cite journal | author=Keele, B. F., van Heuverswyn, F., Li, Y. Y., Bailes, E., Takehisa, J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V., Liegois, F., Loul, S., Mpoudi Ngole, E., Bienvenue, Y., Delaporte, E., Brookfield, J. F. Y., Sharp, P. M., Shaw, G. M., Peeters, M., and Hahn, B. H. | title=Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 | journal=Science | date=28 July 2006| volume=313 | issue=5786 | pages=523–6 | doi = 10.1126/science.1126531 | pmc=2442710 | pmid=16728595|bibcode = 2006Sci...313..523K }}</ref> The closest relative of HIV-2 is SIV(smm), a virus of the [[sooty mangabey]] (''Cercocebus atys atys''), an Old World monkey living in litoral West Africa (from southern [[Senegal]] to western [[Côte d'Ivoire]]).<ref name="Reeves" /> [[New World monkey]]s such as the [[Night monkey|owl monkey]] are resistant to [[Subtypes of HIV|HIV-1]] infection, possibly because of a genomic [[fusion gene|fusion]] of two viral resistance genes.<ref name=Goodier>{{cite journal | author=Goodier, J., and Kazazian, H. | title=Retrotransposons Revisited: The Restraint and Rehabilitation of Parasites | journal=Cell | year=2008 | pages=23–35 | volume=135 | issue=1 | doi = 10.1016/j.cell.2008.09.022 | pmid=18854152}}(subscription required)</ref>
+Both HIV-1 and HIV-2 are believed to have originated in non-human [[primate]]s in West-central Africa and were [[zoonosis|transferred to humans]] in the early 20th century.<ref name=Orgin2011/> HIV-1 appears to have originated in southern [[Cameroon]] through the evolution of SIV(cpz), a [[simian immunodeficiency virus]] (SIV) that infects wild [[chimpanzee]]s (HIV-1 descends from the SIVcpz endemic in the chimpanzee subspecies ''Pan troglodytes troglodytes'').<ref name="pmid9989410">{{cite journal |author=Gao F |title=Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes |journal=Nature |volume=397 |issue=6718|pages=436–41 |year=1999 |month=February |pmid=9989410 |doi=10.1038/17130 |url=|bibcode = 1999Natur.397..436G |author-separator=, |author2=Bailes E |author3=Robertson DL |display-authors=3 |last4=Chen |first4=Yalu |last5=Rodenburg |first5=Cynthia M. |last6=Michael |first6=Scott F. |last7=Cummins |first7=Larry B. |last8=Arthur |first8=Larry O. |last9=Peeters |first9=Martine }}</ref><ref name=Keele>{{cite journal | author=Keele, B. F., van Heuverswyn, F., Li, Y. Y., Bailes, E., Takehisa, J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V., Liegois, F., Loul, S., Mpoudi Ngole, E., Bienvenue, Y., Delaporte, E., Brookfield, J. F. Y., Sharp, P. M., Shaw, G. M., Peeters, M., and Hahn, B. H. | title=Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 | journal=Science | date=28 July 2006| volume=313 | issue=5786 | pages=523–6 | doi = 10.1126/science.1126531 | pmc=2442710 | pmid=16728595|bibcode = 2006Sci...313..523K }}</ref> The closest relative of HIV-2 is SIV(smm), a virus of the [[sooty mangabey]] (''Cercocebus atys atys''), an Old World monkey living in litoral West Africa (from southern [[Senegal]] to western [[Côte d'Ivoire]]).<ref name="Reeves" /> [[New World monkey]]s such as the [[owl monkey]] are resistant to [[Subtypes of HIV|HIV-1]] infection, possibly because of a genomic [[fusion gene|fusion]] of two viral resistance genes.<ref name=Goodier>{{cite journal | author=Goodier, J., and Kazazian, H. | title=Retrotransposons Revisited: The Restraint and Rehabilitation of Parasites | journal=Cell | year=2008 | pages=23–35 | volume=135 | issue=1 | doi = 10.1016/j.cell.2008.09.022 | pmid=18854152}}(subscription required)</ref>
 HIV-1 is thought to have jumped the species barrier on at least three separate occasions, giving rise to the three groups of the virus, M, N, and O.<ref name=Sharp2001>{{cite journal |last1=Sharp |first1=P. M. |last2=Bailes |first2=E. |last3=Chaudhuri |first3=R. R. |last4=Rodenburg |first4=C. M. |last5=Santiago |first5=M. O. |last6=Hahn |first6=B. H. |title=The origins of acquired immune deficiency syndrome viruses: where and when? |journal=Philosophical Transactions of the Royal Society B: Biological Sciences |volume=356 |pages=867–76 |year=2001 |doi=10.1098/rstb.2001.0863 |pmid=11405934 |pmc=1088480|url=http://www.aidsorigins.com/pdfs/rs/sharp.pdf |issue=1410}}</ref>
@@ Line 268: / Line 269: @@
 [[File:Ryan White.jpg|thumb|alt=A teenage male with the hand of another resting on his left shoulder smiling for the camera|[[Ryan White]] became a [[poster child]] for HIV after being expelled from school because he was infected.]]
 {{main|Discrimination against people with HIV/AIDS}}
-AIDS stigma exists around the world in a variety of ways, including [[shunning|ostracism]], [[Social rejection|rejection]], discrimination and avoidance of HIV infected people; compulsory HIV testing without prior [[consent]] or protection of [[confidentiality]]; violence against HIV infected individuals or people who are perceived to be infected with HIV; and the [[quarantine]] of HIV infected individuals.<ref name=UNAIDS2006Ch4>{{Cite book| publisher =[[Joint United Nations Programme on HIV/AIDS|UNAIDS]]| year = 2006| title = 2006 Report on the global AIDS epidemic| chapter = The impact of AIDS on people and societies| chapterurl = http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH04_en.pdf| accessdate =June 14, 2006| format= PDF| isbn =92-9173-479-9}}</ref> Stigma-related violence or the fear of violence prevents many people from seeking HIV testing, returning for their results, or securing treatment, possibly turning what could be a manageable chronic illness into a death sentence and perpetuating the spread of HIV.<ref name=Ogden>{{cite web| author =Ogden J, Nyblade L| publisher = [[International Center for Research on Women]] | year = 2005 | title = Common at its core: HIV-related stigma across contexts | url = http://www.icrw.org/docs/2005_report_stigma_synthesis.pdf | format = PDF | accessdate =February 15, 2007}}</ref>
+AIDS stigma exists around the world in a variety of ways, including [[shunning|ostracism]], [[Social rejection|rejection]], discrimination and avoidance of HIV infected people; compulsory HIV testing without prior [[consent]] or protection of [[confidentiality]]; violence against HIV infected individuals or people who are perceived to be infected with HIV; and the [[quarantine]] of HIV infected individuals.<ref name=UNAIDS2006Ch4>{{Cite book| publisher =[[UNAIDS]]| year = 2006| title = 2006 Report on the global AIDS epidemic| chapter = The impact of AIDS on people and societies| chapterurl = http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH04_en.pdf| accessdate =June 14, 2006| format= PDF| isbn =92-9173-479-9}}</ref> Stigma-related violence or the fear of violence prevents many people from seeking HIV testing, returning for their results, or securing treatment, possibly turning what could be a manageable chronic illness into a death sentence and perpetuating the spread of HIV.<ref name=Ogden>{{cite web| author =Ogden J, Nyblade L| publisher = [[International Center for Research on Women]] | year = 2005 | title = Common at its core: HIV-related stigma across contexts | url = http://www.icrw.org/docs/2005_report_stigma_synthesis.pdf | format = PDF | accessdate =February 15, 2007}}</ref>
 AIDS stigma has been further divided into the following three categories:
@@ Line 278: / Line 279: @@
 Often, AIDS stigma is expressed in conjunction with one or more other stigmas, particularly those associated with homosexuality, [[bisexuality]], [[promiscuity]], prostitution, and [[Intravenous drug use (recreational)|intravenous drug use]].<ref>{{cite book|last=Sharma|first=A.K.|title=Population and society|publisher=Concept Pub. Co.|location=New Delhi|isbn=9788180698187|pages=242|url=http://books.google.ca/books?id=sE-VDhEuxmsC&pg=PA242}}</ref>
-In many [[Developed country|developed countries]], there is an association between AIDS and homosexuality or bisexuality, and this association is correlated with higher levels of sexual prejudice such as [[homophobia|anti-homosexual]]/[[biphobia|bisexual]] attitudes.<ref name=Herek2002>{{cite journal|last=Herek|first=GM|coauthors=Capitanio, JP; Widaman, KF|title=HIV-related stigma and knowledge in the United States: prevalence and trends, 1991–1999|journal=American journal of public health|date=2002 Mar|volume=92|issue=3|pages=371–7|pmid=11867313|pmc=1447082|doi=10.2105/AJPH.92.3.371}}</ref> There is also a perceived association between AIDS and all male-male sexual behavior, including sex between uninfected men.<ref name=Herek1999/> However, the dominant mode of spread worldwide for HIV remains heterosexual transmission.<ref>{{cite journal|last=De Cock|first=KM|coauthors=Jaffe, HW; Curran, JW|title=The evolving epidemiology of HIV/AIDS.|journal=AIDS (London, England)|date=2012 Jun 19|volume=26|issue=10|pages=1205–13|pmid=22706007|doi=10.1097/QAD.0b013e328354622a}}</ref>
+In many [[developed countries]], there is an association between AIDS and homosexuality or bisexuality, and this association is correlated with higher levels of sexual prejudice such as [[homophobia|anti-homosexual]]/[[biphobia|bisexual]] attitudes.<ref name=Herek2002>{{cite journal|last=Herek|first=GM|coauthors=Capitanio, JP; Widaman, KF|title=HIV-related stigma and knowledge in the United States: prevalence and trends, 1991–1999|journal=American journal of public health|date=2002 Mar|volume=92|issue=3|pages=371–7|pmid=11867313|pmc=1447082|doi=10.2105/AJPH.92.3.371}}</ref> There is also a perceived association between AIDS and all male-male sexual behavior, including sex between uninfected men.<ref name=Herek1999/> However, the dominant mode of spread worldwide for HIV remains heterosexual transmission.<ref>{{cite journal|last=De Cock|first=KM|coauthors=Jaffe, HW; Curran, JW|title=The evolving epidemiology of HIV/AIDS.|journal=AIDS (London, England)|date=2012 Jun 19|volume=26|issue=10|pages=1205–13|pmid=22706007|doi=10.1097/QAD.0b013e328354622a}}</ref>
 === Economic impact ===
@@ Line 286: / Line 287: @@
 HIV/AIDS affects the economics of both individuals and countries.<ref name=M117/> The [[gross domestic product]] of the most affected countries have decreased due to the lack of [[human capital]].<ref name=M117/><ref name="Bell-et-al-2003">{{Cite journal|author= Bell C, Devarajan S, Gersbach H |year=2003|url=http://econ.worldbank.org/external/default/main?pagePK=64165259&theSitePK=478060&piPK=64165421&menuPK=64166093&entityID=000160016_20031110113834|title=The long-run economic costs of AIDS: theory and an application to South Africa|accessdate=April 28, 2008|version= World Bank Policy Research Working Paper No. 3152|format=PDF}}</ref> Without proper nutrition, health care and medicine, large numbers of people die from AIDS-related complications. They will not only be unable to work, but will also require significant medical care. It is estimated that as of 2007 there where 12&nbsp;million [[AIDS orphan]]s.<ref name=M117/> Many are cared for by elderly grandparents.<ref name=Greener>{{Cite book| author =Greener R| year = 2002| title = State of The Art: AIDS and Economics| chapter = AIDS and macroeconomic impact| editor = S, Forsyth (ed.)| pages = 49–55| publisher = IAEN|url=http://pdf.usaid.gov/pdf_docs/PNACP969.pdf}}</ref>
-By affecting mainly young adults, AIDS reduces the taxable population, in turn reducing the resources available for [[government spending|public expenditure]]s such as education and health services not related to AIDS resulting in increasing pressure for the state's finances and slower growth of the economy. This results in a slower growth of the tax base, an effect that is reinforced if there are growing expenditures on treating the sick, training (to replace sick workers), sick pay and caring for AIDS orphans. This is especially true if the sharp increase in adult mortality shifts the responsibility and blame from the family to the government in caring for these orphans.<ref name=Greener />
+By affecting mainly young adults, AIDS reduces the taxable population, in turn reducing the resources available for [[public expenditure]]s such as education and health services not related to AIDS resulting in increasing pressure for the state's finances and slower growth of the economy. This results in a slower growth of the tax base, an effect that is reinforced if there are growing expenditures on treating the sick, training (to replace sick workers), sick pay and caring for AIDS orphans. This is especially true if the sharp increase in adult mortality shifts the responsibility and blame from the family to the government in caring for these orphans.<ref name=Greener />
 At the household level, AIDS results in both the loss of income but also increased spending on healthcare.  A study in [[Côte d'Ivoire]] showed that households with an HIV/AIDS patient, spent twice as much on medical expenses as other households.  This additional expenditure also leaves less income to spend on education and other personal or family investment.<ref name="WBank">
@@ Line 320: / Line 321: @@
 Complementing efforts to control viral replication, [[immunotherapy|immunotherapies]] that may assist in the recovery of the immune system have been explored in past and ongoing trials, including [[Interleukin-2|IL-2]] and [[Interleukin-7|IL-7]].<ref name="Tincati-2009">{{cite journal|last=Tincati|first=C|coauthors=d'Arminio Monforte, A; Marchetti, G|title=Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease|journal=Current molecular pharmacology|date=2009 Jan|volume=2|issue=1|pages=40–5|pmid=20021444|doi=10.2174/1874467210902010040}}</ref>
-The failure of vaccine candidates to protect against HIV infection and progression to AIDS has led to a renewed focus on the biological mechanisms responsible for HIV latency. A limited period of therapy combining anti-retrovirals with drugs targeting the latent reservoir may one day allow for total eradication of HIV infection.<ref name =Bowman>{{cite journal | author=Bowman MC, Archin NM, Margolis DM. | title=Pharmaceutical approaches to eradication of persistent HIV infection | journal=Expert Reviews in Molecular Medicine |year=2009|  volume=11 | issue=e6 | pmid=19208267 | doi=10.1017/S1462399409000970 | pages=e6 }}</ref> Researchers have discovered an [[abzyme]] that can destroy the protein [[gp120]] CD4 binding site. This protein is common to all HIV variants as it is the attachment point for [[B cell|B lymphocytes]] and subsequent compromising of the immune system.<ref>{{Cite journal|author=Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S |title=Catalytic antibodies to HIV: Physiological role and potential clinical utility |journal=Autoimmun Rev |volume=7 |issue=6 |pages=473–9 |year=2008 |month=June |pmid=18558365|doi=10.1016/j.autrev.2008.04.002 |url=  |pmc=2527403}}</ref>
+The failure of vaccine candidates to protect against HIV infection and progression to AIDS has led to a renewed focus on the biological mechanisms responsible for HIV latency. A limited period of therapy combining anti-retrovirals with drugs targeting the latent reservoir may one day allow for total eradication of HIV infection.<ref name =Bowman>{{cite journal | author=Bowman MC, Archin NM, Margolis DM. | title=Pharmaceutical approaches to eradication of persistent HIV infection | journal=Expert Reviews in Molecular Medicine |year=2009|  volume=11 | issue=e6 | pmid=19208267 | doi=10.1017/S1462399409000970 | pages=e6 }}</ref> Researchers have discovered an [[abzyme]] that can destroy the protein [[gp120]] CD4 binding site. This protein is common to all HIV variants as it is the attachment point for [[B lymphocytes]] and subsequent compromising of the immune system.<ref>{{Cite journal|author=Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S |title=Catalytic antibodies to HIV: Physiological role and potential clinical utility |journal=Autoimmun Rev |volume=7 |issue=6 |pages=473–9 |year=2008 |month=June |pmid=18558365|doi=10.1016/j.autrev.2008.04.002 |url=  |pmc=2527403}}</ref>
 == Notes ==

v t e State of Maine
Augusta (capital)
Topics	Index Geography Government Congressional districts Governors History Images Islands People Symbols Tourist attractions Transportation
Society	Abortion Cannabis Climate change Culture Demographics Economy Education Gun laws LGBT rights Politics Party strength
Regions	Down East Highlands Kennebec Valley Lake Country Mid Coast North Woods Penobscot Bay Southern Coast Western Mountains
Counties	Androscoggin Aroostook Cumberland Franklin Hancock Kennebec Knox Lincoln Oxford Penobscot Piscataquis Sagadahoc Somerset Waldo Washington York
Cities	Auburn Augusta Bangor Bath Belfast Biddeford Brewer Calais Eastport Ellsworth Gardiner Hallowell Lewiston Old Town Portland Presque Isle Rockland Saco Sanford South Portland Waterville Westbrook
Largest towns	Bridgton Brunswick Cape Elizabeth Falmouth Gorham Kennebunk Kittery Lisbon Old Orchard Beach Orono Sanford Scarborough Skowhegan Standish Topsham Wells Windham Winslow York
Maine portal

v t e Diseases of poverty
Diseases of poverty	AIDS Malaria Tuberculosis Measles Pneumonia Diarrheal diseases Plague
Neglected diseases	Cholera Chagas disease African sleeping sickness Schistosomiasis Dracunculiasis River blindness Leishmaniasis Trachoma
Miscellaneous	Malnutrition Priority review voucher

v t e Sexually transmitted infections (STI)
Bacterial	Chancroid (Haemophilus ducreyi) Chlamydia, lymphogranuloma venereum (Chlamydia trachomatis) Donovanosis (Klebsiella granulomatis) Gonorrhea (Neisseria gonorrhoeae) Mycoplasma hominis infection (Mycoplasma hominis) Syphilis (Treponema pallidum) Ureaplasma infection (Ureaplasma urealyticum)
Protozoal	Trichomoniasis (Trichomonas vaginalis)
Parasitic	Crab louse Scabies
Viral	AIDS (HIV-1/HIV-2) Cancer cervical vulvar penile anal Human papillomavirus (HPV) Genital warts (condyloma) Hepatitis B (Hepatitis B virus) Herpes simplex HSV-1 & HSV-2 Molluscum contagiosum (MCV) Zika fever (Zika virus)
General inflammation	female Cervicitis Pelvic inflammatory disease (PID) male Epididymitis Prostatitis either Proctitis Urethritis/Non-gonococcal urethritis (NGU)